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Résumé 
Les récepteurs tyrosine kinases sont un groupe de molécules clés de signalisation, qui ont 2 
fonctions: la détection des stimuli de l'environnement extérieur des cellules et la transmission 
de ces signaux à l’intérieur des cellules. Dans les 20 dernières années, notre laboratoire a 
choisi d'étudier la fonction d’Ephb6 kinase, un récepteur tyrosine kinase fortement exprimé 
dans les lymphocytes T.Comme Efnb1 et Efnb2 sont tous des ligands pour Ephb6, nous avons 
ensuite procédé à étudier leur rôle dans la fonction des cellules T in vitro et in vivo. Des 
cellules T spécifiques mutants (KO) dans les gènes Efnb1 ou Efnb2 ainsi que les doubles 
mutants Efnb1/b2 (double KO) ont été générés, mais il n’y avait que les souris double KO qui 
ont démontré de la déficience dans le développement des thymocytes, fonction de Th1 et Th17, 
la signalisation du récepteur d’IL-6, et les réponses antivirales. 
Des preuves solides indiquent que la reconnaissance d’auto-antigène par les cellules T est un 
événement précoce dans la pathogenèse de la PR. Donc, nous avons postulé que les cellules T 
spécifique Efnb1 / b2 double KO chez la souris peuvent protéger les souris de l’arthrite induite 
par collagène (CIA), un modèle de souris de la PR humaine. Nous avons trouvé que Efnb1et 
Efnb2 dans les cellules T étaient essentielles pour la production d'anticorps pathogéniques et 
de la migration des lymphocytes T vers les pattes enflammées chez les souris CIA. Notre 
étude clinique suggère que l'expression de EFNB1 dans les cellules T pourrait être un 
paramètre utile pour surveiller l'activité de la maladie de RA et la réponse de traitement. 
Pour élucider les événements dans le programme d'activation des lymphocytes T, nous avons 
exploré par l'analyse des micropuces d'ADN pour identifier des molécules qui ont été 
exprimées de manière différente dans le WT par rapport aux cellules T Ephb6 KO dans le 
stade précoce de l’activation des cellules T. Environ 30 molécules étaient sur ou sous 
exprimées plus de 3 fois dans les cellules T WT par rapport aux cellules T KO pendant les 16 
premières heures après stimulation par l'anti-CD3. Stra6 (stimulée par le gène de l'acide 
rétinoïque 6) et Armc5 (Armadillo répéter contenant 5) ont été parmi ceux qui ont été validées 
pour leur expression altérée. 
STRA6 est un récepteur de haute affinité pour le plasma rétinol-binding protéine (RBP) et un 
médiateur pour absorption cellulaire de vitamine A. Cellules T KO et WT étaient similaires en 
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termes de prolifération et les réponses immunitaires anti-virales de virus de la chorioméningite 
lymphocytaire (LCMV). Ainsi, la sur-régulation de Stra6 est soit un événement parallèle qui 
ne soit pas essentiel pour le programme d'activation des lymphocytes T, ou il est très essentiel 
que la redondance existe, et sa suppression ne montre aucun effet apparent sur l'activation des 
cellules T. 
ARMC5 est une protéine intracellulaire contenant sept répétitions en tandem d’armadillo et un 
domaine BTB. Les fonctions du ARMC5 dans le système immunitaire ne sont pas encore 
connues. Nos résultats d'hybridation in situ ont montré une expression élevée de Armc5 dans 
le thymus, et une expression modérée dans les ganglions lymphatiques et la rate. Nous avons 
généré des souris KO Armc5. Fait interessant, les cellules T Armc5 KO présentaient de la 
prolifération diminuée et de la différenciation compromise vers Th1 et Th17 in vitro. Les 
souris KO étaient résistantes à l'induction expérimentale d’encéphalite auto-immune, et ont été 
compromises dans les réponses immunitaires anti-LCMV. En utilisant de la levure 2-hybride 
test, nous avons identifié 8 protéines ARMC5-associantes, qui sont connues pour les rôles 
dans l'activation de la cellule, le cycle cellulaire et l'apoptose. Une étude mécanique est en 
cours. Nos résultats montrent que Armc5 est essentiel dans la programme d'activation/de 
prolifération/de différenciation des lymphocytes T. 
Nos études ont augmenté nos connaissances sur EFNB1, EFNB2, STRA6 et ARMC5 en 
biologie des lymphocytes T et leur pertinence à des troubles immunitaires dans des modèles 
animaux ainsi que chez l'être humaine. 
 
Mots-clés : cellules T, EFNB1, EFNB2, STRA6, ARMC5, la polyarthrite rhumatoïde, la 
sclérose en plaques 
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Abstract 
Receptor tyrosine kinases are a group of key signaling molecules, which have dual functions: 
sensing the environmental stimuli outside the cells and transmitting them into the cells. 20 
years ago, our laboratory started to study the function of Ephb6 kinase, a receptor tyrosine 
kinase highly expressed in T lymphocytes. As both Efnb1 and Efnb2 are the ligands for 
Ephb6, we then proceeded to study their roles in T cell function in vitro and in vivo. T cell-
specific Efnb1, Efnb2 single gene knockout (KO), as well as Efnb1/b2 double KO mice were 
generated, but only the double KO mice showed compromised thymocyte development, Th1 
and Th17 function, IL-6 receptor signaling, and anti-virus responses.    
Strong evidence indicates that T cells play a crucial role in the pathogenesis of rheumatoid 
arthritis (RA). Thus, we postulated that T cell-specific Efnb1/b2 double KO in mice may 
protect mice from collagen-induced arthritis (CIA), a mouse model for human RA. We found 
that Efnb1 and Efnb2 in T cells were essential for pathogenic antibody production and T cell 
migration to the inflamed paws in mice with CIA. Our clinical study suggests that the 
expression of EFNB1 in T cells might be a useful parameter for monitoring RA disease 
activity and treatment responses. 
Naïve T cells have the ability to expansion and differentiation into effector cells once they 
encounter foreign antigens, during which a large number of molecules are modulated. Some of 
these molecules play essential regulatory roles, while others exert house keeping functions 
and/or act as supporters to cope with increased or changed metabolic demands. To fully 
elucidate events in the T cell activation program, we undertook unbiased exploration with 
DNA microarray analysis to identify molecules that were differentially expressed in WT 
versus Ephb6 KO T cells in the early T-cell activation stage. About 30 molecules were up- or 
down-regulated more than three folds in WT T cells compared with KO T cells. Stra6 
(stimulated by retinoic acid gene 6) and Armc5 (Armadillo repeat-containing 5) were among 
those that had been validated for their altered expression. We generated mice with these two 
genes deleted to study their roles in T cell function in vitro and in vivo. 
STRA6 is a high-affinity receptor for plasma retinol-binding protein (RBP) and mediates 
cellular vitamin A uptake. Stra6 KO mice manifest normal spleen and thymus in size, 
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cellularity and lymphocyte subpopulations. KO and WT T cells were similar regarding 
proliferation, differentiation and anti-viral immune responses to lymphocytic choriomeningitis 
virus (LCMV). Thus, the up-regulation of Stra6 is either a parallel event which is not essential 
for the T cell activation program or it is so critical that heavy redundancy exists. 
ARMC5 is an intracellular protein containing seven tandem armadillo repeats and one BTB 
domain. Functions of ARMC5 in the immune system are not known previously. Our in situ 
hybridization results showed high expression of Armc5 in the thymus and moderate 
expression in the spleen and lymph nodes. A transient increase of Armc5 expression in T cells 
after TCR activation was found. To investigate its roles in T cell function, Armc5 KO mice 
were generated. The KO mice weighed 40% less than their WT counterparts. Lymphoid 
organs (the thymus, spleen and lymph nodes) of the KO mice appeared to be of normal size, 
weight, cellularity, and lymphocyte subpopulations. Intriguingly, Armc5 KO T cells presented 
decreased proliferation and compromised differentiation towards Th1 and Th17 in vitro. The 
KO mice were resistant to experimental autoimmune encephalitis induction and were 
compromised in anti-LCMV immune responses. Using yeast 2-hybrid assay, we have 
identified 8 ARMC5-assciating proteins, which have known functions in cell cycling and 
apoptosis. Further mechanistic study is underway. Our results reveal that Armc5 is vital in the 
T cell activation/proliferation /differentiation program.  
Our studies have augmented our knowledge about EFNB1, EFNB2, STRA6 and ARMC5 in T 
cell biology and their relevance to immune disorders in animal models as well as in humans.  
 
Keywords: T cells, STRA6, EFNB1, EFNB2, ARMC5, rheumatoid arthritis, multiple 
sclerosis 
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PSA: Psoriatic arthritis  
PTB: Phosphotyrosine binding 
PTP-BL: Rrotein tyrosine phosphatase BAS-like 
RA: Rheumatoid arthritis  
RALDH: Retinal dehydrogenase 
RANK: Receptor activator of nuclear factor Κb  
RANKL: RANK ligand 
RAR: Retinol acid receptor 
RBD: Receptor-binding domain  
RF: Rheumatoid factor 
RRMS: Relapsing-remitting MS 
RTK: Receptor tyrosine kinases 
 RXR: Retinoid X receptors 
SCID: Severe combined immunodeficiency  
SF: Synovial fluid 
SH2: Src homology 2 
SLE: Systemic lupus erythematosus 
SM: Synovial membrane 
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STRA6: Stimulated by retinoic acid 6 
T1D: Type 1 diabetes 
T-bet: T-box transcription factor 
TCF: T cell-specific factor 
TEC: Thymic epithelial cell 
Tfh: T follicular helper  
TM: Transmembrane  
TMEV-IDD: Theiler’s murine encephalomyelitis virus-induced demyelinating disease  
TPC: Tumor-propagating cell 
Treg: Regulatory T cell 
VEGF: Vascular endothelial growth factor 
WT: Wild type 
βTrCP: β-transducin repeat containing protein 
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Liste des abréviations 
ARM: Armadillo 
PSO: Psoriasis 
 
  
 6 
Chapter 1 Introduction 
Autoimmune diseases are conditions with an inappropriate activation of the immune 
responses, which can cause diseases such as rheumatoid arthritis (RA) and multiple sclerosis 
(MS) (Davidson & Diamond, 2001). There are about 80 types of autoimmune diseases. 
According to Cooper et al., more than 3% of the US population suffers from one or more of 
these diseases. The incidence of diseases are higher in women than in men (Cooper & 
Stroehla, 2003). It is a chronic disease which makes it a contributor to decreased life quality 
for individuals and also increase the costs of the whole health care system. 
1.1 Risk factors for autoimmune diseases 
Earlier twin studies and familial studies proved that genetic factors are essential for the 
development of autoimmune diseases. More recent studies show that non-genetic factors, such 
as hormones, infections, and environmental factors, interact with the existing genetic factors to 
trigger a particular kind of autoimmune disease in individuals bearing certain genetic 
variations. 
1.1.1 A variety of genetic factors related to distinct signaling pathways are 
involved in the initiation of autoimmune diseases 
In the past decade, the extraordinary technical advances in this area have lead to the discovery 
of new factors that may contribute to human autoimmune diseases. For example, genome-wide 
association scans (GWAS) is a major approach to detect the relatively common (>1% or more) 
genetic variants, which is the dominant form of genetic variation for autoimmune diseases. 
These genetic changes also present in healthy populations. What’s more, the genetic 
associations found by GWAS turned out to be modest. The predisposition of autoimmune 
diseases represents the total effects of the genetic variations in different genes which influence 
the position and the strength of genetic signals and functions (Encinas & Kuchroo, 2000). 
Moreover, autoimmune diseases share a common set of susceptibility genes. For example, a 
variation within the human leukocytes antigen (HLA) is associated with almost every 
autoimmune disease. Copy number variations (CNV) and rare genetic variants are also present 
in the population. CNVs in genes like CCL3L1, FCGR3B, DEFB4, etc. have been linked to 
 7 
many types of autoimmune diseases. A rare variant in TREX1, which is a DNA exonuclease, is 
found to be associated with sporadic lupus. Current published data suggest a variety of genetic 
heterogeneities related to distinct signaling pathways are involved in the initiation of 
autoimmuny  
1.1.2 Infectious agents, sex hormones, smoking, and ultraviolet radiation 
play a role to initiate autoimmune diseases 
Environmental factors are also critical in the initiation of autoimmune diseases (Fagnani et al., 
2015). Components of pathogens bear the potential to evoke autoreactivity through molecular 
mimicry (Cusick, Libbey, & Fujinami, 2012), which is due to the antigens from some 
microbes that share epitopes with endogenous antigens. For instance, peptides from Epstein-
Barr virus can be presented to CD4+ T cells, which can also react with myelin basic protein 
(Wucherpfennig & Strominger, 1995). Moreover, infectious agents will lead to inflammation 
and lymphocytes activation, both of which lower the threshold of autoimmunity.   
Women, especially women in their fertile period are most often affected, indicating an 
essential part of sex hormones in disease onset and perpetuation (Cutolo et al., 2006). Estrogen 
exerts dose- and time-dependent effects on cell growth and apoptosis for B cells and synovial 
fibroblasts in RA (Kawasaki, Ushiyama, Inoue, & Hukuda, 2000). It also has influences on 
Th1/Th2 cytokines in RA (Janele et al., 2006). 
Smoking is related to SLE, RA, and myositis (Wahren-Herlenius & Dorner, 2013). It triggers 
inflammatory responses and sustains autoimmunity by the toll-like receptor pathways, 
autophagy, and apoptosis in the lung through reactive oxygen species.  
Ultraviolet radiation can trigger systemic autoimmunity via immune pathways or by induction 
of apoptosis in diseases like SLE and dermatomyositis. Self-antigen-exposure during 
apoptosis prolongs the contact with autoantigen-specific B cells, which will lead to 
autoimmunity in individuals with genetic defects (Wahren-Herlenius & Dorner, 2013). 
1.2 Mechanism of autoimmune diseases 
Our immune system is designed to have a low level of autoreactivity. Exaggerated immune 
responses result in tissue damages and autoimmune diseases. For decades, studies from animal 
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models and humans have led to a hint that immune cells and the molecules they produce vary 
in different stages of disease pathogenesis.   
1.2.1 Rheumatoid arthritis 
RA is a chronic autoimmune disease that involves the activation of immune response both 
systemically and locally. Joints are the dominant organ that are targeted in the inflammatory 
responses.  
1.2.1.1 ‘‘RA is the most common inflammatory joint disease’’ 
‘‘RA is the most common inflammatory joint disease’’ (Cooper & Stroehla, 2003). The annual 
incidence of RA has been estimated to be around 40 per 100, 000 (Cooper & Stroehla, 2003). 
The disease prevalence is about 0.9 percent of the Canadian population  (Canada, 2011). 
However, the prevalence varies between 0.1 percent (in rural Africans) and 5 percent (some 
populations in India, Australia, New Zealand and Netherlands), indicating the initiation of RA 
can be influenced by ethnic and/or environmental elements (Helmick et al., 2008; Peschken & 
Esdaile, 1999). While affects all age groups, more than one-half of new RA cases occur 
between ages of 40 and 75 years (Cooper & Stroehla, 2003). Females have two to three times’ 
higher prevalence rate than that of males. A decreasing trend has been observed in the US 
(Doran, Pond, Crowson, O'Fallon, & Gabriel, 2002), as well as in high-risk populations in 
Indians (Jacobsson et al., 1994). RA causes economic burden due to disability in the 
workforce and the cost of treatment, especially the cost of biologic agents in recent years 
(Michaud, Messer, Choi, & Wolfe, 2003). RA increases the mortality rate in patients, and this 
death rate has not changed since 1990. Whether this is due to an inflammatory pathology, or 
due to the exposure to anti-rheumatic drugs, or due to both, is unclear (Wolfe et al., 1994). 
1.2.1.2 Clinical manifestation of RA  
1.2.1.2.1 ‘‘The 2010 ACR/EULR classification criteria for RA’’  
RA is characterized by symmetrical synovitis involving multiple diarthrodial joints with extra-
articular manifestations. In 2010, the criteria for the classification of ‘‘RA were revised by the 
American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 
’’  (Aletaha et al., 2010). The 2010 criteria help to identify patients earlier and also helps to 
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identify those who may respond to ‘‘disease-modifying anti-rheumatic drugs (DMARDs)’’ 
(Aletaha et al., 2010). 
1.2.1.2.2 Chronic pain and swelling leading to bone damage in RA joints 
The disease onset of RA is usually insidious, with the observation of tenderness and subtle 
swelling of one or more joints in hands and wrists. Some patients with RA have a slowly 
progressive course with exacerbations, which usually takes over weeks to months. However, 
some patients have a waxing and waning course known as “palindromic rheumatism”, which 
may take several years before the chronic, persistent features of RA become evident. 
Typically, RA involves the ‘‘metacarpophalangeal joints and the proximal interphalangeal 
joints of the fingers, the interphalangeal joints of the thumbs, the metatarsophalangeal joints of 
the toes, the wrists, elbows, shoulders, hips, knees, and ankles’’ (Aletaha et al., 2010). RA 
patients commonly have stiffness, which usually presents in the morning (morning stiffness) 
or after long periods of inactivity. 
 
Seventy percent of patients with RA display radiographic evidence featured by ‘‘joint space 
narrowing and bone erosions’’ in small joints of hands and feet within few years after 
diagnosis. However, about 25% of patients with early RA may not develop erosive damage 
even after eight years of follow-up. The development of magnetic resonance imaging (MRI) is 
particularly useful for the measurement of the inflammatory process in the synovial membrane 
(McQueen, 2000). The use of ultrasonography enables the visualization of bone erosions, 
joints fluids, and synovial hypertrophy (Terslev et al., 2003). 
1.2.1.2.3 Systemic symptoms, elevated autoantibodies and acute phase proteins in RA patients 
Systemic symptoms, including fatigue, emaciation, low-grade fever, weakness, and depression 
often accompany the early signs of joint inflammation. Anemia of chronic inflammation, 
thrombocytosis, and sometimes mild leukocytosis are common hematologic abnormalities in 
active RA. The majority of RA patients have the positive test for rheumatoid factor (RF), anti-
citrullinated protein antibodies (ACPA), or both. Some of them are antinuclear antibodies 
positive. The acute phase proteins, including the erythrocytes sedimentation rate (ESR) and C-
reactive protein (CRP), are often elevated in patients with active RA. Significant correlations 
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are frequently observed between the degrees of elevation of these proteins and RA activity 
(Cylwik, Chrostek, Gindzienska-Sieskiewicz, Sierakowski, & Szmitkowski, 2010).     
1.2.1.2.4 Subcutaneous nodule formation, pleuropulmonary disease, and cardiovascular 
disorders are also found in RA patients 
Other systemic manifestations, including subcutaneous nodule formation, pleuropulmonary 
disease, and cardiovascular disorders are also found in RA patients. Rheumatoid nodules are 
the most frequently observed manifestation. Typically, subcutaneous nodules are hard and 
non-tender. These nodules vary in sizes, being associated with the present of serum 
rheumatoid factors, erosive joint destruction, necrotizing vasculitis and other ‘‘extra-articular 
manifestations of RA’’ (Vlak, 2003). The pleuropulmonary disease is a primary reason for the 
morbidity and mortality of RA. Interstitial lung disease, pleural thickening, and effusions are 
the most common pleuropulmonary manifestation of rheumatoid arthritis lung disease (Shaw, 
Collins, Ho, & Raghu, 2015). RA patients are more inclined to have myocardial infarction and 
stroke (Dhawan & Quyyumi, 2008). Rare manifestations, such as Felty’s syndrome which  
features with neutropenia and splenomegaly, were also reported. RA patients have a similar 
incidence of cancer than their healthy controls in general. However, RA patients have a higher 
incidence of lymphomas and lung cancer. Until now, how rheumatoid arthritis causes systemic 
illness remains obscure.     
1.2.1.3 Animal models of RA 
There are two major reasons for the extensive use of animal models in RA. Firstly, the 
mechanisms of RA, which can trigger articular disease onset and define chronicity of the local 
and systemic inflammation, remain obscure. Secondly, the rarely obtainable human tissues, 
such as synovial tissues, lymph node, bone marrow and spleen, hinds the research of finding 
out contributors to immune responses in human. Currently, numerous arthritis models 
including the induced- and spontaneous- models are developed (Asquith, Miller, McInnes, & 
Liew, 2009). Even though none of them can entirely mimic human RA, studies based on 
animal models have been proved to be helpful in understanding the potential mechanism and 
treatment of RA.  
 11 
1.2.1.3.1 CIA is ‘‘the gold standard animal model of human RA’’, while CAIA proves a role of 
humoral immunity in RA 
CIA is considered as ‘‘the gold standard animal model of human RA” (Brand, Latham, & 
Rosloniec, 2007). DBA/1 mice are the most popular strain for CIA model in research. These 
mice are susceptible to CIA because of their MHC class II haplotype (I-Aq). CIA bears 
similarity to human RA regarding the breach of tolerance, the role of lymphocytes in the 
initiation and persistence of the disease, and the histological findings in the arthritis joints. 
Studies reveal that mouse MHC Aq peptide binding part are conformationally similar to that of 
human HLA DR4 (DRB1*0401/DRA), which is the human MHC highly associated with RA 
(Holmdahl, Bockermann, Backlund, & Yamada, 2002). Also, the majority of collagen II-
specific T cells in both human and mouse recognizes a peptide from aa256-270 of the collagen 
II peptide. Moreover, CIA mouse shares local features with human RA regarding the 
infiltration of immune cells in the rheumatoid synovium, the synovial lining cell hyperplasia, 
and the secretion of inflammation mediators, which resulting in local joint damage. The 
detailed mechanism of lymphocytes in the development of CIA will be discussed in detail in 
the “Pathogenesis of RA” part. 
The biggest problem of the CIA model in DBA/1 background is its limited usefulness in 
genetically modified mice. This is due since most genetically modified mice are on the 
C57BL/6 background, which is not a CIA-susceptible strain. Studies showed that the use 
chicken collagen II and a boost with IFA (Incomplete Freund’s Adjuvant) overcome the 
resistant issue of C57BL/6 mice (Inglis, Simelyte, McCann, Criado, & Williams, 2008). After 
the refinement of the protocol, C57BL/6 mice share the basic pathological features with 
DBA/1 mice. However, they develop less severe CIA with later onset, lower incidence, and 
lower clinical scores. Also, intergroup inconsistency is observed in C57BL/6 mice, 
underscoring that precise, independent internal controls are necessary. 
The injection of antibodies against type II collagen leads to collagen-antibody-induced 
arthritis (CAIA) (Khachigian, 2006). The antibodies trigger similar clinic development of 
arthritis as that of CIA. CAIA model itself proves the importance of auto-antibodies in the 
development of joint damage. Other antigens are also reported to induce arthritis (Asquith et 
al., 2009; Maffia et al., 2004). Arthritis can also be caused by other factors related to the T 
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cell-dependent signalling pathway as that of CIA; others may trigger cell signaling pathways 
in other immune cells. For example, zymosan, a component of Saccharomyces cerevisiae can 
trigger TLR2 signaling in macrophages (Frasnelli, Tarussio, Chobaz-Peclat, Busso, & So, 
2005). 
1.2.1.3.2 Spontaneous arthritis models, including human “TNF-α transgenic mice, K/BxN 
mice, and SKG mice”, have similarities with human RA 
The spontaneous arthritis models are characterized by the development of chronic and 
progressive polyarthritis, which is similar to the human disease. These include “human TNF-α 
transgenic mice” (Li & Schwarz, 2003), “K/BxN mice” (Monach, Mathis, & Benoist, 2008) 
and “SKG mice” (Hata et al., 2004). In the human TNF-α transgenic arthritis model, treatment 
with anti-human TNF-α monoclonal antibody completely rescued mice from the disease. This 
model is particularly useful in exploring novel treatment targeting downstream signaling 
molecules of the TNF-α pathway. The K/BxN mice also develop spontaneous arthritis. The 
K/BxN mice express the TCR transgene “KRN, the MHC class II molecule Ag7”, as well as 
autoantibodies against “glucose-6-phosphate isomerase” in sera (Monach, Mathis, & Benoist, 
2008). This model provides a useful tool for investigating the innate immune systems in the 
initiation of arthritis. SKG model is caused by a point mutation of ZAP-70, which depends on 
environmental factors to induce inflammatory arthritis. Severe combined immunodeficiency 
(SCID) mice have also been used to exploit the underlying mechanism of RA by implanting 
them with human synovial tissues (Pierer et al., 2003). This model reveals the contribution of 
a local factor in cartilage destruction and bone erosion. It is also useful in identifying novel 
targets for the prevention of local damage in RA. 
 
1.2.1.4 Pathogenesis of RA 
1.2.1.4.1 Macrophages orchestrate in RA inflammatory responses 
Macrophages are a subpopulation of white blood cells, which function in infectious microbe 
clearance, normal tissue remodeling, wound repair and angiogenesis. The classically activated 
M1 and the alternatively activated M2 are activated macrophages with distinct functions (Sica 
& Mantovani, 2012). In normal synovial membrane, macrophages (type A synovial cells) are 
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not the predominant cell type. However, in rheumatoid condition, the macrophage number 
significantly increases (Maruotti, Cantatore, Crivellato, Vacca, & Ribatti, 2007).    
Macrophages play important roles in RA by phagocytosis. They differentiate into M1 
macrophages in response to LPS and secrete proinflammatory cytokines like IFN-γ and TNF-
α. These proinflammatory cytokines act as autocrine stimulator, as well as potent paracrine 
inducer of other inflammatory cytokines. For example, TNF-α can induce ‘‘IL-1, 6, 8 and 
granulocyte-macrophage-colony-stimulating factor (GM-CSF) in RA joints’’ (Butler, Maini, 
Feldmann, & Brennan, 1995; Haworth et al., 1991). It also induces matrix metalloproteinases 
(MMPs) in the synovium. MMPs are responsible for cartilage matrix destruction. Moreover, in 
the synovium, TNF-α induces NO production, which could promote synovial cells to produce 
TNF-α  (Chae et al., 1997; McInnes et al., 1996).    
Conversely, the activation of macrophages with IL-4 or IL-13 promotes the M2 phenotype, 
which suppressing destructive immunity, while promoting angiogenesis and matrix 
remodeling. Macrophages in rheumatoid arthritis synovium contribute to pathological 
angiogenesis by producing vascular endothelial growth factor (VEGF). Deletion of certain 
domain of VEGF receptor-1 in mice protects mice from a murine model of RA. This 
protection is due to the decrease of the phagocytosis and the secretion of IL-6 and VEGF-A 
(Murakami et al., 2006). Macrophages can also promote pathological angiogenesis through the 
release angiogenic chemokines and cytokines. The former includes  CXCL5 (Koch et al., 
1994),  while the latter includes ‘‘IL-8, IL-15, IL-17, et al.’’ (Koch et al., 1991; Pickens et al., 
2010). In contrast, antiangiogenic factors such as thrombospondin 2, are also produced (Park 
et al., 2004).  
1.2.1.4.2 ‘‘B cells play a role in RA pathogenesis through autoantibody production’’, antigen 
presentation and costimulation, neogenesis of lymphoid microstructures and cytokine 
secretion 
The discovery of autoantibodies in the 1950s’ (Holman & Deicher, 1959; Rose, Ragan, & et 
al., 1948) had brought the humoral autoimmunity into the center stage, which was followed by 
the identification of numerous autoantibodies as the diagnostic markers of autoimmunity. 
However, as plasmapheresis showed disappointing results, treatment strategies no longer 
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focused on this area. It was the unexpected success of anti-CD20 antibody treatment to deplete 
B cells that brought them back to the central of the stage in autoimmunity. 
Autoreactive B cells 
Numerous evidence showed that subtle alterations in B cell receptor (BCR) signaling 
pathways triggered by autoantigens can be the predisposing causes for autoantibody 
production in both mice and human beings (LeBien & Tedder, 2008). Also, any aberrant in B-
cell selection centrally in the bone marrow or peripherally in the lymphoid tissues during B 
cell development and/or disruption of the normal BCR somatic hypermutation during affinity 
maturation within the germinal center can lead to autoimmunity. An early break in B cell 
tolerance is proposed as different studies proved the presence of autoantibodies in the patients’ 
serum many years before the presence of any clinical symptoms. However, the exact role of 
autoantibodies in RA remains elusive.  
Diverse functions of B cells in autoimmune diseases 
1. Autoantibody production 
Autoantibody production is a characteristic feature in most autoimmune diseases. Some 
autobodies have remarkable specificity and can be used as biomarkers for disease diagnosis 
and indicators of therapeutic interventions. Autoantibodies are usually high-affinity, 
somatically mutated IgG, which might lead to pathogenic consequences. Autoantibodies exert 
their function through direct binding or forming immune complexes. The former usually 
happens in organ-specific autoimmune diseases, like myasthenia gravis, where they directly 
damage the target organ. The latter often occurs in systemic autoimmune diseases, where 
tissue injury is caused by immune complex composed of autoantibodies conjugated with free 
molecules, cell surface antigens, and nucleoprotein antigens.  
Autoantibodies may also cause damage through the engagement of complement and/or Fc 
receptor (FcR) effector pathways. In the K/BxN mouse model, the administration of 
autoantibodies activates the alternative complement pathway. This activation attracts 
neutrophils, leading to the accumulation of proteolytic enzymes and cytokines in the 
inflammatory joints (Monach, Benoist, & Mathis, 2004; Wipke, Wang, Nagengast, Reichert, 
& Allen, 2004).  
It is still elusive to define the role of autoantibodies in the initiation of autoimmune diseases 
like RA. Autoantibodies alone are unable to initiate autoimmune diseases in multiple mice 
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models. Some of them are even proven to have protective functions (Shoenfeld & Toubi, 
2005). What’s more, autoantibodies themselves are often not pathological. The co-existing 
secondary triggers of autoantibodies, such as infectious agents, will lead to a vicious chronic 
state of inflammation (McClain et al., 2005).  
2. Antigen presentation and costimulation  
Besides antibody production, B cells can also promote disease development by presenting 
antigens to T cells. B cells are required to start autoimmune diseases in mice model for 
arthritis, lupus, diabetes, etc. (Chan, Hannum, Haberman, Madaio, & Shlomchik, 1999; 
O'Neill et al., 2005; Wong et al., 2004). However, their antibody-secreting capabilities are not 
required that early. B cells capture antigen through their B-cell receptors, which is over 1,000-
fold more efficient than other APCs. Therefore, B cells can present antigens at extraordinarily 
low concentrations and also focus the immune response to a specific antigen in certain 
autoimmune diseases (Rivera, Chen, Ron, Dougherty, & Ron, 2001). What’s more, B cell may 
have specific roles in providing costimulatory signals to antigen-specific T cells. In 
NZB/NZW mice, a spontaneous lupus model, elevated expression of costimulatory molecules 
are found in B cells from spleen (Wither, Roy, & Brennan, 2000).  
3. Neogenesis of lymphoid microstructures 
Neogenesis of lymphoid microstructures is found ectopically in multiple chronic 
inflammations. The size and organization of these neogenesis lymphoid structures vary 
depending on the context. These structures have been described in SLE, T1D, Sjögren’s 
syndrome, MS and RA (Aloisi & Pujol-Borrell, 2006; Drayton, Liao, Mounzer, & Ruddle, 
2006). The exact function of these structures remains unknown. However, the locally 
generated plasma cells are found to secrete autoantibodies (Salomonsson et al., 2003), 
suggesting their potential role in the maintenance of autoimmunity.  
4. Cytokine secretion 
Activated B cells ‘‘produce multiple cytokines, including IL-6, IFN-γ, lymphotoxin-α, TGF-β, 
IL-4, and IL-10’’ (Duddy, Alter, & Bar-Or, 2004; Harris et al., 2000; Lund, Garvy, Randall, & 
Harris, 2005). B cell-derived cytokines play pathologic roles in regulating functions of  
multiple cells, such as macrophages, dendritic cells and T cells. In addition, signals from these 
cells can activate B cells in turn, creating a feedback loop  They also play protective roles in 
immune responses to autoantigens, as in the case of IL-10, which will be described below. 
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5. Regulatory B cells 
Regulatory B cells (Bregs)  (Mizoguchi & Bhan, 2006) are B cells that can produce anti-
inflammatory cytokines like IL-10, TGF-β. Bregs can be found in a variety of B-cell subsets 
and participate in the pathogenesis of autoimmune diseases, including SLE (Lenert, Brummel, 
Field, & Ashman, 2005), RA (Mauri, Gray, Mushtaq, & Londei, 2003), and MS (Matsushita, 
Yanaba, Bouaziz, Fujimoto, & Tedder, 2008). The regulatory properties of B cells in 
autoimmune diseases were originally reported in B10.PL mice. These mice are lack of B cells 
and are unable to recover from EAE as compared to their healthy counterparts (Wolf, Dittel, 
Hardardottir, & Janeway, 1996).   
Like it is in Tregs, the IL-10 secreted by B cells also (Fillatreau, Sweenie, McGeachy, Gray, & 
Anderton, 2002) suppresses Th1 polarization and inhibits macrophage functions. B cells can 
regulate the T cell co-stimulation pathways by direct cell-cell contacts with CD40 and B7.  
Autoantibodies in RA 
The autoantibodies found in RA patients target quite diverse molecules, including ‘‘cartilage 
components, chaperons, enzymes, nuclear proteins and citrullinated proteins’’ (Song & Kang, 
2010). In recent years, new technologies, like protein arrays, have been used to detect RA-
associated autoantibodies with better specificity and sensitivity (Hansson et al., 2012; W. H. 
Robinson, Steinman, & Utz, 2003). However, only two of them are used in clinical practice 
currently.  
1. Rheumatoid factor  
RFs are autoantibodies that are against the Fc region of IgG. The IgM isotype is the primary 
type that exists in the sera of RA patients (Nell et al., 2005). RFs can be detected physically in 
ordinary old people, but also in other diseases like Sjögren’s syndrome, SLE. When the titer 
goes higher than 50IU/ml (RF50), it is quite specific for RA (Song & Kang, 2010). High titer 
IgM RF status is associated with poor disease prognosis. Notably, the co-presence of high titer 
IgM RF and IgA isotype usually indicate erosive RA (Jonsson et al., 1998; Scott, 2000).  
Furthermore, higher RF does not occur in experimental models of RA. Up to now, the role of 
RF in RA is still not entirely clear. 
2. Anti-citrullinated protein antibodies (ACPAs)  
The identification of ACPAs is one of the most meaningful event in RA diagnostic marker 
studies. Comparing with RF, it has a better diagnostic value regarding specificity and 
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sensitivity. ACPAs are referred to antibodies against ‘‘perinuclear factor, keratin, filaggrin and 
cyclic citrullinated peptide (CCP)’’ (Song & Kang, 2010).  Citrulline is the common epitope 
of these antibodies, which can be generated post-translationally from arginine (Schellekens, de 
Jong, van den Hoogen, van de Putte, & van Venrooij, 2015). The ACPAs can be found in 70-
90% of RA patients, with a specificity of 96% (Suzuki et al., 2003). They are highly specific 
for RA. As IgM RF, they are indicators of worse outcome in RA (Im et al., 2009; Kroot et al., 
2000). Of all the ACPAs, anti-CCP is the most wildly used one in clinical diagnosis.   
1.2.1.4.3 T cells are critical  for disease onset and to sustain of RA 
Role of T cell activation and tolerance in RA 
T cell activation is essential for the onset and maintenance of RA. To fully activate T cells, the 
signaling transduce through both TCR complex and the co-stimulators are needed. The former 
is identified as signal 1. It is stimulated when the major histocompatibility complex (MHC) 
with antigen peptide (pMHC) binds to TCR. The latter is called signal 2. It is stimulated when 
B7-1 and B7-2 on antigen presenting cells conjugate to CD28 on T cell surface (Figure 1.1). 
The engagement of signal 1 leads to TCR aggregation, which enables closer pMHC/TCR 
contact. TCR aggregation and activation of signal 2 will then initiate the phosphorylation and 
the activation of a variety of molecules, resulting in the signaling transduction through 
PI3K/AKT/mTOR pathway, MAPK/Erk pathway, PKCθ pathway, and Ca2+-mediated 
signaling pathways (Smith-Garvin, Koretzky, & Jordan, 2009). These signaling pathways are 
regulated by a variety of molecules at multiple levels in response to particular environment 
stimulation.  Abnormal T cell activation involves both breakdowns of T cell tolerance and 
aberrant T cell response, leading to the autoimmune disease state. 
CD4+ T helper cells control both the cell-mediated and humoral immune responses, which 
makes it the most important subpopulation of T cells in immune tolerance. T cell tolerance 
may occur during their maturation in the thymus (central tolerance) or occur in peripheral 
when they meet antigens (peripheral tolerance) (Xing & Hogquist, 2012). In central tolerance, 
the majority of immature T cells that recognize self-antigens with high avidity are deleted, 
while some of them differentiate into regulatory T cells (Tregs). In the past decades, the 
underlying mechanism of central tolerance has been well studied in animal models. However, 
it is still not known about how much it contributes to a human autoimmune disease. The 
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peripheral tolerance mechanism is another important aspect for T cell tolerance. Prolonged 
TCR activation may result in anergy. Defects and/or lack of the co-stimulation will contribute 
to peripheral tolerance. Moreover, the activation of death signal and the dysfunction of Tregs 
may also lead to the breakdown of peripheral tolerance. 
Role of co-stimulation (signal 2) in T cell activation 
As shown in Fig 1.1, signal 2 (co-stimulatory) is an essential part of T cell activation. The 
B7.1/B7.2 expressed on APCs conjugate both CD28 and (or) CTLA4 on T cells, depending on 
the cell type and context. The interaction of B7.1/B7.2 and CD28 promotes T cell activation, 
as well as T cell differentiation. In contrast, their interaction with CTLA-4 will lead to the 
suppression of T cell activation. The binding capacity of CTLA-4 with B7.1/B7.2 is much 
higher than that of CD28, making it efficient in regulating T cell activation signaling (Greene 
et al., 1996; Peach et al., 1994). CTLA-4-Ig (Abatacept) is approved by FDA for the treatment 
of RA (Kremer et al., 2005). It is a protein fuse with ‘‘the extracellular binding domain of 
CTLA-4 and the Fc region of IgG’’ (Kremer et al., 2005). Thus, abatacept is highly 
efficacious in treating RA, leading to well-improved physical function. It significantly reduces 
the progression of structural damage in patients with established RA (Provan et al., 2015; N. 
Takahashi et al., 2015). A combination of methotrexate (MTX) and abatacept can deliver 
significant clinical benefits and radiographic improvement (T. Hirota et al., 2015; Mochizuki 
et al., 2015). Abatacept is currently prescribed to patients with RA unresponsive to regular 
doses of existing DMARDs. 
 Later studies proved that many co-stimulation and co-inhibition molecules are involved in T 
cell regulation, such as ‘‘ICOS, PD1, OX40 (also known as CD134, TNFRSF4) et al.’’ (L. 
Chen & Flies, 2013). 
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Figure 1.1 T cell activation 
Role of CD4+ T cell differentiation in RA 
The etiology of autoimmune diseases has not been fully investigated up till now, however, 
accumulating evidence proves that CD4+ T cells is essential for the development and maintain 
of both systemic and local inflammation. Studies show that about one-third of cells infiltrated 
into the inflammatory joint are T cells. Naive CD4+ T cells will be driven into different 
subsets, named Th1, Th17, and Tregs, depending on the cytokine environments (signal 3) 
(Figure 1.1). Activated T cells can infiltrate into the inflammatory sites. These effector T cells 
will secrete molecules, such as chemokines and cytokines, which will further recruit other 
inflammatory cells and enhance local inflammation. 
1. Th1 & Th17 cells are the principal players in the pathogenesis of RA 
TCR activation and cytokine IL-12 will drive naive CD4+ T cells into IFN- γ-secreting Th1 
subpopulation. T-box transcription factor (T-bet) is the master regulator that promotes Th1 
differentiation. T-bet can also suppress the development of opposing cell lineages like Th2 and 
Th17. Th1 subpopulation mainly functions as the pro-inflammatory factor, while Th2 
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basically works as the anti-inflammatory factor. Studies showed that early administration of a 
monoclonal antibody against IFN-γ could protect mice from CIA (Boissier et al., 1995). The 
frequency of Th1 cells with citrulline-specific epitopes are increased in rheumatoid arthritis, 
and this is influenced by therapy and disease activity (James et al., 2014). In the past, the 
balance of Th1/Th2 was once thought to be critical in the pathogenesis of autoimmune disease 
including RA. In 2005, the recognition of Th17 subpopulation refreshed this notion (described 
in detail in the MS part) (Cua et al., 2003). 
Th17 is a subpopulation of T helper cells, which secrete IL-17A, IL-17F, and IL-22. RORγt is 
the master transcription factor of Treg. Cytokines like TGF-β and IL-6 drive naive CD4+ T 
cells differentiation into Th17 subpopulation, while IL-23 promotes Th17 cells expansion. 
Fossiez and colleagues reported the first evidence of the involvement of Th17 in RA. They 
showed that IL-17 is capable of stimulating synovial fibroblast in vitro from RA patients.  
(Fossiez et al., 1996). Emerging reports coming from animal models show that less severe 
arthritis is found in genetically modified mice of Th17-related cytokines and transcription 
factors, including ‘‘IL-17 knockout mice, IL-23 p19 subunit knockout mice, and STAT4 
knockout mice’’ (Langrish et al., 2005; Hildner et al., 2007). 
Th17 cells are the primary T cell subpopulation in the pathogenesis of RA. The receptor of IL-
17 is found to be expressed in cells from the immune system (monocytes and macrophages), 
as well as cells in the RA joint (fibroblasts and osteoblasts), which are essential for RA 
inflammation. First of all, Th17 cells exert their function through IL-17, which is able to 
generate other pro-inflammatory cytokines once the IL-17 receptors are activated. Secondly, 
these pro-inflammatory cytokines will further enhance the Th17 function in turn, which might 
trigger autoimmunity in genetic sensitive individuals. Thirdly, IL-17 can synergize with other 
proinflammation mediators, like TNF-α and IL-1β in RA. Particularly, IL-17 promotes 
germinal center (GC) formation in the K/BxN model (H. J. Wu et al., 2010). Recently, it was 
reported that Toll-like receptors expressed by synovial fibroblasts could induce IL-17 
production (F. Hu et al., 2014). 
Besides cytokines, Th17 also triggers chemokines production, which is critical for the 
recruitment of other inflammatory cells to the inflamed joint. This recruitment will lead to the 
local inflammatory cascade. Particularly, Th17 subset with the expression of CCR6+ will be 
recruited to the inflammatory site in response to the CCL-20 produced by synovial fibroblasts. 
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What makes it more interesting is the treatment against CCR6 in Th17 has proved to be 
effective. More over, IL-17 can also upregulate enzymes, small molecules, and cell surface 
receptors in cells such as synovial fibroblasts, causing bone and cartilage damage (Nakashima 
et al., 2011). 
2. Tregs play a regulatory role in RA 
Tregs, either natural or inducible, are subsets of T cells which play regulatory roles in immune 
inflammatory processes. Nature Tregs (nTregs) express CD25 (IL-2Rα) on the cell surface 
and FoxP3 in the cell nucleus. nTregs are developed in the thymus during the positive 
selection stage with a higher than the normal affinity for self-antigens. Inducible Tregs 
(iTregs) are generated out of thymus. IL-10 and TGF-β are two major cytokines which can 
drive naive CD4+ T cells to iTregs. Self-antigen-specific nTregs are the major subset of T cells 
that is critical for the maintenance of self-tolerance and the prevention of autoimmune 
diseases. iTregs, on the other hand, are a key subset of T cells in fighting against foreign 
pathogens.  
CD25 and FoxP3 are cell surface markers for Tregs. However, recent studies showed that both 
CD25 and FoxP3 could also be found in newly activated human effector CD4+ T cells. The IL-
7 receptor α chain (CD127) is found to be inversely correlated with nTreg status (Liu et al., 
2006). Thus, the combination marker CD4+CD25+FoxP3+CD127low is widely used to identify 
human nTregs. Fletcher and colleagues reported that CD39+FoxP3+ T cells also have the 
suppressive effect (Schuler, Harasymczuk, Schilling, Lang, & Whiteside, 2011). Further 
potential surface markers for the assessment of nTregs are ‘‘CTLA-4, GITR, CD73, and 
LAP’’ (T. Takahashi et al., 2000; McHugh et al., 2002; Deaglio et al., 2007; M. L. Chen, Yan, 
Bando, Kuchroo, & Weiner, 2008).  
In autoimmune diseases, regulatory T cells not only offer a new perspective of self-tolerance 
establishment and maintenance, but also actually engaging in systemic and local 
inflammation, memory and resolution. Autoimmunity with immune dysregulation, 
polyendocrinopathy, enteropathy X-linked syndrome (IPEX) in children links to several 
mutations of Foxp3 gene (Bennett et al., 2001), while in mice mutation or depletion of the 
Foxp3 gene resulted in fatal autoimmune diseases (Brunkow et al., 2001). Data about the 
frequency of Tregs in RA are contradictory, especially in the peripheral blood (PB) (Kawashiri 
et al., 2011; van Amelsfort, Jacobs, Bijlsma, Lafeber, & Taams, 2004). Accumulating 
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evidence indicates the enrichment of Treg population in the synovial fluid (SF) and synovial 
membrane (SM) (Jiao et al., 2007; Moradi et al., 2014). The transfer of CD4+Foxp3+ Treg cells 
reduces the severity of CIA when it is done prior to collagen immunization (Wright et al., 
2009). The administration of monoclonal antibody specific for CD25 targeting CD4+CD25+ 
Tregs on collagen-induced arthritis (CIA) worsens the disease (Morgan et al., 2003). Some 
studies showed that Tregs from RA patients, especially Tregs from PB, have impaired 
suppressive function (Ehrenstein et al., 2004). 
Tregs are capable of inhibiting other proinflammatory cell function in both contact-
independent and contact-dependent manner. IL-10 impairs the ability of dendritic cells to 
promote Th1 differentiation and suppress the production of IL-12 by Th1 cells (Rubtsov et al., 
2008). Blockade of TGF-β expression on Tregs with neutralizing antibodies resulted in the 
abolishment of Treg suppression (Nakamura, Kitani, & Strober, 2001). The contact-dependent 
inhibition involves the cell surface receptors on Tregs. Receptors like CTLA-4, GITR, and 
OX40 could trigger the suppressive effects of Tregs. CTLA-4 gene polymorphisms have been 
reported to be correlated with RA (Daha et al., 2009; Lei et al., 2005). Tregs from RA patients 
showed a less CTLA-4 expression, as well as a reduced function compared to healthy Tregs 
(Walker et al., 2009). Furthermore, signaling pathways triggered by CTLA-4 can regulate the 
balance between the anti- and pro-inflammatory cytokines, resulting in the inhibition effect 
(Kormendy et al., 2013). The third mechanism is that Tregs can deplete IL-2 through CD25, 
which is also known as the IL-2 receptor. With the high expression of CD25, Tregs will 
deprive IL-2, which is necessary for other effector CD4+ T cells. Effector  CD4+ T cells will 
undergo apoptosis because of this deprivation (Pandiyan, Zheng, Ishihara, Reed, & Lenardo, 
2007). Lastly, Tregs can execute target cells by making its own granzyme A and perforin (Cao 
et al., 2007) or releasing metabolites like adenosine to exert their immunosuppressive 
functions (Ohta & Sitkovsky, 2014).  
3. Tfh cells are crucial for T-cell helped function in RA 
T follicular helper (Tfh) cells are characterized by the expression of CXCR5 on CD4+ T cells. 
Bcl-6 is the signature transcription factor, and IL-21 is the signature cytokine. ‘‘PD-1, ICOS, 
CD40 ligand (CD40L)’’ (Ueno, Banchereau, & Vinuesa, 2015) et al. are their surface markers, 
which usually apply in combination with CXCR5. Tfh cells are essential for T-cell helped 
function, including B cell maturation and antibody production in germinal centers.  
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Tfh cells play important roles in the inflammatory responses of RA. Elevated circulating Tfh 
and IL-21 are found in patients with RA, and they are correlated with disease activity (Arroyo-
Villa et al., 2014; Y. Zhang, Li, Lv, Yin, & Wang, 2015). Tfh cells could also be found in 
rheumatoid synovium tissues from RA patients, but are absent in OA synovium (Chu, Wang, 
Zhou, Chen, & Lu, 2014). In RA synovium and synovial fluid, enrichment of PD-1+ T cells is 
found, reflecting the existence of negative feedback at the inflammatory sites (Raptopoulou et 
al., 2010). Several strategies targeting Tfh-related molecules and cytokines showed impressive 
therapeutic effects, opening new venues for possible immune regulatory therapy in RA (Jang 
et al., 2009; Odegard et al., 2008).  
4. CD8+ cells are predominantly proinflammatory T cells in RA 
Earlier studies of CD8+ T cell functions in RA yield conflicting results, causing the research in 
this cell type became almost complete oblivion (Carvalheiro, da Silva, & Souto-Carneiro, 
2013). However, recently, more and more evidence support that CD8+ T cells present in the 
inflammatory joint mainly contribute to the chronic inflammation locally (Fekete et al., 2007; 
Maldonado et al., 2003; Masuko-Hongo et al., 1997; Wagner et al., 1998). CD8+ T cells 
promote the local inflammation not only through their secretion of proinflammatory cytokines, 
but also kill the target cells by their lytic enzymes. It is also approved that CD8+ T cells can 
exert their suppressive role in an IL-10 dependent manner in RA (Carvalheiro et al., 2013).   
1.2.2 Multiple sclerosis 
1.2.2.1 MS is the second cause of disability in young adults 
About 350,000 people suffer from MS in US, and this number is 2.5 million worldwide. MS 
affects adults of 20-40 years old. It is the second cause of disability in young people. The 
incidence of MS in women is about twice higher than that of men. Epidemic studies showed 
that MS has a familial distribution pattern (Weinshenker, 1996). It is also reported that 
monozygotic twins got higher chance to have MS than the dizygotic twins (Hansen et al., 
2005). The prevalence rates of MS have been reported to be high in northern parts of Europe 
and North America (5-30 per 100,000), but low in Asia and South America (<5 per 100,000) 
(Pugliatti et al., 2006). Some reports show that the epidemic pattern of MS can be changed due 
to migration. In the majority of the case, MS does not influence longevity. However, due to 
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the long duration of disease, the loss of productivity, the need for assistance in activities of 
daily life and the use of immunomodulatory treatments, MS is a heavy socioeconomic burden 
(Sospedra & Martin, 2005). 
1.2.2.2 Clinical manifestation of MS  
1.2.2.2.1 Symptoms of MS 
The clinical features of MS are highly variable, but an attack (relapse or exacerbation) of 
neurologic dysfunction heralds the onset of the disease in approximately 90% of patients. 
Common symptoms of an MS attack include optic neuritis, long tract symptoms/signs (e.g., 
numbness, paresthesia, or weakness), a brainstem syndrome (e.g., internuclear 
ophthalmoplegia), or a spinal cord syndrome (e.g., transverse myelitis). Symptoms due to 
cortical syndromes such as aphasia or visual field disturbances are less common. Symptoms of 
MS range from mild to severe, depending on lesion locations and the extent of tissue 
destruction. 
1.2.2.2.2 Relapsing-remitting with chronic, persistent progression is the most common clinical 
pattern of MS 
Relapsing-remitting with chronic, persistent progression is the most common clinical pattern 
of MS. Eighty-five to ninety percent of patients initially present with relapsing-remitting MS 
(RRMS) (Nylander & Hafler, 2012). The first attack typically occurs acutely. The duration for 
each attack lasts from days to weeks. Recovery from each attack in the early course of the 
disease is often virtually complete. Most RRMS will become secondary-progressive MS 
(SPMS), which is featured by the progressive accumulation of disability. RRMS may relate to 
myelin-reactive T cells, which will migrate into the CNS resulted in acute inflammation, while 
SPMS may be caused by progressive chronic CNS inflammation.  
Approximately 10% of patients have primary-progressive MS (PPMS). In this form of disease, 
patients usually present spinal syndrome, a spastic paraparesis usually with no apparent effect 
on sensory level. The time course of the disease is commonly found to be associated with the 
progressive deterioration of neurologic function. Plateaus and slight fluctuations may occur 
occasionally, but no relapses (Rice, Cottrell, Wilkins, & Scolding, 2013). 
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1.2.2.2.3 McDonald criteria 2010 for the diagnosis of MS  
From its first historical depictions, MS has always been described and diagnosed by its clinical 
semiology, as no specific laboratory test is available for the disease. Currently, the use of 
McDonald criteria 2010 has allowed for earlier diagnosis of MS with higher specificity and 
sensitivity, making it possible for the earlier treatment and better counseling of patients 
(Polman et al., 2011). MRI provides a non-invasive support for diagnosis and monitors the 
prognosis of MS (Traboulsee & Li, 2006). Oligoclonal IgG in CSF helps in diagnosis of MS in 
the appropriate clinical context (Rojas, Patrucco, Tizio, & Cristiano, 2012). 
1.2.2.3 Animal models of MS 
Animal models have been critical for addressing MS pathogenesis due to the rarity of diseased 
human tissues. Even though each animal model has its drawbacks, they did contribute to our 
understanding of MS, as well as to the exploration of the new treatment for MS in the past 
decades. The representative models are described below (Ransohoff, 2012).  
1.2.2.3.1 Both EAE and TMEV-IDD are immune-models for human MS, with the former 
mainly induces CD4+ T cell responses  
EAE model shares many similarities with human MS, including breach of tolerance, and many 
of the pathological changes observed in the CNS lesions (Croxford, Kurschus, & Waisman, 
2011; A. P. Robinson, Harp, Noronha, & Miller, 2014). The generation of autoreactive T cells 
against self-antigen specific for myelin proteins is the initial step in the pathogenesis of both 
EAE and MS. Then, these cells will migrate to the central nerves system to trigger the 
immune-inflammatory responses locally. This will lead to the accumulation of other immune 
cells, the release of inflammatory mediators, and finally demyelination or even axonal loss in 
both EAE and MS lesions. EAE also creates the opportunity to investigate the role of Th1 and 
Th17 effector CD4+ T cells in the development of MS (see in the “Adaptor immune system in 
MS” part).  
Mice EAE model and human MS share common pathologic features, including infiltrating T 
cells and other inflammatory cells in the CNS and the demyelination. C57BL/6 background 
mice are the most popular strain for this model (Tse et al., 2012). Ascending paralysis 
typically starts from the hind limps, which is related to the pathologic changes in the axon. 
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Moreover, adoptive transfer of Th1 and Th17 cells from immunized donors can directly 
induce effector phase of EAE. However, relapse rarely happens in EAE model (Ransohoff, 
2012). Thus, it can’t be used in studying remyelination, which often happens in MS patients. 
Moreover, due to the strong inflammatory responses after EAE induction, the predictive value 
for treatment efficacy of this model is limited (Ransohoff, Howe, & Rodriguez, 2002). Lastly, 
EAE induction mainly induces CD4+ T cell responses, which is not ideal for CD8+ T cell 
responses and B cell functions in MS pathogenesis.  
The TMEV-IDD model, which is short for Theiler’s murine encephalomyelitis virus-induced 
demyelinating disease, also features with immune-mediated demyelination. Mononuclear cell 
infiltration and PLP131-151-specific CD4+ Th1 cells are found early in TMEV-IDD CNS lesions 
(Katz-Levy et al., 2000). Autoantibodies against other myelin antigens appear in serum with 
the progress of the disease. Inflammation and demyelination similar to that in MS are found. 
However, unlike MS, virus infections are continually found in the CNS during the persistence 
of TMEV-IDD (Miller et al., 1997).  
1.2.2.3.2 Administration of toxins enables the study of remyelination, and some spontaneous 
EAE models are explored  
Administration of toxins, such as cuprizone, enables the study of remyelination. The copper 
chelator, cuprizone, is fed to mice in chow for 4-6 weeks to induce demyelination 
(Matsushima & Morell, 2001). Cuprizone lead to the apoptosis of oligodendrocytes, which 
results in the demyelination of axons. In this model, remyelination occurs once cuprizone is 
discontinued, making it an ideal model for study the underlying mechanism of 
oligodendrocyte death and remyelination. 
Myelin-specific peptide TCR transgenic mice are generated as a spontaneous demyelination 
model of EAE (Bettelli et al., 2003; Waldner, Whitters, Sobel, Collins, & Kuchroo, 2000). 
Approaches to induce selective expression of suicide gene expression in oligodendrocyte 
(Pohl et al., 2011; Traka et al., 2010) are also explored. These approaches are relative novel, 
the application of which might bring unique insights into the pathogenesis of MS. 
1.2.2.4 Innate immune system in MS 
1.2.2.4.1 Viral infections can be the trigger of MS 
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Viral infections, like human herpesvirus 6 (HHV-6), Epstein-Barr virus (EBV), human 
herpesvirus 1 (HSV-1), et al., have been considered as environmental triggers of MS. This fact 
indicates the involvement of innate immune mechanisms in MS.   
1.2.2.4.1 γδ T cells undergo massive expansion, produce cytokines, chemokines, and cytokine 
receptors in the CNS 
γδ T cells are important in the autoimmune inflammation of the CNS. γδ T cells are found in 
the CSF and CNS inflammatory lesions of both MS patients and EAE model (Battistini et al., 
1995; Wohler, Smith, Zinn, Bullard, & Barnum, 2009). In EAE model, γδ T cells are found to 
have the ability to migrate into the local lesions in the CNS. These cells undergo massive 
expansion there, and then quickly leave the CNS (Wohler et al., 2009). γδ T cells secrete 
cytokines, chemokines (Murzenok, Matusevicius, & Freedman, 2002; Rajan, Klein, & 
Brosnan, 1998). Recently, γδ T cells are found to be the primary source of IL-17 in 
demyelinating diseases (Blink & Miller, 2009). γδ T cells can also directly mediate cytotoxic 
responses to kill primary human oligodendrocytes (Saikali et al., 2007). Also, γδ T-cell 
knockout mice have attenuated EAE (Spahn, Issazadah, Salvin, & Weiner, 1999). Even 
though studies using anti-γδ T cell antibodies show controversial results, most of these studies 
show attenuated EAE severity (Dandekar & Perlman, 2002; Rajan, Gao, Raine, & Brosnan, 
1996). What’s more, features like restricted TCR usage and tissue-specific location make γδ T 
cells a therapeutic advantage in targeting T cell subpopulation for MS. 
1.2.2.5 Adaptor immune system in MS 
1.2.2.5.1 Role of B cells in MS 
For decades, T cells had been regarded as the major contributor in MS pathogenesis. However, 
recent studies suggested that this point of view is overly simplistic. Numerous researchers 
reported the presence of B cells and autoantibodies in the CNS of MS patients, indicating the 
potential role of B cells in the propagation of MS (Cepok et al., 2005; von Budingen, Harrer, 
Kuenzle, Meier, & Goebels, 2008; M. J. Walsh & Tourtellotte, 1986).  
Generally, the effector mechanisms of B cells and autoantibodies are similar to those in RA, 
which were described in detail previously. The most important point about B cells and 
autoantibodies is the oligoclonal IgG bands (OCBs) in CNS. Interestingly, it does not exist in 
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serum, indicating the production of IgG might occur in the CNS inflammatory lesion (Kabat, 
Freedman, & et al., 1950). Moreover, the exhibition of OCBs in CSF correlates with the 
clinical and MRI findings, making it helpful in the MS diagnosis (Disanto, Morahan, Barnett, 
Giovannoni, & Ramagopalan, 2012).  
Autoantibodies against the components of myelin, including proteolipid protein (PLP), myelin 
basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), are important in the 
pathogenesis of MS. Antibodies against these proteins are found in both human MS and in 
animal models. In CSF and (or) serum of MS, these antibodies can be found. However, none 
of them are sensitive or specific enough as diagnostic markers of disease activity (Egg, Reindl, 
Deisenhammer, Linington, & Berger, 2001; Reindl et al., 1999; Sellebjerg, Christiansen, & 
Garred, 1998). 
1.2.2.5.2 T cells are the major population in the pathogenesis of MS 
Like they are in RA, T cells are the driving force in the pathogenesis of MS. Therefore, the 
mechanisms involving T cell activation, co-stimulation and tolerance also apply to the 
pathogenesis of MS. For this part, I will highlight on different T helper subtypes in the 
pathogenesis of MS.  
Th1 and Th17 are the main effector T cells responsible for the pathogenesis of MS 
Before the discovery of Th17 cells, Th1 cells were considered as the major driving force for 
the pathogenesis of MS. Earlier studies show that IL-12 is increased in MS lesions 
(Windhagen et al., 1995). Further ex vivo studies show that the T cells from MS patients have 
the ability to produce more Th1 cytokines, such as IL-12 and IFN-γ (Balashov, Smith, 
Khoury, Hafler, & Weiner, 1997). The knockout of Th1 master transcription factor, T-bet, 
leads to less severe EAE in mice (Bettelli et al., 2004). Also, glatiramer acetate directly kills 
Th1 cells in the treatment of MS (Racke & Lovett-Racke, 2011; Ziemssen & Schrempf, 2007). 
What’s more, treatment of MS patients with the recombinant IFN-γ results in exacerbation of 
disease (Panitch, Hirsch, Haley, & Johnson, 1987). However, knockout of IFN-γ in mice is 
found to develop more severe EAE (Ferber et al., 1996).  
The Th17 subset was initially recognized through the studies of EAE mice. In this study, Cua 
et al. proved that IL-23, but not IL-12, is the critical cytokine for EAE (Cua et al., 2003). After 
that, extensive study on IL-23 and Th17 in MS and other autoimmune diseases started.    
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Like Th1 cells, IL-17 expressing Th17 cells can be detected in MS brain lesions. Moreover, in 
MS patients, the association of IL-17+ population in the peripheral blood with disease activity 
are also confirmed (Durelli et al., 2009; Lock et al., 2002). What’s more, in vitro induced PLP-
specific Th17 cells are capable of inducing EAE after passive transplantation (Langrish et al., 
2005). Furthermore, neutralization of IL-17 by anti-IL-17 antibody and IL-17-receptor-Fc-
protein protects mice from EAE (Hofstetter et al., 2005; Langrish et al., 2005). Also, IL-17 
can mediate BBB breakdown by activating neutrophils to secrete MMP-3 and proteases, 
which directly participate in BBB disruption (Yong, Power, Forsyth, & Edwards, 2001). “IL-
17 can stimulate the secretion of ROS” (Huppert et al., 2010), which activates the brain 
endothelial cell contractile machinery. Nevertheless, mice lacking IL-17 are not protected 
from disease (Haak et al., 2009). Currently, numerous findings support the consensus view 
that IL-17 and other Th17-derived cytokines are important for both mice EAE and human MS.  
Since the identification of Th17, Th1 cells have been out of the attentions of researchers for a 
long time. Recently, it is reported that Th1 is another arm for the pathogenesis of EAE.  
Harrington et al. reported that adoptively transferred with Th1 induces EAE. Th17 cells, 
however, are not able to do that (Harrington et al., 2005). This indicates that Th17 cells do not 
have the ability to migrate into the CNS to initiate the disease. Moreover, the Th1 cytokine, 
IL-12 can recruit macrophages into the inflammatory site. The Th17 cytokine, IL-23, on the 
other hand, can recruit neutrophils (Kroenke, Carlson, Andjelkovic, & Segal, 2008). More 
recently, it is reported that a new population of T cells, which are IL-17+IFN-γ+, are found in 
MS and EAE. This IL-17+IFN-γ+ population is preferentially recruited into CNS (Kebir et al., 
2009). In addition, T-bet+ Th1 cells could be sub-divided into T-bet+/RORγt+ IL-17-producing 
cells to induce EAE, suggesting the existence of plasticity within these populations 
(Abromson-Leeman, Bronson, & Dorf, 2009; Damsker, Hansen, & Caspi, 2010).   
Treg cells are functionally compromised in MS 
Similar as they are in RA, Tregs are functionally compromised. In MS patients, the frequency 
of Tregs in peripheral blood is similar as their healthy controls. However, in the CSF, MS 
patients have more elevated Treg percentage than normal controls (Feger et al., 2007; Haas et 
al., 2005; Kouchaki, Salehi, Reza Sharif, Nikoueinejad, & Akbari, 2014). Interestingly, one 
study has found reduced Tregs in CSF of RRMS but not in SPMS, indicating a potential role 
of Tregs in the down-regulation of local inflammation in the former (Venken et al., 2008). 
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CD39+ Tregs from RRMS patients has a compromised ability to suppress IL-17 (Fletcher et 
al., 2009), suggesting the discrepancy may partially due to a lack of representative cell surface 
marker for Tregs. Recently, Dhaeze et al. reported that MS patients have a significantly lower 
frequency of circulating follicular regulatory T cells accompanied by a sharply reduced 
suppressive function of these cells (Dhaeze et al., 2015).  
In EAE models, Treg cells also controls the initiation of the disease. CD4+CD25+ Treg cells 
have the ability to suppress T effector cell function in an Ag-dependent manner. The transfer 
of CD4+CD25+ Treg cells to mice lead to the resistance of EAE (Kohm, Carpentier, Anger, & 
Miller, 2002). In the PLP-induced model, the percentage of Ag-specific CD4+CD25+ Treg 
cells inversely correlates with the susceptibility of EAE (Reddy et al., 2004). Expansion of 
Tregs in vivo by IL-2 can suppress the immune response and significantly ameliorate EAE 
(Rouse, Nagarkatti, & Nagarkatti, 2013).  
Local factors also play critical roles in controlling Treg dysfunction. In patients with MS, their 
nonregulatory CD4+ T cells express more granzyme B, which could inhibit Treg suppression 
without altering Treg viability (Bhela et al., 2015). Tregs can be skewed to Th17-like cells 
when stimulated by TLR2. Therefore, they will lose their suppressive function accordingly  
(Nyirenda et al., 2011). Similar to recent observations in mouse T cells, human T helper 
precursors have the plasticity to further differentiate into Th17 by TLR2 stimulation. TLR2 
stimulation, with the presence of  TCR activation signaling, enhances Th17 cell differentiation 
and expansion from Tregs.  
Some in vitro studies prove that immunomodulators of MS, such as IFN-β, glatiramer acetate, 
can reverse the impairments of Treg functions from MS patients (Trinschek, Luessi, Gross, 
Wiendl, & Jonuleit, 2015).  Part of the mechanism for the treatment effect of IFN-β is due to 
its ability to induce the proliferation of Treg cells (M. Chen et al., 2012). Fingolimod 
(FTY720) is a drug that has been proved for the treatment of MS by FDA. It reduces the 
autoreactive T cells egress from the secondary lymph nodes into circulation. On the other 
hand, it increases the frequency of circulating Treg cells, thus, increase the suppressive 
function (Muls, Dang, Sindic, & van Pesch, 2014; Serpero et al., 2013).  
As mentioned above, Treg inhibitory effects can be mediated by cytokines, cell-cell contact, 
and depriving of cytokines (Takizawa et al., 2014; K. P. Walsh, Brady, Finlay, Boon, & Mills, 
2009; X. Zhang et al., 2004).  
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The dual role of CD8+ T cells in MS 
Specific MHC I alleles has been shown to be associated with MS, indicating the potential role 
of CD8+ T cells in MS (Fugger, Friese, & Bell, 2009). In MS plaques in CNS, more 
infiltrating CD8+ T lymphocytes are found than CD4+ T cells. These CD8+ T cells undergo 
oligoclonal expansion locally (Denic, Wootla, & Rodriguez, 2013; Gregersen, Hingorani, & 
Monteiro, 1995; Huseby, Huseby, Shah, Smith, & Stadinski, 2012). As majority of the 
resident cells in the local lesion express MHC class I molecule, they could be killed by the 
CD8+ T cells. This happens both in human MS and mice EAE lesions (Babbe et al., 2000). 
Also, CD8+ T cells can regulate local immune-inflammatory responses through the Fas-FasL-
dependent pathway. CD8+ T cells can promote cell apoptosis through the upregulation of FasL 
and the secretion of pro-inflammatory cytokines (Chavez-Galan, Arenas-Del Angel, Zenteno, 
Chavez, & Lascurain, 2009; Slifka, Rodriguez, & Whitton, 1999). CD8+ T cells also showed a 
suppressive role in a TGF-β-dependent manner (M. L. Chen, Yan, Kozoriz, & Weiner, 2009). 
 
 
Receptor tyrosine kinases are a group of key signaling molecules, which are important in the 
immune cell functions. In the past 20 years, our laboratory has elected to study the function of 
Ephb6 kinase in T cells. Efnb1 and Efnb2, which are ligands for Ephb6, were also studied for 
their roles in T cell function in our lab and in this thesis.  
 
1.3 Eph receptors and ephrins 
1.3.1 Structure characteristics of EPH receptors & ephrins 
Both erythropoietin-producing hepatocyte kinases (EPHs) and their ligands, ephrins (EFNs) 
are cell surface receptors. There are fourteen EPH receptors (EPHA1-8, EPHA10, EPHB1-4 
and EPHB6) (Aasheim, Patzke, Hjorthaug, & Finne, 2005; Brantley-Sieders & Chen, 2004) 
and nine EFNs (EFNA1-6, EFNB1-3) (Pasquale, 2004). EPH receptors and ephrins are 
expressed in virtually all tissues of developing embryos. In adult, however, their expression is 
relatively less. Some tissues or regions of certain organs express high levels of some Ephs or 
EFNBs. Even though EPHs/EFNs have been widely studied during development, their 
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physiological and pathological functions in the adult are coming to light. Recent studies show 
that their expression is high in cells like neurons, vascular cells, immune cells, indicating their 
potential roles in these cells.  
Eph receptors are transmembrane proteins (Figure 1.2). The protein domains that are 
contained in the ectodomain and the cytoplasmic region are illustrated in Figure 1.2 
(Gucciardo, Sugiyama, & Lehti, 2014) (Daar, 2012). As illustrated in Figure 1.2, the EFNA 
subfamily members are GPI-anchored proteins, while the EFNBs are transmembrane proteins 
(Pitulescu & Adams, 2014). The extracellular domain of both EFNA and EFNB contains a 
conserved extracellular receptor-binding domain (RBD). However, unlike the membrane-bond 
EFNAs, EFNBs have a transmembrane helix and an intracellular domain.  
1.3.2 Signal transduction of EPHs and EFNs 
As both Eph receptors and ephrins are cell surface molecules, they can transduce bidirectional 
signals. When it goes to the receptor-expressing cells, it is called forward signalling; when it 
goes to the ligand-expressing cells, it is called reverse signaling (Figure 1.2). Besides 
bidirectional signalling, the other property of this signaling system is that the direction of 
signaling is highly sensitive to the microenvironment. 
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Figure 1.2 Signalling transduction of EPHs/EFNs  
EPHs and EFNs interact promiscuously with each other. Usually,  EPHAs selectively interact 
with EFNAs, while EPHBs are more likely to intact with EFNBs. Recent experiments indicate 
considerable crosstalk between the A and B family members. There are several exceptions, 
including EPHA4 can bind to EFNB2 (Hu, Li, Jiang, Li, & Zhou, 2014; Qin et al., 2010) and 
EFNA5 can bind to EPHB2 (Himanen et al., 2004).    
1.3.2.1 Ligand-induced forward signaling transduction 
The binding of ephrins to Eph receptors can activate the downstream signalling. Moreover, the 
clustering of ephrins after binding enhances the forward signalling (Himanen, 2012; Himanen 
& Nikolov, 2003). The interaction of EPH receptor and its ligand will lead to the conformation 
change to create more interaction interface and clustering of multiple EPH subclasses.  
The signal can be transmitted in two ways, the PDZ-independent pathway and the PDZ-
dependent pathway. The activation of the first pathway results in the juxtamembrane tyrosine 
residue phosphorylation, which will recruit adaptor proteins in the cytosol. A variety of 
downstream signalling pathways, like ‘‘the FAK pathway, the JAK/STAT pathway, the 
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RAS/MAPK pathway” (Genander et al., 2009; Lim, Manser, Leung, & Hall, 1996; Macrae et 
al., 2005; Miao et al., 2015), will be triggered. The second way is the PDZ-dependent 
signaling pathway. The PDZ-dependent pathway, will employ its PDZ-domain-binding motif 
at the C-terminus of Eph to bind to adaptor proteins, such as glutamate receptor interacting 
protein (GRIP) 1/2, Ras-binding protein ALL1-fused gene from chromosome 6 (AF6), or 
protein interacting with C kinase (PICK) 1 (Hock et al., 1998; Pitulescu & Adams, 2010).  
1.3.2.2 Receptor-induced reverse signaling transduction 
Besides serving as ligands, EFNs are also able to transduce signals into their host cells. The 
GPI-anchored EFNAs are reported to cluster to recruit adaptor proteins to transduce 
signalling. For example, EFNA5 can cluster and recruit the Fyn tyrosine kinase in regulating 
cell adhesion (Davy et al., 1999; Davy & Robbins, 2000). Once encounter Eph receptors, 
ephrin Bs are capable of triggering the reserve signaling through the activation of conserved 
tyrosine residues within their cytoplasmic tails. This will provide docking sites for SH2-SH3 
family adaptor proteins, such as Src, Grb4, STAT3, CRK and Fyn. Their binding will lead to 
further signal transduction (Bong et al., 2007; Davy et al., 1999; Nagashima et al., 2002; N. J. 
Xu & Henkemeyer, 2009). EFNs are also able to transduce the signal by PDZ-domain-binding 
domain at the end of their intracellular domain. Several proteins including GRIP1, protein 
tyrosine phosphatase BAS-like (PTP-BL), TIAM1, Dishevelled and PDZ-RGS3 are reported 
to bind to EFNBs directly via their PDZ domains (Bruckner et al., 1999; Lee et al., 2006; 
Tanaka et al., 2004). Recently, it has been reported that EFNB2 can regulate endothelial cell 
morphology and motility in the presence of the C-terminal PDZ motif in the absence of EPH-
receptor binding (Bochenek, Dickinson, Astin, Adams, & Nobes, 2010).  
1.3.2.3 Both EPH receptors and EFNs have direct cross-talk with a variety of molecules 
Besides bidirectional signal transduction, EPH receptors and EFNs do not only act in isolation, 
but also have direct cross-talks with other cell-surface receptors and a variety of intracellular 
effector proteins. 
Several growth factor receptors, such as VEGF receptors, EGF receptors, IL-7 receptor, etc.,  
are reported to interact with EPH receptors and EFNs. The common mechanism of such 
interaction involves different levels of cooperation between Eph receptors and many 
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intracellular signalling effectors. Up till now, the non-receptor tyrosine kinase Src, Rho/Rac1 
axis, Akt pathway and Ras/Erk pathway can be triggered by growth factor receptor activation 
(Bromann, Korkaya, & Courtneidge, 2004; Hiramoto-Yamaki et al., 2010; Macrae et al., 
2005; Yang, Pasquale, Owen, & Ethell, 2006). For example, growth factor receptor 
downstream kinase Akt phosphorylates Ser897 of ligand-unbound Epha2, thereby promoting 
invasion of cancer cells (Miao et al., 2015; Miao et al., 2009). Tyrosine on the cytoplasmic tail 
of EFNB1 can be phosphorylated by RTKs, which are associated with FGF receptor activation 
(Chong, Park, Latimer, Friesel, & Daar, 2000).  
EPH/EFN signaling has a close connection with the cytoskeletal dynamics. Rho, Rac, and 
Cdc42 are the most studied Rho family proteins, which can interact with Eph receptors by 
guanine nucleotide exchange factors (GEFs). These interactions provid a link between Eph 
receptors and cytoskeleton (Noren & Pasquale, 2004). Ephexin, which is a member of Rho 
GEFs, can directly interact with the C-terminal of EPHA4 by its tandem Dbl-homology-
pleckstrin-homology (DH-PH) domain in the modulation of growth cone collapse (Sahin et al., 
2005). Other mediators like Tiam1 and Vav family GEFs are reported to interact with EPHA 
receptors to activate Rho GTPases, whereas Intersectin and Kalirin GEFs mediate the 
interaction of EPHBs and Rho GTPase (Gucciardo et al., 2014; Hunter et al., 2006; Irie & 
Yamaguchi, 2002). 
EPHs/EFNs have also been reported to interact with chemokines (Lu, Sun, Klein, & Flanagan, 
2001) and adhesion molecules (Arvanitis & Davy, 2008). For instance, binding of Eph 
receptor with Efnb1 can selectively inhibit CXCL12-induced CXCR4-mediated cerebellar 
granule cell migration via PDZ-RGS3 (Lu et al., 2001). Our group proved that Efnb1 and 
Efnb2 interact with IL-7Rα by stabilizing IL-7R expression at the post-translational level. 
Moreover, this stabilization prolongs IL-7R signaling (Luo, Wu, et al., 2011).  
Also, the cellular response can be controlled by the degradation and (or) removal of EPH/EFN 
interaction complex mechanisms, in which the duration and intensity of the receptor/ligand 
interaction changed. Zimmer et al. reported that blockage of internalization of EPHB2 and its 
ligand ephrin B1 expressed on fibroblasts and neurons converts repulsion into adhesion of the 
cells (Zimmer, Palmer, Kohler, & Klein, 2003). A more recent report showed that the 
extracellular domains of Efns could be removed by ADAM10 (Kaushal & Shah, 2000; 
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Primakoff & Myles, 2000), MMPs (Georgakopoulos et al., 2006) and (or) γ-secretase (Tomita, 
Tanaka, Morohashi, & Iwatsubo, 2006). This study suggests an underlying mechanism of 
EPHs/EFNs in repulsion and the shaded EPHs/EFNs might have long-range paracrine 
functions.  
1.3.3 Functional roles of EPH/EFN signaling pathways 
EPH/EFN signaling contributes to a variety of processes during development, tissue 
homeostasis, and disease pathogenesis. In this part, I will focus on EPH/EFN signaling 
pathways in neural development, bone homeostasis, and cancer, which are the most 
extensively studied. Their roles in the immune system are also reviewed here, as it is the major 
focus of my thesis. 
1.3.3.1 EPH/EFN signaling pathways control cell proliferation, adhesive function, and 
migration in neural development 
EPH/EFN signaling pathways mainly participate in axon guidance and synaptogenesis during 
neural development, as well as neuronal plasticity in the adult. During neural development, 
EPH/EFN signaling pathways are known for their roles in controlling cell proliferation, 
adhesive function, and migration at the cellular level.  
EPHs and ephrins exhibit highly complex spatial and temporal expression pattern in central 
nerves system, suggesting their duties in specific neurons or at a specific time point (Buchert 
et al., 1999; Grunwald et al., 2004; Henderson et al., 2001). Precise expression gradients and 
sharp boundaries are also displayed. For instance, in the recipient anterior-posterior axis in the 
tectum, the complementary gradient of Efna2 and Efna5 expression are found (Cheng & 
Flanagan, 1994; Cheng, Nakamoto, Bergemann, & Flanagan, 1995; Drescher et al., 1995).  
In axon guidance and synaptogenesis, Eph receptors and ephrins co-operator with multiple 
other cellular pathways both in the PDZ-dependent and PDZ-independent signaling pathways. 
The first report about EPH/EFN signaling in axon guidance was published in 1994 (Cheng & 
Flanagan, 1994). With the use of Eph/Efn-specific Abs and recombinant Eph/Efns, and 
genetic manipulation on Eph receptors and ephrins, the function and molecular mechanism of 
this family of molecules have been further explored. Mice deficient for Efna2, Efna3 and 
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Efna5 present disrupted shape and location of eye-specific retinogeniculate layers 
(Pfeiffenberger et al., 2005). Truncation of the Ephb2/b3 cytoplasmic domain leads to higher 
frequency of axon guidance errors, indicating that reverse signaling plays an essential role in 
axon pathfinding (Birgbauer, Cowan, Sretavan, & Henkemeyer, 2000).  
Besides axon guidance, EPHs/EFNs are critical for regulating synaptogenesis. Ephrins support 
presynaptic forms of long-term potentiation (LTP) by promoting presynaptic differentiation 
and neurotransmitter release (Klein, 2009). Bidirectional signaling is not always necessary, as 
in some cases Eph receptors are only needed to trigger reverse signaling. Interestingly, several 
groups observed a discrepancy of Ephb2 in synaptogenesis. Both overexpression and 
knockdown of Ephb2 in vitro can regulate presynaptic and postsynaptic specialization 
(Kayser, McClelland, Hughes, & Dalva, 2006; Kayser, Nolt, & Dalva, 2008). Surprisingly, 
synapse formation is normal in Ephb2 knockout mice, suggesting multiple synaptogenic 
pathways can compensate for the lack of Ephb2 in vivo (Sloniowski & Ethell, 2012). 
Moreover, evidence reveals that EFNA6 interacts with neurotrophin receptor TrkB and 
EPHB2 binds to NMDA receptor to control synaptogenesis (Dalva et al., 2000; Marler et al., 
2008).  
1.3.3.2 EPH/EFN signaling maintains the balance between bone formation and resorption  
Bone homeostasis is strictly controlled by proper communication between osteoclasts and 
osteoblasts to keep the balance between bone formation and resorption (Edwards & Mundy, 
2008). EPHB4 and its ligand ephrin B2 remain at the center of the focus in this regard. The 
forward signaling activated by EPHB4, which is expressed on osteoblasts, promote osteogenic 
differentiation. In contrast, reverse signaling through ephrin B2 on osteoclasts results in the 
suppression of osteoclast differentiation (C. Zhao et al., 2006). Furthermore, the activation of 
ephrin B1 and ephrin B2 expressed by mesenchymal stem/stromal cells, which are the primary 
source of the osteoblasts, leads to increased osteogenic differentiation (Arthur et al., 2011).    
1.3.3.3 Dysregulation of EPHs and ephrins are frequently found in cancer 
In human cancer, the dysregulation of EPHs and ephrins are common. EPHA2, for instance, is 
upregulated in many solid cancers and its expression has been found to be associated with 
poor clinical prognosis (Dunne et al., 2015; Shen et al., 2014). In contrast, EPHB6 is 
 38 
downregulated in advanced human ovarian, prostate and colorectal cancers (Gu et al., 2015; 
Mohamed et al., 2015; Peng et al., 2014). Furthermore, EPH expression in cancer can be 
dynamic. Several EPHBs and EPHA1 are upregulated during early stages of cancer 
progression and can be subsequently silenced leading to tumor suppress (Batlle et al., 2005; 
Herath, Doecke, Spanevello, Leggett, & Boyd, 2009; Herath et al., 2012). 
Functional alterations are also found in the signaling pathways of EPHs/EFNs and their 
crosstalk with other oncogenic signaling pathways in tumor initiation, progression, and 
metastasis at different levels. EPHs/EFNs, such as EPHA2 and EPHB4, are involved in the 
regulation of RhoA activity (Wakayama, Miura, Sabe, & Mochizuki, 2011; Yang et al., 2006). 
Intriguingly, increased adhesion of HEK cells and endothelial cells presents upon ligand-
induced EPHB1 activation. However, EPHB3 activation in HEK cells leads to reverse effects 
(Miao et al., 2005).   
In the past decade, tumor-propagating cells (TPCs) bearing stem cell properties were 
identified among cancer cells. Both EPHA2 and A3 are highly expressed in TPCs (Binda et 
al., 2012; Day et al., 2013). The overexpression of these two molecules on TPCs results in 
better self-renewal. In breast and prostate cancer, the overexpression of EPHA2 and its 
presence on TPCs have been reported, making EPHA2 a new therapeutic target (Sugiyama et 
al., 2013; X. D. Wang et al., 2007).  
EPHs/EFNs also regulate the stromal compartments in cancer. The EPH/EFN system 
participates in the regulation of segregation at the boundary of the tumor and the normal 
tissues. Eph receptors and ephrins also regulate angiogenesis in tumor through the influence of 
vascular cell patterning. They can also influence immue cell migration to the tumor lesions 
(Astin et al., 2010; Ogawa et al., 2000). 
1.3.3.4 EPH receptors and EFNBs can be found in different immune cells, their role in T 
cell biology are most extensively studied 
Many studies evaluated the expression of EPHs and EFNs in immune cells. Almost all 
receptors and ligands of the B family are expressed in immune cells, including lymphocytes, 
monocytes, dendritic cells. Some of the receptors and ligands from the A family are also 
expressed in immune cells (Aasheim et al., 2000; de Saint-Vis et al., 2003; Ivanov & 
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Romanovsky, 2006; Munthe, Finne, & Aasheim, 2004). Both Eph receptor and ephrin 
expression are rapidly induced in T cells within 4 to 24 hours after they are cultured in 
medium containing heat-inactivated fetal calf serum (Luo, Yu, Wu, & Wu, 2002; Yu, Luo, 
Wu, & Wu, 2003a). Furthermore, a higher percentage of the Ephb6+ population are found in 
naïve (CD45RA+) T cells than that of recently activated (CD45RO+) T cells (Gurniak & Berg, 
1996; Holen, Nustad, & Aasheim, 2010; Luo et al., 2002). EPHs and ephrins expressed on 
immune cells exert their role in the immune system at multiple levels, including lymphatic 
valve development (Makinen et al., 2005; G. Zhang et al., 2015), T cell development and 
function (J. Wu & Luo, 2005), as well as fighting against infection and cancer (Ivanov & 
Romanovsky, 2006; Tian et al., 2015).  
There are two major features for the functional roles of EPHs/EFNs in the immune system. 
Firstly, the expression level of receptors and ligands are tightly regulated under certain 
conditions to modulate their functions. For instance, ‘‘the expression of EPHA1, EPHA3, 
EPHB3 and EPHB4 on leukocytes decreases’’ (Ivanov, Steiner, Scheck, & Romanovsky, 
2005) at later stages of inflammation, thus promoting leukocytes adhesion, extravasation, and 
tissue transmigration. Secondly, controversial functional results are reported upon different 
receptor and ligand activation. One study reveals that the activation of EPHA2 with ephrin 
A3-Fc leads to increased adhesion of dendritic cells to fibronectin (de Saint-Vis et al., 2003), 
whereas another study demonstrates that stimulation of EPHA3 resulting in the loss of cell 
adhesion to the same matrix protein (Smith et al., 2004).        
EPHs/EFNs in T cell biology are most extensively studied among all different types of 
immune cells. Several Eph receptors (Ephb2, b3, b4) and ephrins (Efnb1, b2) expressed on T 
cell progenitors and (or) thymic epithelial cells (TECs) are shown to influence T cell 
maturation and thymic architecture integrity (Alfaro et al., 2015; Cejalvo et al., 2015; Luo, 
Charpentier, et al., 2011). Previous work in our group demonstrated that T cell-specific 
knockout of Efnb1 and Efnb2 results in less T cell number in the thymus as well as in the 
periphery (Jin, Luo, & Wu, 2014; Luo, Charpentier, et al., 2011). Using the Cre-LoxP model 
in mice, Cejalvo et al. reported that Efnb1 and Efnb2 on TECs affect the size of the thymus, 
especially the medullary compartment, starting at the perinatal stage (Cejalvo et al., 2015).      
Several EPH/EFN family members are capable of interacting with TCR complex and playing 
a costimulatory role. Our earlier studies revealed that Efnb1, b2 and b3 are critical 
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costimulatory factors for T cell activation, which lead to increased cytokine secretion and T 
cell proliferation (Yu et al., 2003a; Yu, Luo, Wu, & Wu, 2003b, 2004). EFNB1 is also 
important for the control of lipid-rafts in malignant T cells (Jiang et al., 2008). Furthermore, 
Ephb6-/- mice show compromised T cell function manifested in lymphokine secretion, 
proliferation, as well as reduced EAE. Ephb6 clusters after TCR activation, and then regulates 
ZAP-70 activation, LAT phosphorylation and MAPK activation (Luo, Yu, Tremblay, & Wu, 
2004). Besides, in vitro studies showed that from T cell-specific Efnb1 and b2 double 
knockout naive T cells are impaired in skewing into Th1 and Th17 subpopulations. In the 
same study, Efnb1 and b2 are revealed to modulate IL-6 signaling through the induction of 
STAT3 phosphorylation (Luo, Charpentier, et al., 2011). Lastly, EFNA1 expression on CD4+ 
T cells from asthma patients is decreased, and EFNA1 suppresses Th2 cell activation 
(Wohlfahrt et al., 2004).   
The EPHs/EFNs are known to control cell migration in different tissues, raising the possibility 
that they may similarly regulate lymphocyte migration. Stimamiglio et al. demonstrates that 
Ephb2 is essential for T cell progenitor migration during fetal thymus colonization 
(Stimamiglio et al., 2010). Ephrin A activation can alter T cell trafficking to peripheral lymph 
nodes in vivo (Sharfe et al., 2008). Further studies reveal that EFNA1 are important for both 
CD4+ and CD8+ T migration (Aasheim, Delabie, & Finne, 2005; Hjorthaug & Aasheim, 2007) 
and the activation Lck and Pyk2 are involved in the downstream signaling pathway. Also, 
CD45RO+ T cells migrate towards EFNA1 better compared with CD45RA+ cells (Holen et al., 
2010). The signaling pathways downstream of EPHs/EFNs and chemokines can be regulated 
by adapter molecules including Grb2, Nck, and SLAP, which will ultimately influence 
cytoskeleton regulation through the members of Rho family proteins. For example, EFNA1 
specifically inhibits CDC42 from the Rho family downstream of chemokine receptor CXCR4 
but does not alter the receptor expression (Sharfe, Freywald, Toro, Dadi, & Roifman, 2002). 
Recently, EPHs/EFNs are reported to interact with other molecules in the immune system. 
Maddigan et al. reported that EPHB3 is consistently expressed by malignant T lymphocytes 
and such expression lead to strong suppression of Fas-induced apoptosis (Maddigan et al., 
2011). EPHB2 expressed on dendritic cells is also reported to be modulated by the ligation of 
TLR4 and TLR9 (Mimche et al., 2015). Moreover, our group has demonstrated that Efnb1/b2 
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expressed on T cells can physically interact with IL-7Rα and retard its internalization (Luo, 
Wu, et al., 2011). 
 
When studying the role of Ephb6 in T cells activation/proliferation, we want to get a full 
picture of molecules that may be involved in T cell activation. Thus, an unbiased DNA 
microarray analysis was conducted. As a result, Stra6 (stimulated by retinoic acid gene 6) and 
Armc5 (Armadillo repeat-containing 5) were identified. We then generated mice with these 
two genes knockout to study their roles in T cell biology. 
1.4 STRA6 
Vitamin A is required throughout life and performs diverse functions in numerous cellular 
activities including vision, reproduction, growth and development. 
1.4.1 Vitamin A homeostasis 
Vitamin A is absorbed in enterocytes in the form of vitamin A precursors (i.e. β-carotene). 
Once in enterocytes, vitamin A precursors can be processed into retinyl esters, which are then 
transferred into the lymphatic system. Retinyl esters are then taken up and processed in 
hepatocytes and transferred to hepatic stellate cells (HSCs) for storage. In times of dietary 
retinoid-insufficiency, retinyl esters stored in HSCs will be hydrolyzed back to retinol and 
transferred to the hepatocyte, where it can bind to retinol binding protein (RBP) (D'Ambrosio, 
Clugston, & Blaner, 2011).  
Retinol-bound RBP (holo-RBP) in blood is maintained stably and serves as a buffering system 
between dietary intake of retinoids and a stable supply for tissues that need vitamin A 
(Kawaguchi, Zhong, Kassai, Ter-Stepanian, & Sun, 2012). RBP receptors, such as STRA6, 
mediates cellular vitamin A uptake (Kawaguchi et al., 2007). Besides holo-RBP, retinoids in 
circulation can also present in other forms by binding to lipoproteins and albumin. However, 
up till now, how retinoids are transferred into cells remains elusive.   
Once inside a cell, oxidization occurs, which will change retinol into retinal (ADH mediated). 
Further oxidation might happen, which results in the production of retinoic acid (RALDH 
mediated) (Mic, Molotkov, Benbrook, & Duester, 2003). There are two critical active 
derivatives of vitamin A to elicit its biological function, the aldehyde form and the acid form. 
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The aldehyde form is the chromophore for visual pigments in the eyes. The aldehyde form 
also modulates adipogenesis (von Lintig, Kiser, Golczak, & Palczewski, 2010; Ziouzenkova et 
al., 2007). The acid form, through its binding to the nuclear retinoic acid receptors, has the 
most diverse functions (Napoli, 1996;  Stock, Napolitani, & Cerundolo, 2013). 
1.4.2 STRA6 expression pattern and structure 
The existence of a cellular receptor for RBP, which can transfer holo-RBP from the blood to 
the cytoplasm of target cells by crossing the cell membranes, was postulated as early as 1970’s 
(Heller & Bok, 1976). Thirty years later, Kawaguchi et al. reveals that RBP bind to membrane 
protein STRA6, which mediates the cellular uptake of vitamin A (Kawaguchi et al., 2007). 
Accumulating evidence shows that STRA6 is expressed in a variety of tissues including the 
brain, testis, ovary, kidney and spleen (Bouillet et al., 1997). Recently, it is described that 
STRA6 homologs are encoded in all known genomes of vertebrates (J. Wu et al., 2014).  
STRA6 is a 74 kDa multi-transmembrane protein, which contains a short N-terminal tail in the 
extracellular space, nine transmembrane segments, and a C-terminal tail in the cytosol 
(Kawaguchi, Yu, Wiita, Honda, & Sun, 2008; Kawaguchi, Yu, Wiita, Ter-Stepanian, & Sun, 
2008). Two large intracellular loops, as well as one large extracellular loop, are found with the 
presence of several smaller loops on each side of the membrane (Kawaguchi, Zhong, Kassai, 
Ter-Stepanian, & Sun, 2015). STRA6 binds to RBP with high affinity. Alanine-scanning 
mutagenesis reveals that the large extracellular loop between transmembrane segments 6 and 7 
of STRA6 is the region for RBP binding (Kawaguchi, Yu, Wiita, Honda, et al., 2008).  
1.4.2.1 STRA6 is a cellular transmembrane retinol binding protein for vitamin A 
transport 
The mechanism of STRA6 in vitamin A exchange in and out of cells assembles the gate for 
ion channels (Kelly & von Lintig, 2015). Proteins such as lecithin retinol acyl transferase 
(LRAT), cellular retinol binding protein-1 (CRBP1), are important in assisting STRA6 
functions. LRAT can enhance the retinol transfer into cells mediated by STRA6 (Isken et al., 
2008). And the enhancement depends on the ratio of holo-RBP to STRA6. This phenomenon 
is possibly because of the accumulation of retinol in cells inhibits its further intake 
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(Kawaguchi et al., 2011). Moreover, retinol uptake in Lrat knockout mice is impaired 
(Amengual, Golczak, Palczewski, & von Lintig, 2012).  
STRA6 also couples effectively with CRBP1 and CRBP2 for retinol efflux.  In the presence of 
apo-RBP, STRA6 can promote the loading of retinol onto RBP (Kawaguchi et al., 2012). Pure 
apo-RBP can completely deplete retinol taken up by CRBP1 in an STRA6-dependent manner. 
STRA6 influx activity can be inhibited by free retinol outside the cells (Kawaguchi et al., 
2011). 
In 2012, the first Stra6 strain knockout mice were established (Ruiz et al., 2012). “Stra6 
knockout mice are viable” (Amengual et al., 2014). When bred on diets repleted in vitamin A, 
Stra6 null mice have normal eye diameter, but display a reduction of retinal thickness. Also, in 
Stra6 KO mice, both retinol and its derivatives are decreased in both RPE and neurosensory 
retina (Ruiz et al., 2012). Also, most peripheral tissues do not display altered retinoid levels in 
Stra6 KO mice, indicating that Stra6 might not be the only vitamin A transport mode in these 
tissues (Amengual et al., 2014).   
Mathew Wood Syndrome (MWS) is a rare clinical entity, which is mainly featured by “severe 
bilateral microphthalmia, pulmonary dysplasia, cardiac defects and diaphragmatic hernia” 
(Kelly & von Lintig, 2015). MWS is highly associated with mutations in STRA6 gene. Berry 
et al. reports that STRA6 can also bind to RBP-retinol and trigger the activation of 
JAK2/STAT5 signaling, indicating its potential role in type 2 diabetes (Berry, Jin, Majumdar, 
& Noy, 2011).      
1.4.2.2 RBPR2 is a new retinol binding protein other than STRA6  
In addition to STRA6, another RBP receptor was newly identified in 2013, namely RBPR2 
(RBP4 receptor-2, RBPR2) (Alapatt et al., 2013). Overall, the amino acid sequence homology 
between murine Rbpr2 and Stra6 is 17.8%. Among them, some short fragments of the amino 
acid are more than 50% homology to Stra6. The expression of Rbpr2 is highest in liver, 
followed by small intestine, jejunum and ileum, and colon. Its expression is also inducible 
when preadipocytes are driving into adipocytes in vitro. RBPR2 is also a transmembrane 
receptor, which confers high RBP4 binding affinity and retinol transport, whereas Rbpr2 
knockdown reduces both of these abilities (Alapatt et al., 2013). Further studies are needed for 
its role in vitamin A homeostasis.   
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1.4.3 Role of vitamin A and STRA6 in T cell function 
Retinoic acid is the active form of vitamin A in the immune system. Retinoic acid can bind to 
retinoic acid receptors (RAR), retinoid X receptors (RXR) expressing on nuclei, and also, 
under certain conditions, PPARβγ (Schug, Berry, Shaw, Travis, & Noy, 2007). RXRs (RXRα, 
β and γ) can only bind to 9-cis-retinoic acid, whereas RARs (RARα, β and γ) bind and respond 
to both all-trans-RA and 9-cis-retinoic acid with high affinity (Allenby et al., 1993). RARs 
heterodimerizes with RXRs upon the ligation of a retinoic acid to modulate gene expression 
by binding to retinoic acid responsive elements located in the regulatory regions of target 
genes.  
Recent evidence from studies utilizing retinol acid therapy or different animal models of 
retinoid receptor deficiency reveal that retinoic acid is critical for T cell activation, effector 
functions, and homing (Dawson et al., 2009; Hall, Cannons, et al., 2011; Yamada, Mizuno, 
Ross, & Sugawara, 2007). Retinoic acid stimulates human T lymphocytes proliferation 
through the IL-2-induced signaling pathway (Engedal, Gjevik, Blomhoff, & Blomhoff, 2006). 
Both RARα and γ are expressed in naïve CD4+ T cells, whereas only RARα is critical for T 
cell activation (Dzhagalov, Chambon, & He, 2007; Hall, Cannons, et al., 2011). During 
infection with Toxoplasma gondii, a parasite inducing a strong Th1 response, vitamin A is 
critical for parasite clearance (Hall, Cannons, et al., 2011). Significant inhibition of Th17 cell 
differentiation is found in mouse small intestine in the absent of retinol acid (Cha et al., 2010). 
The addition of retinoic acid in culture dramatically enhances iTreg induction (Mucida et al., 
2007) and retinoic acid acts as a cofactor for FoxP3 induction depending on TGF-β (Coombes 
et al., 2007).  
Accumulating evidence demonstrates that the diet in developed countries fails to maintain 
homeostasis of the intestine, thus resulting in inflammatory intestinal disorders (Garrett, 
Gordon, & Glimcher, 2010; J. Wang & Sampson, 2011). Mice experiment support this with 
the fact that excess vitamin A in the diet is associated with a higher chance of inflammatory 
immune disorders (Hall, Grainger, Spencer, & Belkaid, 2011). Retinoic acid acts as a co-
adjuvant in activating dendritic cells (DePaolo et al., 2011). 
 45 
1.5 ARMC5 
1.5.1 Characteristic of Armadillo repeat 
Armadillo (ARM) was first found influencing the segmentation of Drosophila larva 
(Nusslein-Volhard & Wieschaus, 1980; Riggleman, Wieschaus, & Schedl, 1989). The core 
component of Armadillo protein is called "Armadillo repeat," which is a ~42-amino acid 
sequence motif (Peifer, Berg, & Reynolds, 1994). There are three alpha helices in each ARM 
repeat. More than one ARM repeats join tandemly to form ARM domain, which is a right-
handed superhelix. ARM domains provide diverse protein-protein interactions in versatile cell 
biology process (Huber, Nelson, & Weis, 1997) (Figure 1.3). ARM domain-containing 
proteins are a large protein family, which can be found from yeast to humans. Armadillo 
protein family members are not necessarily identical in gene sequence at high percentages, but 
they share a similar structures (Tewari, Bailes, Bunting, & Coates, 2010). This family of 
proteins, like β-catenin, p120 catenin, etc., can bind to classical cadherins using their ARM 
domain, thus playing pivotal roles in controlling cell adhesion (Franz & Ridley, 2004; Gates & 
Peifer, 2005; W. Xu & Kimelman, 2007). The stability of β-catenin is the key to the canonical 
Wnt signaling pathway, which controls carcinogenesis and embryonic development (Clevers 
& Nusse, 2012). Importin-α, an ARM-domain-containing protein, serves as a binding scaffold 
for the transportation of hundreds of proteins into the nucleus (Goldfarb, Corbett, Mason, 
Harreman, & Adam, 2004). ARM-proteins, such as ARMC8, act as E3 ubiquitin ligases in 
protein degradation (Tomaru et al., 2010). Moreover, ARM-proteins can also form protein 
complexes, which act as adapters or molecular chaperones (D'Andrea & Regan, 2003; Szretter 
et al., 2010).  
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Figure 1.3 Diagram and structure of ARMC5 and β-catenin 
1.5.2 Structure and function of β-catenin 
The mouse β-catenin consists of 781 amino acids with twelve ARM-repeats. Distinct terminal 
domains can be found at both ends of its ARM domain, namely the amino-terminal domain 
(NTD) and the carboxyl-terminal domain (CTD) (Figure 1.3). NTD serves as the glycogen 
synthase kinase 3β (GSK3β) phosphorylation site, while CTD provides the binding sites for 
multiple proteins related to the function of β-catenin in transcription regulation. β-catenin is 
important in cell adhesion and plays a crucial role in the Wnt signaling pathway.  
In cadherin-based adherent junctions, β-catenin uses its ARM domain to interact with the 
cytoplasmic part of cadherin, and also binds to α-catenin at the same time, to regulate the actin 
cytoskeleton. Moreover, this function is conserved among species. 
β-catenin is a central molecule in the Wnt signaling pathway. With the activation of the Wnt 
signaling pathway, β-catenin will travel from cytoplasm to the nucleus, where it can bind to 
 47 
multiple transcription factors to exert its function (Clevers & Nusse, 2012; Valenta, 
Hausmann, & Basler, 2012) .  
Numerous evidence shows that the dysregulation of β-catenin signalling contributes to 
multiple malignancies, including colon cancer, prostate cancer melanoma, and endometrial 
cancer, etc. (H. Huang et al., 1999; Kaler, Augenlicht, & Klampfer, 2012; Miyaki et al., 1999). 
β-catenin mutations are frequently observed in these cancers. These mutations lead to 
increased stability of β-catenin. β-catenin knockout mice are embryonic lethal during the 
gastrulation stage, as no mesoderm formation is observed (Haegel et al., 1995). Tissue- or cell-
specific knockout mice reveal that it is essential for tissue homeostasis and normal cell 
function (Behari et al., 2010; Gao, Arlotta, Macklis, & Chen, 2007; Kato et al., 2011). 
1.5.3 Role of β-catenin and other ARM proteins in T cell function 
The Wnt signaling pathway is critical for regulating of DC mutation, for lymphocytes 
development in the central lymphoid organs, and also for T cell activation in peripheral 
lymphoid tissues. However, recent studies have observed controversial results, especially in T 
cell biology. By Lck-Cre drive T cell-specific deletion of β-catenin, Xu et al. reports that T 
cell development in the thymus is impaired (Y. Xu, Banerjee, Huelsken, Birchmeier, & Sen, 
2003). However, this is not supported by other studies (Cobas et al., 2004). Huang and 
colleagues report increased CD4 SP T cells in the thymus by forced expression of stabilized β-
catenin (Z. Huang et al., 2006). TCF-1 and β-catenin are required to promote Th2 
differentiation by stimulating GATA-3 expression. On the other hand, TCF-1 blocks Th1 
differentiation by repressing IFN-γ. Moreover, TCF-1 is negatively regulated by T-bet 
(Oestreich, Huang, & Weinmann, 2011). By using retroviral constructs to express the stable 
form of β-catenin, Ding et al. reported that the stable β-catenin-expressing Treg cells show 
enhanced function in protecting mice against inflammatory bowel disease. T effector cells, on 
the other hand, become anergic with stable β-catenin expression (Ding, Shen, Lino, Curotto de 
Lafaille, & Lafaille, 2008). In contrast, a study from Zhao et al. does not support this (D. M. 
Zhao et al., 2010). They report that stabilized β-catenin expression is necessary for increased 
Ag-specific CD4 T cells in response to Listeria monocytogenes infection. In this study, 
enforced overexpression of β-catenin together with TCF-1 results in higher percentages and 
increased numbers of Ag-specific memory CD8+ T cells. Heightened secondary expansion of 
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Ag-specific memory CD8+ T cells and increased bacteria clearance are found after 
rechallenging in β-catenin and TCF-1 double transgenic mice. However, using genetic 
approaches of gain- and loss-of-function studies with adenoviral vectors or loxP-mediated T 
cell specific β-catenin KO mice, β-catenin is demonstrated to be dispensable for CD8+ T cell 
memory function (Driessens, Zheng, & Gajewski, 2010; Prlic & Bevan, 2011). 
Several explanations may be worth considering for the controversial results described above. 
Firstly, the different experiment conducted in different labs may result in different expression 
levels and different function levels of β-catenin in cells. β-catenin with partial deletion at the 
C-terminus can still interact with the histone acetylases CBP/p300 (De Vries et al., 2004). 
Secondly, at some stage of T cell development, alternative pathways are more easily triggered 
to compensate for the dysfunction caused by the gain- and loss-of-function studies. While in 
other stages or cells, this may not happen.   
1.5.4 ARMC5 published papers mainly focus on the association of its 
mutations and PMAH   
The mouse armadillo repeat containing 5 is an intracellular protein containing 926 amino acids 
(aa) with seven tandem copies of armadillo repeats from 139aa to 440aa, and 1 BTB domain 
lies in 745aa-813aa ("http://www.uniprot.org/uniprot/Q5EBP3,") (Figure 5). 
Currently, all the publications related to ARMC5 are those describing its mutation being 
associated with human primary macronodular adrenal hyperplasia (PMAH), which is a rare 
cause of Cushing’s syndrome (CS). Assie and colleagues first detect ARMC5 mutations in 
tumors obtained from 18 of 33 patients (Assie et al., 2013). In this study, one germline 
mutation and one somatic ARMC5 mutation are identified. The association of ARMC5 
mutations with PMAH is further confirmed by three independent studies in the US (Faucz et 
al., 2014), Brazil (Alencar et al., 2014), and Australia (Gagliardi et al., 2014). ARMC5 
mutations are detected in 4 of 5 familial PMAH cases (Gagliardi et al., 2014). Comparing to 
their wild-type counterparts, ARMC5-mutated PMAH patients show more frequent overt CS as 
well as bigger and higher number of nodules (Espiard et al., 2015).  
How does ARMC5 mutation lead to the development of PMAH? Transcriptome analysis of 10 
tumor specimens from PMAH suggests a group of genes related to RNA processing is 
significantly enriched in the ARMC5 mutated group comparing with nonmutated controls, 
 49 
indicating the effect of ARMC5 in gene expression. Higher levels of apoptosis are found with 
the overexpression of nonmutated ARMC5 gene in adrenocortical cells. In contrast, 
overexpression of ARMC5 mutations failed to do so (Assie et al., 2013). These findings could 
only partially explain the increased cell numbers in PMAH. The function of ARMC5 in 
adrenal gland and other organs remains obscure. 
 
1.6 Hypotheses 
Hypothesis 1. Efnb1/b2 is essential in 1) T-cell help for Ab production, and 2) T-cell 
chemotaxis, which will result in reduced CIA pathogenesis. The T cell-specific EFNB1 and 
EFNB2 expression might be used as a marker for the RA disease activity. 
Hypothesis 2. Stra6 is critical in transporting vitamin A into lymphoid cells. Lack of Stra6 
may lead to impaired T cell function.  
Hypothesis 3. Armc5 is critical in fetal development, and T-cell biology. ARMC5 functions 
depend on its interaction with molecules in different signaling pathways. 
1.7 Research Objectives 
1. To explore the mechanisms of Efnb1/Efnb2 expressed in T cells in the pathogenesis of CIA. 
To check whether the T cell specific EFNB1 and EFNB2 can be useful marker of RA disease 
activity. 
2. To understand the potential job that Stra6 do in T cell function and anti-virus response. 
3. To study the functional roles and molecular mechanisms of Armc5 in T cell biology. 
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Chapter 2 Article-1 
The role of EFNB1 and EFNB2 in mouse collagen-induced 
arthritis and human rheumatoid arthritis 
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Abstract 
Objective EFNB1 and EFNB2 are ligands of EPH receptor tyrosine kinases. We investigated 
how their expression on T cells influences the pathogenesis of collagen-induced arthritis (CIA) 
in mice, and assessed correlations between the T-cell expression of these 2 molecules and 
rheumatoid arthritis (RA) disease activity.  
Methods CIA was studied in mice with T cell-specific deletion of both Efnb1 and Efnb2 
(dKO) mice. Efnb1 and Efnb2 mRNA expression in peripheral blood T cells from patients 
with rheumatoid arthritis was determined by reverse transcription/quantitative polymerase 
chain reaction. 
Results In dKO mice, CIA clinical scores were reduced compared to wild type (WT) controls. 
Serum collagen-specific antibody (Ab) titres in dKO mice were lower than those in WT 
controls. On an equal-cell-number basis, dKO T cells provided vastly inferior help to B cells 
for collagen-specific Ab production in vitro. dKO T cells were compromised in their ability to 
migrate to arthritic paws in vivo and in their ability of chemotaxis towards CXCL12 in vitro. 
Deletion mutation of Efnb1 and Efnb2 intracellular tails revealed critical regions in controlling 
T-cell chemotaxis. T cells from RA patients expressed higher EFNB1 mRNA levels which 
correlated with RA symptoms and laboratory findings.  
Conclusions We have found that Efnb1 and Efnb2 in T cells were essential for pathogenic Ab 
production and for T-cell migration to inflammatory paws in mouse CIA. Our clinical study 
suggests that the expression of EFNB1 in T cells might be a useful parameter for monitoring 
RA disease activity and treatment responses. 
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Introduction 
Rheumatoid arthritis (RA) is a polygenic autoimmune disease characterized by chronic, 
systemic inflammation that can affect a number of tissues and organs, but the joints and 
surrounding tissues are most frequently impacted. The pathogenesis of RA is not fully 
understood. Toll-like receptor agonists, such as proteoglycans and bacterial DNA, might play 
an etiological role in initiating the disease [1]. Some auto-Abs are RA pathogenic [2]. Various 
inflammatory cytokines, such as tumour necrosis factor-alpha, interleukin-1beta (IL-1β) [3], 
IL-6 [4] and IL-17 [5] are produced within the synovium by infiltrating leukocytes including T 
cells. Local macrophage-like synovial fibroblasts (SF) are key mediators of inflammation and 
tissue destruction in RA. In mice with severe combined immunodeficiency, activated SF are 
sufficient to invade and damage cartilage [6]. This indicates that, at a later stage in RA, 
inflammation and destruction can be mediated and sustained by SF. 
EPHs comprise the largest family of cell surface receptor tyrosine kinases, representing about 
25% of known receptor tyrosine kinases [7]. There is a total of 15 EPHs, classified by 
sequence homology into subfamilies A with 9 members, and B, with 6 members.  EPHs bind 
to their EFN ligands, which are also cell surface molecules [7]. The 9 known EFNs are divided 
into A and B subfamilies based on the manner in which they anchor to the cell surface. 
Interactions between EPHs and EFNs are promiscuous. One EPH can interact with multiple 
EFNs and vice versa. In general, EPHA members preferentially interact with EFNA members, 
and EPHB members with EFNB members [8, 9].  
EPHs can initiate signal transduction via their intracellular domain upon ligand binding 
(forward signaling). Also, EPHs can cross-talk with other receptor tyrosine kinases [10, 11], 
chemokine receptors [12] and adhesion molecules [13]. Their ligands, EFNs, can transduce 
signals into cells [8, 9] by a phenomenon called reverse signaling. Upon activation by EPHs, 
EFNs can rapidly undergo tyrosine phosphorylation and recruit adaptor proteins to start the 
signaling cascade [14, 15]. EFNBs can also transmit reverse signaling through the C-terminal 
PDZ domain-binding motif, which binds to PDZ domain-containing proteins [12, 16-18]. Like 
EPHs, EFNs can interact, directly or indirectly, with other cell surface molecules, such as 
chemokine receptors [19, 20].  
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EPHs and EFNs have crucial functions in many organs, systems and processes, such as the 
central nervous system [8, 9], angiogenesis [21], bone metabolism [22], intestinal epithelial 
cell maturation [23], kidney glomerular filtration [24], insulin secretion [25], blood pressure  
regulation [26, 27], etc.  
We and others have reported that EPHs and EFNs, particularly their B family members as well 
as some A family members, are important in the immune system [28]. We have shown that 
EFNB1, EFNB2 and EFNB3 initiate signaling through their EPH receptors and can co-
stimulate peripheral T cells [29-31]. We have reported that EPHB6 can transmit signals into T 
cells [32] and that its null mutation compromises T-cell responses in vitro and in vivo [33]. We 
have generated T cell-specific Efnb1/Efnb2 double gene knockout mice and have observed 
that their T-cell development and function are compromised [19, 20].  
In the present study, we investigated roles of EFNB1 and EFNB2 in the pathogenesis of RA 
using both animal models and human clinical studies.  
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Materials and Methods 
Mouse CIA induction, clinical scoring and histology 
The methodology for the mouse CIA model as well as its clinical and histology scoring has 
been described previously [34]. The mice were either in the C57BL/6 background or in the 
DBA/1LacJ background. Chick type II collagen (CTIIC; Chondrex, Redmond, WA) was used 
as an immunogen (with CFA on day 0, and with IFA on day 20 for boost) for the former 
strain, and bovine type II collagen (BTIIC; Chondrex), for the latter (with CFA on day 0). 
Enzyme-linked immunosorbent assay (ELISA) for anti-CTIIC Ab titres 
The method for andti-CTIIC Ab measurement was detailed in our previous publication [34].    
Flow cytometry 
Rat anti-mouse PD-1 monoclonal antibody (mAb), rat anti-mouse GL7 mAb, rat anti-mouse 
CD40L mAb and rat anti-mouse CXCR5 mAb were from BD Biosciences (Mississauga, ON, 
Canada). The remaining mAb used in flow cytometry are described in a previous publication 
[19].   
T-B cell co-culture 
Draining LN (dLN; inguinal and iliac) were harvested from WT and dKO mice 35 days after 
immunization with CCTII/CFA. T cells from dLN were enriched by Mouse T Cell Enrichment 
Kit (Stemcell Technologies, Vancouver, BC, Canada), and B cells, by Mouse B Cell 
Enrichment Kit (Stemcell Technologies). Purified T and B cells were mixed at different ratios 
and cultured in the absence or presence of T-cell proliferation grade CTIIC (50 µg/ml). The 
culture supernatants were harvested at different days for the measurement of CTIIC-specific 
IgG.  
T-cell transfer and isolation from paws 
C57BL/6 X B6.SJL F1 mice (CD45.1+CD45.2+) were immunized with CTIIC to induce CIA 
as described above. On day 35 after the first immunization, a mixture of (10-20) x106 T cells 
from non-immunized WT B6.SJL (CD45.1+) mice and non-immunized EFNB1B2 dKO 
(CD45.2+) mice at a 1:1 ratio was transferred to the immunized mice. Twelve hours after cell 
injection, the mice were perfused with 20 ml PBS under anesthesia to remove peripheral blood 
cells in paws. The paws were harvested, skinned and minced into small pieces, which were 
then digested with collagenase II (2 mg/ml, Chondrex) and dispase II (250 µg/ml, Roche 
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Diagnostics, Indianapolis, IN) in 15 ml Hank’s balanced salt solution at 37oC in a shaker-
incubator at 250 rpm for 40 min. The digested product was washed and passed through cell 
strainers (BD Bioscience) of 70-µm pore size. Cells isolated from paws as well as those from 
blood, spleen, and mesenteric, inguinal, and iliac lymph nodes were analyzed by flow 
cytometry.  
Lentivirus preparation and infection 
PCR-based deletion mutations of Efnb1 and Efnb2 intracellular tails were generated and were 
cloned into pLenti CMV/TO PGK GFP Destination vector (Addgene, Cambridge, MA). These 
constructs were transfected into HEK 293T cells along with packaging constructs pLp1, pLp2 
and pLpSV. Viruses were isolated from the supernatants 72 h later. T cells from LN of non-
immunized WT mice were isolated and stimulated with soluble anti-CD3 mAb (0.05 µg/ml; 
clone 145-2C11, BD Biosciences). After 12-16 h, the T cells were infected with lentiviruses in 
96-well plates (0.8x106 cells/well) in the presence of 10 µg/ml polybrene infection/transfection 
reagent (Millipore, Billerica, MA) for the expression of full-length or deletion mutants of 
Efnb1 and Efnb2. They were cultured in the presence of 0.05 µg/ml anti-CD3 mAb for an 
additional 48 h and then underwent in vitro chemotaxis assay. 
In vitro T-cell chemotaxis assay 
LN T cells or spleen T cells (0.7x106) without or with lentivirus infection were placed on the 
top chamber of Transwell (pore size 5 µM; Corning, Mississauga, ON, Canada) in 100 µl 
RPMI 1640 medium containing 0.5% BSA and 10 nM HEPES. The bottom chamber was 
filled with 600 µl of the same medium but contained CXCL12 (200 ng/ml, R&D Systems). 
The Transwell plates were incubated for 2 h at 37oC. The numbers of total input cells and cells 
that migrated into the lower chamber were counted 3 times by flow cytometry. Mean 
percentages of migrated T cells were calculated according to the following formula: 
% of migrated cells = 100 x cells in the bottom chamber at the end of assay/total input cells at 
the beginning of assay  
Patients and healthy controls 
Thirty-two patients diagnosed with RA, according to 2010 American College of 
Rheumatology against Rheumatism classification criteria for RA [35], were recruited from the 
Rheumatology Clinic of Sichuan Provincial People’s Hospital, West China Hospital, and the 
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General Hospital of Chengdu Military Region in Chengdu, China. None of the patients was 
treated with disease modifying anti-rheumatic drugs at the time of the study. Patients with 
renal insufficiency or under corticosteroid treatment were excluded. Twenty-eight gender- and 
age-matched healthy volunteers were recruited as controls. The numbers of tender and swollen 
joints were ascertained after examination of 28 joints.  
Reverse transcription-quantitative PCR (RT-qPCR) for human T cell EFNB1 expression 
Peripheral blood mononuclear cells were isolated from heparinized blood by Ficoll density 
gradient (Axis-Shield, Oslo, Norway). T cells were then purified by T Cell-Negative Selection 
Kit (Miltenyi Biotec, Auburn, CA). EFNB1 mRNA levels in T cells were assessed by RT-
qPCR; the primers used were 5’-AAG AAC CTG GAG CCC GTA TC-3’ and 5’-AAC ACG 
TTG GGG TCG AGA AC-3’. GAPDH mRNA expression served as internal control, using 
primers 5’-GTG AAC CAT GAG AAG TAT GAC AAC-3’ and 5’-CAT GAG TCC TTC 
CAC GAT ACC-3’.  The qPCR condition was: 10 min at 95℃, followed by 40 cycles of 3 
steps: 10 s at 95℃, 15 s at 60℃, and 20 s at 72℃. mRNA expression was normalized to 
GAPDH expression levels, and relative expression was calculated by the 2−ΔΔCt method [36].  
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Results 
Reduced CIA pathogenesis in dKO mice 
We investigated whether T cell-specific Efnb1 and Efnb2 dKO would affect CIA pathogenesis. 
dKO in the C57BL/6 background showed delayed CTIIC-induced CIA onset as well as 
significantly lower clinical scores than WT (Fig. 2.1A, left panel). The CIA incidence of the 
dKO mice in this model was moderately lower than that of the WT mice. In the last 3 days of 
the experiment (days 57-60), there seems to be a significant drop of CIA incidence in the dKO 
mice (Fig. 2.1A, right panel). It is to be noted that the CIA scores in the dKO mice of the 
C57BL/6 background were very low (around 0.5). Therefore, a small variation will result in 
the disappearance of CIA manifestation, hence a drastic drop in disease incidence. Thus, the 
drop of the CIA incidence in the last 3 days, although seems quite big in the diagram, does not 
reflect a meaningful difference in CIA clinical scores. A more robust BTIIC-induced CIA 
using dKO mice in the DBA/1LacJ background was also employed with the clinical scores of 
WT mice reaching 14. In this CIA model, dKO mice also had significantly lower clinical 
scores than their WT counterpart, although the disease incidence of the dKO and WT mice 
was similar (Fig. 2.1B).  
The CIA mice in the C57BL/6 background were sacrificed on day 60, and their paws 
underwent histopathological examination. As illustrated in Fig. 1C, dKO paws presented less 
synovial membrane hyperplasia (asterisks), less immune cell infiltration and mild cartilage 
erosion (arrowheads). Total pathological, lining hyperplasia, bone destruction and cell 
infiltration scores of dKO paws were significantly lower than those of WT paws (Fig. 2.1D). 
These results clearly show that EFNB1 and EFNB2 dKO in T cells leads to decreased CIA 
severity.   
Lower collagen-specific Ab titres in dKO mice 
Auto-Abs contribute significantly to RA pathogenesis [37, 38], and anti-collagen Ab are 
pathogenic in CIA. We assessed CTIIC-specific Ab titres in dKO and WT mice in the 
C57BL/6 background after CTIIC immunization. CTIIC-specific total IgG, IgG1, IgG3 and 
IgM titres in dKO sera on day 14 after immunization were significantly lower than in WT 
controls (Figs. 2.2A, 2B, 2C and 2D). Although CTIIC-specific IgG2a, IgG2b and IgG2c titres in 
dKO mice were lower than those of WT controls, they did not reach statistical significance 
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(Data not shown). At the later time points than day 14, the CTIIC-specific IgG titres in the 
dKO and WT sera became similar (data available upon request). 
Consistent with findings of lower CTIIC-specific Ab titres, on day 14 after initial CTIIC 
immunization, dKO mice presented significantly reduced percentages of Fas+GL7+ germinal 
centre (GC) B cells (Fig. 2.3A), and B220lowCD138+ plasma cells (Data available upon request) 
in dLN, compared to their WT counterparts, although no consistent decrease of these cells was 
seen in either spleen (for both cell types) or bone marrow (for plasma cells).   
dKO T cells failed to provide help to B cells  
Follicle T helper cells (Tfh), a T-cell subset, are important in GC B cell differentiation to Ab-
producing plasma cells [39, 40]. Tfh development was assessed in mice 14 days after 
CTIIC/CFA immunization in mice in the C57BL/6 background, a midpoint between time of 
immunization and full-fledged CIA. dKO dLN were smaller in size (data not shown), and the 
absolute numbers of T cells in dLN were significantly lower (Fig. 2.3B) than in their WT 
counterparts. The percentage of CRCXR5+/PD-1+ Tfh cells in dLN was significantly lower in 
dKO mice than in WT controls (Fig. 2.3C), although no such difference was discerned in the 
spleen (data not shown). 
As dKO mice have fewer T cells in the spleen and LN [19], we wondered whether, on an 
equal-number basis, dKO T cells were compromised in providing help to B cells in Ab 
production. T and B cells were isolated from WT and dKO mice (in the C57BL/6 background) 
35 days after the initial CTIIC/CFA immunization. WT or dKO T cells were cultured with B 
cells from WT or dKO mice at 1:1 and 1:5 T/B cell ratios in the absence or presence of CTIIC 
for 7 days. Collagen-specific IgG titres were measured in the supernatants. As seen in Fig. 3D, 
in the absence of CTIIC, little collagen-specific IgG was produced in all combinations. The 
presence of collagen boosted collagen-specific IgG production in WT T and WT B cell co-
culture, but did not in dKO T and WT B cell co-culture. In these combinations, as the B cells 
in these combinations were all from immunized WT B cells, failed CTIIC-specific Ab 
production in dKO T and WT B cell co-culture was clearly due to lack of help from dKO T 
cells. Since the absolute input T-cell number of WT and dKO T cells was the same in this co-
culture experiment, this result indicates that, on a per-cell basis, dKO T cells are compromised 
in providing help to B cells in arthrogenic Ab production, compared to WT T cells. When WT 
T cells were cultured with B cells from dKO mice, the CTIIC-specific Ab titres were very low 
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either in the presence of absence of CTIIC. This suggests that CTIIC-specific B cells from 
CTIIC-immunized dKO were not sufficiently primed and/or expanded in vivo. Since the 
EFNB1 and EFNB2 deletion was T-cell specific, the compromised priming/expansion of B 
cells from dKO mice is likely due to insufficient T-cell help received during in vivo 
immunization before the B cells were isolated. No CTIIC-specific Ab was detectable in the 
culture with T cells and B cells all from dKO mice, because the compromised in vitro help by 
dKO T cells is compounded by defective priming/expansion of B cells from the dKO mice 
during the immunization.  
Reduced T-cell infiltration in arthritic joints of dKO mice 
We isolated infiltrating cells from CIA paws, and flow cytometry found that dKO mice paws 
contained fewer T cells (Thy1.2+; Fig. 2.4A). These findings corroborate our histologic 
observations (Fig. 2.1C).   
Was the lower T cell number in dKO CIA paws due to reduced migration of dKO T cells into 
the paws, or simply reflected lower T cell numbers in dKO mice, which was demonstrated in 
our previous publication [19]? We conducted a cell transfer experiment to address this 
question. C57BL/6 x B6.SJL F1 mice (CD45.1+CD45.2+) were immunized with CTIIC/CFA 
on day 1 and CTIIC/IFA on day 21 to induce CIA. On day 35 after the initial immunization, T 
cells from non-immunized WT B6.SJL (CD45.1+) and Efnb1/Efnb2 dKO in the C57BL/6 
background (CD45.2+) mice were co-transferred i.v. at a 1:1 ratio to F1 CIA mice. Sixteen 
hours after cell transfer, cells were collected from blood, spleen, LN (mesenteric, inguinal, 
iliac) and paws for flow cytometry. As illustrated in Fig. 4B, the CD45.1+/CD45.2+ (WT/KO) 
T cell ratio in CIA paws was ~4 (1.11% versus 0.29%), but the ratio in blood, spleen and LN 
was ~2 (Fig. 2.4B), indicating that dKO T cells were compromised in their ability to migrate 
to arthritic paws. 
We conducted in vitro cell migration assays to evaluate Efnb1 and Efnb2 function in CXCR4-
mediated T-cell chemotaxis. dKO LN T cells showed reduced chemotaxis towards CXCL12, 
the CXCR4 ligand, compared to their WT counterparts (Figs. 2.5A). Conversely, when WT T 
cells were overexpressed with full-length Efnb1 (Fig. 2.5B, left panel) or Efnb2 (Fig. 2.5B, 
right panel) using a lentivirus-mediated expression system, the cells manifested increased 
migration towards CXCL12.  
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We generated deletion mutants of Efnb1 and Efnb2 with different lengths of deletions, as 
illustrated in Figure 2.5C. These mutants, as well as full-length Efnb1 and Efnb2, were 
overexpressed in WT T cells using the lentivirus expression system. WT T cells 
overexpressing a mutant with deletion of C-terminal 16 aa (i.e., deletion of the sequence 
harbouring the PDZ domain-binding motif, and the last 2 Tyr residues, Y342 and Y343, of the 
Efnb1 intracellular tail, Efnb1-Δ2Y) did not reduce but enhanced T cell chemotaxis towards 
CXCL12 in in vitro Transwell assays, compared to T cells overexpressing full-length Efnb1 
(Fig. 2.5D, left panel), suggesting the existence of a negative regulatory element in this 
segment. Additional deletion of a stretch harbouring Y328 and Y323 (Efnb1-Δ4Y, i.e., 
deletion of C-terminal 23 aa) resulted in drastically decreased chemotaxis, indicating that the 
Efnb1 intracellular sequence between aa 323 and aa 329 contains a critical positive element(s) 
controlling T cell chemotaxis towards CXCL12. A further deletion from aa 312 to aa 322 
(including Y316 and Y312; EFNB1-Δ6Y; i.e., deletion of C-terminal 34 aa) did not cause an 
additional reduction of chemotaixis.     
A similar experiment was conducted with lentiviruses expressing deletion mutants of Efnb2 
(Figure 2.5D, right panel). The results were similar, except that deletion of the sequence 
harbouring the PDZ domain-binding motif, Y333 and Y334 of the Efnb2 intracellular tail 
(Efnb2-Δ2Y, i.e., deletion of C-terminal 5 aa), did not enhance chemotaxis. Further deletion 
using Efnb2-Δ4Y lentivirus with deletions of C-terminal 24 aa (including Y314 and Y319 
deletion) significantly reduced the chemotaxis, indicating the existence of a critical positive 
regulatory element between aa 313 and aa 331. A further deletion from aa 306 to aa 312 
(including Y307; Efnb2-Δ5Y; i.e., deletion of C-terminal 31 aa) did not cause an additional 
reduction of chemotaxis. 
EFNB1 expression on T cells correlates with arthritis severity in RA patients 
We measured EFNB1 and EFNB2 expression at the mRNA level in T cells from RA patients 
and     gender- and sex-matched healthy controls, to assess their correlation with the clinical 
findings and laboratory parameters. EFNB1 (Fig. 2.6A) but not EFNB2 (data available upon 
request) expression in T cells from RA patients was significantly higher than in T cells of 
healthy controls. EFNB1 expression levels in RA T cells were significantly correlated with the 
clinical observations, such as numbers of swollen and tender joints (Figs. 2.6B). EFNB1 
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expression levels in RA T cells were also significantly correlated with 4 laboratory parameters 
(Fig. 2.6C), such as serum anti-cyclic citrullinated protein (CCP) Ab, rheumatic factors (RF), 
erythrocyte sedimentation rates (ESR) and plasma C-reactive protein (CRP) levels in RA 
patients. 
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Discussion 
Efnb1/Efnb2 dKO mice have compromised T-cell development and present reduced numbers 
of peripheral T cells in lymphoid organs [19]. It was thus not surprising that dKO mice 
became resistant to CIA induction, as CIA is a T cell-dependent disease model. Novel findings 
in our present work are that, on a per-cell basis, dKO T cells are compromised in providing 
help to B cells for arthrogenic Ab (anti-CTIIC Ab) production, and in migrating to 
inflammatory joints. Previously, we also demonstrated that CD4 dKO T cells are defective in 
developing into Th17 cells [19], which are known to be involved in RA pathogenesis [5]. All 
these defects likely contribute to resistance to CIA pathogenesis in dKO mice, indicating that 
the role of EFNB1 and EFNB2 in RA/CIA pathogenesis is multifaceted. While deletion of the 
2 genes leads to ameliorated CIA in mice, our clinical studies proved that the reverse is also 
true: increased EFNB1 expression in T cells correlates with RA disease activity. The 
upregulation of EFNB1 is unlikely caused by the inflammatory environment in RA, because 
our mouse data showed that inflammatory cytokines such as IL-6, TNFα or IL-17 did not 
affect Efnb1 or Efnb2 expression in T cells (data available upon request). The causative role of 
high EFNB1 expression in T cells in RA pathogenesis in humans has yet to be validated. 
We discovered that Tfh cell percentage in dLN from dKO mice is decreased. Such a decrease 
could lead to reduced T cell help to B cells in B-cell differentiation towards Ab-producing 
plasma cells. We assessed the functionality of dKO Tfh cells, but found that their expression 
of ICOS and CD40L, which play important roles in B-cell differentiation [41], was 
comparable to that in their WT counterparts (data available upon request). Also, in vitro-
differentiated dKO and WT Tfh cells were all capable of producing high levels of IL-21 (data 
available upon request), a cytokine essential in B-cell differentiation and proliferation [41]. 
Admittedly, the dKO Tfh cell functionality tests were not exhaustive, and they could still have 
so-far undetected defects. It is likely that reduced dKO Tfh percentage, absolute number, and 
some general help of non-Tfh cells to B cells all contributed to decreased anti-CTIIC Ab titres 
in dKO mice.  
It is noteworthy that reduced anti-CTIIC Ab titres in dKO mice appeared on day 14 after the 
initial immunization, which was corroborated by reduced GC B cell and plasma cell 
percentages in dLN at that time point. This was a week before the beginning of CIA symptom 
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manifestation, starting on day 21, and was probably a critical period during which arthrogenic 
Abs play a role in triggering CIA pathogenesis, which, at a later stage, could become a self-
sustained, vicious circle locally in arthritic joints independently of T and B cells [37, 38]. The 
vital roles of T cell Efnb1 and Efnb2 in humoral immune responses are probably restricted to 
the early stage after immunization, as decreases of GC B cells (Fig. 3A) and plasma cells only 
appeared in dLN but did not propagate into the spleen and bone marrow, the latter harbouring 
long-lived plasma cells (data available upon request) capable of sustained Ab production. 
Indeed, after day 21, serum anti-CTIIC Ab titres in dKO and WT mice no longer presented 
significant differences (data available upon request).  
In addition to the reduced production of pathogenic Ab, lower inflammatory cytokine 
production in CIA could also be a contributing factor to the reduced CIA severity in dKO mice, 
since we have evidence that serum IL-6 levels in the dKO mice were lower than those in their 
WT counterparts in CIA (data available upon request). 
We revealed that Efnb1 and Efnb2 have critical functions in T-cell chemotactic migration to 
inflammatory joints in CIA. Such functions are not restricted to a single chemokine 
(CXCL12), but seem to be generally applicable to other chemokines, such as CCL5, CCL19, 
CCL20 and CCL21 (data not shown).  
Efnb intracellular tails are about 82-aa long and lack any enzymatic activity. Efnb intracellular 
tails are characterized by 2 major features: the C-terminal PDZ domain-binding motif and 5-6 
Tyr residues, which could be associated with PDZ-domain-containing proteins (e.g., PDZ-
RGS3, GRIP1/2, TIAM1 and DISHEVELED [12, 17, 42-44]), and SH2-domain-containing 
proteins (e.g., GRB4, STAT3 and CRK, respectively [15, 45, 46]). These 2 features are 
located in the last 34 aa for Efnb1 and last 31 aa for Efnb2, which are highly conserved. Efnbs 
can also have PDZ- and SH2-independent functions [14], some of which presumably depend 
on the SH3 domain of associating proteins (e.g., CRK and GRB4 [15, 46]). By deleting 
different lengths of the Efnb1 and Efnb2 intracellular tail, we have identified critical 
intracellular tail regions (i.e., from aa 323 to aa 329 in Efnb1, and aa 313 to aa 331 in Efnb2) 
for T-cell chemotaxis enhancement. Elements in these critical regions, such as Y323 and Y328 
in Efnb1 and Y314 and Y319 in Efnb2, are probably responsible for mediating signals related 
to T-cell chemotaxis. The exact associating proteins involved in this function are yet to be 
identified, but candidates include known EFNB-associating SH2-domain-containing proteins, 
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such as CRK [46], GRB4 [15] and STAT3 [45]. We have also determined that the last 16 aa in 
the C-terminus of Efnb1 (including Y342 and Y343 plus the PDZ-domain-binding motif), and 
the last 5 aa in the C-terminus of Efnb2 (including Y333 and Y334 plus the PDZ-domain-
binding motif) are not important for promoting T-cell chemotaxis, as their deletion did not 
reduce Efnb1’s and Efnb2’s ability to promote T-cell chemotaxis. On the contrary, deletion of 
the region in Efnb1 but not Efnb2 augmented T-cell chemotaxis, suggesting the existence of a 
negative regulator in this region. Adaptor proteins containing the PDZ domain (such as 
GRIP1/2, DISHEVELED, TIAM1 and PDZ-RGS3) or SH2 could be candidates for such a 
function. 
Our clinical study showed that EFNB1 expression in peripheral T cells was correlated with 
RA disease activities. Although such correlation was not found between EFNB2 expression 
and RA disease activities, it is not totally unexpected, given the fact that EFNB2 single gene 
KO in T cells in mice does not result in apparent compromise of T-cell function [47]; the 
defective immune response is only demonstrated when both EFNB1 and EFNB2 are deleted 
due to the possible redundancy of their functions [20]. From an application point of view, 
EFNB1 expression levels in T cells could be a new parameter for monitoring disease severity 
and possibly treatment responses in RA patients.  
In summary, we have identified new functions of Efnb1 and Efnb2 in T cells in their 
contribution to CIA pathogenesis in animal models, and our clinical studies suggest that 
EFNB1 expression in T cells might be a useful parameter for monitoring RA disease activity 
and treatment responses.  
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 Figure legends 
Figure 2.1  dKO mice were resistant to CIA induction 
A.  CIA clinical scores and incidence of mice in the C57BL/6 background 
Mean CIA clinical scores for WT (n=19) and dKO (n=16) ± SEM were plotted. *indicates 
significant difference (p<0.05, Student’s t test). The CIA incidence was also plotted.  
B.  CIA clinical scores and incidence of mice in the DBA/1LacJ background 
Mean clinical scores for WT (n=12) and dKO (n=9) ± SEM were plotted. *indicates 
significant difference (p<0.05, Student’s t test). The CIA incidence was also plotted. 
C. Histology of arthritic paws of CIA mice in the C57BL/6 background 
dKO and WT mice paws (60 days after the first immunization) were sectioned and stained 
with H&E or safranin O (SO; for cartilage staining) as indicated. Representative sections from 
WT and dKO are shown.  
D. Histological scores of arthritic paws of CIA mice in the C57BL/6 background 
Sections were prepared as described in C. The histology scores of all paws from 13 WT and 9 
dKO mice were blindly evaluated for lining hyperplasia (1st panel), bone erosion (2nd panel) 
and cell infiltration (3rd panel). The overall scores for each animal were calculated and shown 
in the last panel. Student’s t tests were performed, and p-values are indicated.  
Figure 2.2  Reduced serum collagen-specific Ab titres in dKO mice   
Arbitrary titres of CTIIC-specific IgG (A), IgG1 (B), IgG3 (C) and IgM (D) in dKO and WT 
mice on day 14 after immunization were analyzed by ELISA. Numbers of mice (n) per group 
are indicated. Data are expressed as means ± SEM. p-values are reported (Student’s t test). 
Figure 2.3  dKO T cells presented less help to B cells in mice of the C57BL/6 background 
A. Reduced percentage of GC B cells in dKO dLN   
The percentages of B220+GL7+Fas+ GC B cells from the dLN and spleen of WT and dKO 
mice 14 days after CTIIC/CFA immunization were analysed by flow cytometry. The 
experiments were conducted 3-5 times and representative histograms are presented.  
B. Reduced absolute T-cell number in dLN of dKO mice 
Total dLN cells were obtained from WT (n=4) and dKO (n=4) mice on day 14 after the initial 
CTIIC/CFA immunization, and absolute numbers of dLN T cells per mouse are presented in a 
line graph. The p-value is indicated (Student’s t test).    
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C. Reduced Tfh numbers in dLN from dKO mice after CTIIC/CFA immunization   
Percentages of PD-1+CXCR5+ Tfh cells among effector CD4 cells (CD4+CD44+CD62L-) in 
the dLN of WT and dKO mice on day 14 after CTIIC/CFA immunization were analyzed by 
flow cytometry. The experiments were conducted 3 times, and representative histograms are 
presented. 
D. dKO T cells failed to help primed B cells to produce collagen-specific IgG in vitro 
CD4+ T cells and B220+ B cells were isolated from dLN of WT and dKO mice 35 days after 
the first immunization.  T and B cells were mixed at a ratio of 1:1 or 1:5 as indicated, and then 
co-cultured in the absence or presence of 50 µg/ml CTIIC. Collagen-specific IgG in the 
supernatants 7 days after culture was measured by ELISA. Data are representative of 3 
independent experiments.  
Figure 2.4  Compromised migration of dKO T cells to arthritic paws in mice of the C57BL/6 
background 
A.  Reduced numbers of infiltrating T cells in dKO mice paws after CTIIC/CFA immunization  
On day 14 after CTIIC/CFA immunization, cells infiltrating WT and dKO mice paws were 
isolated, stained and enumerated by flow cytometry. The numbers of infiltrating Thy1.2+ T 
cells per paw are shown. Mouse numbers per group are indicated. Student’s t test assessed the 
statistical significance of differences between WT and dKO mice, and p-values are reported.   
B.  Compromised migration of transferred dKO T cells into arthritic paws 
T cells from the spleens of naïve WT (B6.SJL) and dKO (C57BL/6) mice were isolated 
through negative selection. WT and dKO T cells were mixed at a 1:1 ratio, and (10-20) x 106 
mixed cells were injected i.v. into C57BL/6 x B6.SJL F1 mice which were immunized with 
CTIIC/CFA 35 days earlier. Twelve hours after the injection, CD45.1+ (WT donor T cells), 
CD45.2+ (dKO donor T cells) in blood, spleen, LN (mesenteric, inguinal, iliac), and paws 
were analyzed by flow cytometry. The experiments were conducted independently 3 times, 
and representative histograms are presented. 
Figure 2.5  Efnb1 and Efnb2 expression affect T cell chemotaxis towards CXCL12 using mice 
in the C57BL/6 background 
A. Impaired dKO T cell migration towards CXCL12 in vitro 
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LN T cells migrated into the lower chamber (containing CXCL12) in a Transwell system were 
counted by flow cytometry. The means ± SEM of total migrated T cells are shown. Data are 
representative of 3 independent experiments.  
B. Enhanced T cell chemotaxis towards CXCL12 after Efnb1 and Efnb2 overexpression 
WT spleen and mesenteric LN cells were infected with lentivirus encoding full-length Efnb1 
(left panel) or Efnb2 (right panel), or control lentivirus. The means + SE of percentages of T 
cells migrated toward 200 ng/ml CXCL12 in 7 independent Transwell experiments are 
reported. p-values are shown (Student’s t test). 
C. Illustration of Efnb1 and Efnb2 deletion mutants  
The general structures of Efnb1 and Efnb2 are depicted. Different deletion mutants and their 
nomenclatures are illustrated. 
D.  Critical regions in the Efnb1 and Efnb2 intracellular tail for T-cell chemotaxis towards 
CXCL12 
WT spleen and mesenteric LN cells were infected with lentiviruses encoding full-length or 
deletion mutants of Efnb1 (left panel) and Efnb2 (right panel). The percentages (means + SE) 
of T cells with different infections migrating towards CXCL12 in Transwell assay are plotted. 
The numbers of independent experiments conducted for different lentiviruses are indicated. p-
values between different infection groups are shown (Student’s t test). 
Figure 2.6  EFNB1 mRNA levels in T cells of RA patients  
A. EFNB mRNA levels are higher in T cells of RA patients than in healthy controls 
T cells from PBMC of RA patients and healthy controls were analyzed for EFNB1 mRNA 
expression by RT-qPCR. Arbitrary EFNB1 expression levels are shown. Each symbol 
represents an individual. Sample numbers (n) are shown. The long and short horizontal bars 
represent means + SE, respectively. Statistical significance was assessed by Student’s t test, 
and the p-value is indicated. 
B. Correlation of EFNB1 mRNA expression in T cells with RA disease activities in RA patients 
Relative EFNB1 mRNA expression levels in RA patients were plotted against RA symptoms  
(numbers of tender and swollen joints per patient). The numbers of patients (n) and correlation 
efficiency (r2) are indicated. The significance of correlation was analyzed by Pearson’s 
correlation test, and p-values are presented. 
C. Correlation of EFNB1 mRNA expression in T cells with laboratory findings in RA patients 
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Relative EFNB1 mRNA expression levels in RA patients were plotted against their serum 
anti-CCP Ab levels, serum rheumatic factor, erythrocyte sedimentation rate and plasma C-
reactive protein levels. The number of patients (n) and correlation efficiency (r2) are indicated. 
The significance of correlation was analyzed by Pearson’s correlation test, and p-values are 
presented.  
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Figures 
Figure 2.1 dKO mice were resistant to CIA induction 
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Figure 2.2 Reduced serum collagen-specific Ab titres in dKO mice   
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Figure 2.3 dKO T cells presented less help to B cells in mice of the C57BL/6 background 
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Figure 2.4 Compromised migration of dKO T cells to arthritic paws in mice of the C57BL/6 
background 
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Figure 2.5 Efnb1 and Efnb2 expression affect T cell chemotaxis towards CXCL12 using mice 
in the C57BL/6 background 
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Figure 2.6 EFNB1 mRNA levels in T cells of RA patients 
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Chapter 3 Article-2 
To investigate the necessity of STRA6 upregulation in T 
cells during T cell immune responses 
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Abstract 
Our earlier study revealed that Stra6 (stimulated by retinoic acid gene 6) was up-regulated 
within 3 h of TCR stimulation. STRA6 is the high-affinity receptor for plasma retinol-binding 
protein (RBP) and mediates cellular vitamin A uptake. We generated Stra6 knockout (KO) 
mice to assess whether such up-regulation was critical for T-cell activation, differentiation and 
function. Stra6 KO mice under vitamin A sufficient conditions were fertile without apparent 
anomalies upon visual inspection. The size, cellularity and lymphocyte subpopulations of 
Stra6 KO thymus and spleen were comparable to those of their wild type (WT) controls. KO 
and WT T cells were similar in terms of TCR-stimulated proliferation in vitro and homeostatic 
expansion in vivo. Naive KO CD4 cells differentiated in vitro into Th1, Th2, Th17 as well as 
regulatory T cells in an analogous manner as their WT counterparts. In vivo experiments 
revealed that anti-viral immune responses to lymphocytic choriomeningitis virus in KO mice 
were comparable to those of WT controls. We also demonstrated that Stra6 KO and WT mice 
had similar glucose tolerance. Total vitamin A levels are dramatically lower in the eyes of KO 
mice as compared to those of WT mice, but the levels in other organs were not significantly 
affected after Stra6 deletion under vitamin A sufficient conditions, indicating that the eye is 
the mouse organ most sensitive to the loss of Stra6. Our results demonstrate that 1) in vitamin 
A sufficiency, the deletion of Stra6 in T cells does no affect the T-cell immune responses so-
far tested, including those depend on STAT5 signaling; 2) Stra6-independent vitamin A 
uptake compensated the lack of Stra6 in lymphoid organs under vitamin A sufficient 
conditions in mice; 3) Stra6 is critical for vitamin A uptake in the eyes even in vitamin A 
sufficiency. 
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Introduction 
During T-cell immune responses, naive T cells are activated by stimuli through TCR in the 
company of co-stimulation signals, and undergo multiple rounds of proliferation before 
entering the differentiation phase, after which they become effector T cells. The expression of 
many molecules is modulated during activation and differentiation stages, with some of them 
playing pivotal regulatory roles, while others exert support and house-keeping functions to 
cope with increased metabolic demands. We undertook unbiased exploration with DNA 
microarray analysis of molecules up- or down-regulated in T cells within the first 16 h after 
stimulation by anti-CD3 with a view to identifying those that are critical in the early T-cell 
activation stage. A group of molecules with the highest levels of altered expression in 
activated T cells was chosen, with resting T cells as reference, and verified by Northern 
blotting analysis. Stra6 (stimulated by retinoic acid gene 6) is among those that have been 
validated. We generated Stra6 gene knockout (KO) mice to assess the significance of its up-
regulation in T-cell activation and, consequently, T-cell immune responses.   
At the outset of our investigation in 2004, no function was ascribed to STRA6, a 74-kDa 
protein with multiple transmembrane domains that was first identified in retinoic acid-
stimulated P19 embryonic carcinoma cells upon retinoic acid stimulation [1]. In 2007, 
Kawaguchi et al. used an unbiased technique to identify STRA6 as a specific cell-surface 
receptor for plasma retinol binding protein (RBP) and showed that STRA6 mediates cellular 
vitamin A uptake from holo-RBP (RBP/vitamin A complex) in bovine retinal pigment 
epithelium cells [2]. STRA6-mediated vitamin A uptake from holo-RBP is coupled to 
intracellular proteins as confirmed by several independent studies [1-5], and its mechanism in 
coupling to specific intracellular proteins has been elucidated [4].  Pasutto et al. [6] observed 
that mutations in STRA6 correlated with many eye, heart, diaphragm and lung malformations 
as well as mental retardation in Matthew-Wood syndrome in humans, corroborating its 
reported roles in vitamin A uptake by cells as vitamin A is vital in organogenesis. Recent 
reports indicate that single nucleotide polymorphisms or mutations in STRA6 gene are 
correlated with the congenital eye malformations microphthalmia, anophthalmia and 
coloboma [7,8] as well as Matthew-Wood syndrome [9]. Genetic null mutation of Stra6 in 
mice results in a significant retinoid reduction in the retinal pigment epithelium and 
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neurosensory retina, diminished visual responses and eye morphology, although the last-
mentioned defect is not as serious as in patients with STRA6 mutations [10]. 
There is a report suggesting that STRA6 is not only a vitamin A transporter but can also 
function as a cytokine receptor. Upon binding with holo-RBP, STRA6 is phosphorylated at 
tyrosine residue 643, which, in turn, recruits and triggers JAK2 and STAT5 activation [11].  
The ascribed roles of STRA6 in vitamin A transport and the STAT5 signalling pathway are 
certainly relevant to T-cell activation and function. Retinoids are known to modulate Th1 (T 
helper 1), Th2, Th17 and reglulatory T (Treg) cell development and function [12-17]. At the 
molecular level, it has been demonstrated that retinoic acid opens up the FoxP3 promoter 
tertiary structure for activated FoxP3 transcription [18]. RARα can interact with STAT5a and 
b [19], which are critical molecules in the signaling pathway of a key T activation cytokine IL-
2 [20]. 
Vitamin A is absorbed from dietary nutrients. There are several possible modes of vitamin A 
transport to cells in different organs. Vitamin A in the diet can be transported to liver cells and 
other cell types in the form of chylomicron-bound retinyl ester [21,22]. The liver is the 
primary storage site for vitamin A in the form of all-trans-retinyl ester, which can be reverted 
to vitamin A [22]. As alluded to above, vitamin A associates with RBP in blood, and such 
complexes can deliver vitamin A to cells via the RBP receptor STRA6 [2].  Transthyretin can 
associate with vitamin A-bound RBP, and such coupling serve to prevent renal filtration of the 
holo-RBP [23], Recently, Alapatt et al. [24] discovered a second RBP receptor, a STRA6 
homologue called RBPR2. RBPR2 is expressed in the liver, intestines, fatty tissues, and 
spleen.  Like STRA6, RBPR2 is fully capable of binding to RBP and transporting vitamin A 
into cells. As vitamin A is hydrophobic, it should also be able to diffuse through cell 
membranes without any specific receptors.    
The relative contribution of STRA6 to vitamin A cellular import in lymphoid organs has not 
been evaluated and is a secondary goal of our study. 
In this study, we demonstrated that Stra6 KO mice were vital and fertile, manifesting no 
apparent anomalies in their lymphoid organs and T cell-dependent immune responses under 
vitamin A sufficient conditions. Intracellular vitamin A concentrations in lymphoid organs, 
such as the thymus and spleen of the KO mice were comparable to those of WT controls, 
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although the vitamin A content in cells from KO eyes was significantly lower that that from 
the WT eyes.  The implications of these data are discussed.  
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Materials and methods 
RT-qPCR 
Stra6 mRNA in cells and tissues from KO, heterozygous and WT mice was measured by RT-
qPCR. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, USA) and then 
reverse-transcribed with Superscript II™ reverse-transcriptase (Invitrogen). The forward and 
reverse primers were 5’-AGG CAT CTG AGA ATG GAA GCC AGA-3’ and 5’-AGC AGA 
ACC AGG AAC GAC AGT GAA-3’, respectively. A 184-bp product was detected with the 
following amplification program: 95oC × 15 min, 1 cycle; 94oC × 15 s, 55oC × 30 s, 72oC × 30 
s, 35 cycles. β-actin mRNA levels were measured as internal controls; the forward and reverse 
primers were 5’-TGG TAC CAC AGG CAT TGT GAT-3’ and 5’-TGA TGT CAC GCA CGA 
TTT CCC T-3’, respectively, with the same amplification program as for STRA6 mRNA.  The 
data were expressed as ratios of STRA6 and β-actin signals. 
Generation of Stra6 KO mice  
A PCR fragment amplified with the Stra6 cDNA sequence served as a probe to isolate 
genomic BAC DNA clone 7O8 from the RPCI-22 129/sv mouse BAC genomic library. The 
targeting vector was constructed by recombination [25] and routine cloning methods using an 
11-kb Stra6 genomic fragment from clone 7O8 as the starting meterial. A 2.7-kb MunI-XbaI 
genomic fragment containing exon 2 was replaced by a 1.1-kb Neo cassette from pMC1Neo-
Poly A flanked by 2 diagnostic restriction sites, XbaI and ScaI, as illustrated in Figure 2A. The 
final targeting fragment was excised from its cloning vector backbone by Not I digestion and 
electroporated into R1 embryonic stem (ES) cells for G418 selection [26]. The targeted ES 
cell clones were injected into C57BL/6 blastocysts. Chimeric male mice were mated with 
C57BL/6 females to establish mutated Stra6 allele germline transmission.  
Southern blotting with probes corresponding to the 5’ and 3’ sequences outside the targeting 
region, as illustrated in Figure 2A (red squares),  were used to screen for gene-targeted ES 
cells and eventually to confirm gene deletion in mouse tail DNA. With the 5’ probe, the 
targeted allele should present a 7.8-kb XbaI band, and the WT allele, a 5.2-kb XbaI band. 
With the 3’ probe, the targeted allele should present a 6.9-kb ScaI band, and the WT allele, a 
4.3-kb ScaI band (Fig. 3.2A). 
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PCR was adopted for routine genotyping of the targeted allele(s). The following PCR 
conditions were applied: 4 min at 94 oC, followed by 35 cycles of 30 s at 94 oC, 30 s at 60 oC, 
and 30 s at 72 oC, with a final incubation at 72 oC for 10 min. The KO forward primer 5'- GCG 
TCA CCT TAA TAT GCG AAG TG-3' and reverse primer 5'-CAA GAA GTC CGT GGC 
TGA GTC TA-3' detected a 400-bp fragment from the targeted allele. The WT forward primer 
5'-TCT CCC AGG TCT GGT TTG AG-3' and reverse primer 5'-TTA GGG CAA CAC CCT 
ACT GG-3' detected a 197-bp fragment from the WT allele. 
The KO mice were backcrossed to the C57BL/6 background for 8 generations and then used 
for experimentation. All mice were housed under specific pathogen-free conditions and fed 
with mouse chow (Teklad Global 2018, Teklan Diets, Madison, WI) containing 15 IU/g 
Vitamin A. The mice had access to water and chow ad libitum. The mouse organs and tissues 
were retrieved after the mice were euthanatized by i.p. injection of 100 µl of Euthanyl 
(pentobarbital sodium, 120 mg/ml containing 1% lidocaine). The same method of euthanasia 
was used for unwanted heterozygous mice or extra unused mice. The studies were approved 
by the Institutional Animal Protection Committees of the CRCHUM and INRS-IAF. 
Flow cytometry 
Single cell suspensions from the thymus, spleen and lymph nodes were prepared and stained 
immediately or after culture with antibodies (Abs) against CD4, CD8, CD25, CD19, B220, 
CD69 and STRA6. In some experiments, intracellular proteins, such as FoxP3, IFN-γ, IL-4, 
IL-17, and TNF-α, were detected after the cells were pre-stained with Abs against cell surface 
antigens fixed with BD Cytofix/Cytoperm™ solution (BD Biosciences, San Diego, CA) and 
then stained with monoclonal Abs (mAb) against intracellular antigens. The Abs deployed for 
flow cytometry are listed in Table 3.1. Flow cytometry analysis of the stained cells are 
described in our previous publications [27-30].  
Flow cytometry was also employed to assess lymphocytic choriomeningitis virus (LCMV)-
specific T cells. Synthetic peptides gp33-41: KAVYNFATC (LCMV-GP, H-2Db); np396-404: 
FQPQNGQFI (LCMV-NP, H-2Db); gp276-286: SGVENPGGYCL (LCMV-GP, H-2Db); and 
gp61-80: GLNGPDIYKGVYQFKSVEFD (LCMV-GP, I-Ab) were purchased from Sigma-
Genosys (Oakville, Ontario, Canada). PE-gp33-41, PE-np396-404 and PE-gp276-286 H-2Db 
tetrameric complexes were synthesized in-house and used at 1/100 dilution as previously 
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described [26]. These MHC-tetramers were used to detect LCMV-specific CD8+ T cells on 
day 8 post LCMV infection. Briefly, splenocytes were first stained with PE-gp33-41, PE-np396-
404 or PE-gp276-286 tetramers for 30 minutes at 37°C, followed by staining with FITC-rat anti-
mouse CD8α and APC-rat anti-mouse CD62L mAbs at 4°C for another 20 minutes. 7-AAD 
was used for exclusion of dead cells. After washing, cells were fixed in 0.5% 
paraformaldehyde and samples were analyzed by flow cytometry.  One million splenocytes 
from LCMV-infected mice were seeded in single wells of 96-well round-bottomed plates. 
They were maintained in 5% RPMI-1640 supplemented with 100 units/ml interleukin-2, 10 
µg/ml brefeldin A, 10 µM gp33-41 or gp61-80 peptide. After 5 h of incubation at 37°C, the cells 
were stained with PE-conjugated rat anti-mouse CD8α or CD4 mAbs and 7-AAD. They were 
then fixed, permeabilized and stained with APC-labeled rat anti-mouse TNF-α and FITC-
labeled rat anti-mouse IFN-γ mAbs. IFN-γ and TNF-α-secreting T cells were counted by flow 
cytometry [31].  
T-cell proliferation in vitro and in vivo after being transferred to sub-lethally-irradiated mice 
Spleen cells were loaded with carboxyfluorescein succinimidyl ester (CFSE; 5µM for 5 mins), 
and then cultured in the presence of soluble hamster against mouse CD3 mAb (clone 2C11; 
0.5 µg/ml) [27, 28, 32, 33]. After 3 days, CFSE fluorescence of the CD4 and CD8 
subpopulations was analyzed by flow cytometry for TCR-stimulated proliferation. T-cell 
homeostatic expansion was evaluated by i.v. injection of 5 x 106 CFSE-loaded spleen cells 
into C57BL/6 recipients 5 h after sub-lethal irradiation (650 Rad). On day 5, the CFSE 
fluorescence of CD4 and CD8 cells from the spleen and LN was studied by flow cytometry.   
In vitro Th1, Th2, Th17 and Treg cell polarization 
In vitro Th and Treg cell differentiation was conducted as follows [27, 34]. Naïve CD4 T cells 
(CD4+CD62L+CD44low) were isolated from KO or WT mouse spleens with MagCellect Mouse 
Naïve CD4+ T cell Isolation kits (R & D Systems). T cell-depleted WT spleen cells were 
irradiated at 3000 Rad and used as feeder cells. The naïve CD4 cells (0.1×106/ well) were 
mixed with the feeder cells (0.5×106/well) and cultured in 96-well plates in the presence of 
soluble anti-CD3ε mAb (clone 145-2C11, 2 µg/ml; BD Biosciences). Cultures were 
supplemented with recombinant mouse IL-12 (10 ng/ml; R & D Systems) and anti-IL-4 mAb 
(10 µg/ml; R & D Systems) for the Th1 condition; recombinant mouse IL-4 (20 ng/ml; R & D 
 89 
Systems), and anti-IL-12 mAb (10 µg/ml; BD Biosciences) and anti-IFN-γ mAb (10 µg/ml; R 
& D Systems) for the Th2 condition; recombinant mouse IL-6 (20 ng/ml; R & D Systems), 
recombinant human TGF-β1 (5 ng/ml; R & D Systems) and anti-IL-4 and anti-IFN-γ mAbs  
(10 µg/ml for each; R & D Systems) for the Th17 condition; recombinant human TGF-β1 (5 
ng/ml; R & D Systems), and anti-IL-4 and anti-IFN-γ mAb (10 µg/ml; R & D Systems) for the 
Treg condition. 
LCMV infection 
LCMV clone 13 was obtained from Dr. R.M. Zinkernagel (University of Zurich, Zurich, 
Switzerland). Viral stock was propagated in vitro, and viral titers were quantified by focus-
forming assay [31]. Mice were infected by the i.v. route with 2 × 106 focus-forming units of 
LCMV clone 13. They were sacrificed 8 days post-infection, and their spleens were harvested 
for primary immune response analysis.  
Glucose tolerance tests 
The KO and WT mice fasted for 16 h and injected i.v. with D-glucose (2 mg/g body weight) in 
PBS. Blood samples from the tail vein were taken at 5, 15, 30, 60, and 90 min after the 
injection for glucose measurements with a glucose meter (Bayer, Toronto, Ontario). 
Measurement of serum and intracellular vitamin A and retinyl ester concentrations by high-
pressure liquid chromatography (HPLC) 
Serum and tissue samples, collected in a dark, cold room, were stored at -80oC until their 
analysis. Retinoids were extracted by homogenizing tissues in a butanol-acetonitrile mixture 
(1:1) with a tissue/solvent ratio of 200 mg/700 µl, in Eppendorf tubes on ice by 5 30-s pulses 
with 1-min intervals. K2HPO4 solution (6.89M) was added to the tubes in proportion to the 
homogenized mixture (20 µl for 900 µl homogenized mixture). For retinoid extraction from 
sera, 200-µl butanol-acetonitrile mixture (1:1) was added to 200-µl serum, and the mixture 
was vortexed for 1 min; 20 µl K2HPO4 solution (6.89M) was then added to the mixture before 
30-s vortexing. The tissue and serum samples thus prepared were centrifuged for 20 min at 
14,000g at 4oC. Cleared supernatants were passed through Spin-X filters (0.45µm pore size; 
Costar, Batavia, Illinois, USA) at 14,000g for 10 min at 4oC. For retinyl ester measurement, 
the samples prepared as aforementioned before the step of filtration were vacuum-dried and 
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re-dissolved in 100% methanol, followed by centrifugation at 14,000 g for 10 min. The 
supernatants were then analyzed by HPLC.  
Vitamin A in extracts was quantified by HPLC in an ÄKTA Purifier (Model UPC10; GE 
Healthcare, Baie d'Urfé, Quebec, Canada) and reverse-phase column (µ-RPC C2/C18 ST 
4.6/100; GE Healthcare). Samples (100 µl) were eluted with a linear gradient from 100% 
eluent A (acetontrile: water = 65:35) to 100% eluent B (acetontrile:water = 90:10) in 5-column 
volumes at a flow rate of 1 ml/min. Both eluates contained 10 mM ammonium acetate. 
Vitamin A was detected at 313 nm wave-length. Its characteristic retention volume was 
identified with pure Vitamin A from Sigma (Oakville, ON, Canada) as a standard. Areas under 
the curves were computed by UNICORN5.11 software (GE Healthcare). The sensitivity of the 
assay was 250 ng.   
Retinyl ester in extracts was quantified by HPLC in an Eclipse XDB-C18 reverse-phase 
column (4.6 X150 mm, 5 µm, Agilent, Santa Clara, CA). Samples (200 µl) were eluted with a 
linear gradient from 100% methanol to 100% ethyl acetate in 5 column volumes at a flow rate 
of 1 ml/min. Retinyl ester was detected at 324 nm wavelength. Its characteristic retention 
volume was identified with retinyl palmitate (Sigma) as standard. Areas under the curves were 
computed by Agilent LC software. Sensitivity of the assay was 1.5 ng.   
Statistics 
Student’s t tests were employed to analyze statistical differences between WT and KO mice 
for their lymphoid organ weight and cellularity, and for their retinoid contents (retinol and 
retinyl esters) in different organs. ANOVA was used to compare the glucose tolerance 
between WT and KO mice. 
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Results 
Stra6 expression in different organs and activated T cells 
Stra6 mRNA expression was assessed by RT-qPCR. Among the organs and tissues examined, 
the thymus had the highest expression level, followed by the heart and kidneys (Fig. 3.1A). 
Stra6 expression in the spleen was moderate. The skeleton muscles and liver had barely 
detectable Stra6 mRNA. The Stra6 mRNA expression levels in the lung, liver, spleen and 
kidney assessed by our RT/qPCR was consistent with Northern results reported previously by 
Bouillet [1]. High STRA6 expression in the thymus suggested that it might have some critical 
functions in T-cell development and T-cell function. As depicted in Figure 3.1B, Stra6 
expression in resting spleen T cells (0 h) was modest, consistent with values of the whole 
spleen. The expression was augmented with in 3 h after T-cell activation by TCR cross-linking 
and reached a peak at 48 h. This result corroborates our initial DNA microarray data, through 
which Stra6 was found upregulated during T-cell activation.  
Generation of Stra6 KO mice 
To evaluate the roles of Stra6 in the immune system in general and T cell-mediated immune 
responses in particular, we produced Stra6 KO mice. The targeting strategy is illustrated in 
Figure 3.2A. Germline transmission was confirmed by Southern blotting of tail DNA (Fig. 
3.2B). With the 5’ end probe, the WT allele after XbaI digestion presented a 7.8-kb band, and 
the KO allele, a 5.2-kb band (Fig. 3.2B, upper panel). With the 3’ end probe, the WT allele 
after ScaI digestion presented a 6.9-kb band, and the KO allele, a 4.3-kb band (Fig. 3.2B, 
lower panel). WT (mice 3, 4, and 5) and heterozygous mice (mice 1, 2 and 6) were thus 
identified. Mouse 1 was backcrossed to the C57BL/6 background for 8 generations and then 
used in the experiments described hereafter.  
To ascertain whether Stra6 gene deletion results in its lack of expression, we measured Stra6 
mRNA in spleen cells by RT-qPCR. STRA6 mRNA was detectable in WT but not in KO 
spleen cells (Fig. 3.2C). The lack of Stra6 expression in KO cells at the protein level was 
confirmed by flow cytometry, as Stra6 was detectable in WT but not KO thymocyte surface 
(Fig. 3.2D). 
Normal lymphoid organs and lymphocyte subpopulations in Stra6 KO mice 
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Stra6 KO mice were viable and fertile with no apparent anomalies upon visual inspection. 
Weight and cellularity of the KO thymus and spleen were comparable to those of WT mice 
(Fig. 3.3A). T-cell (CD4+ plus CD8+ versus non T-cell (CD4-CD8-) subpopulations and CD4 
versus CD8 T-cell subpopulations in the spleen and LN of WT and KO mice showed no 
consistent differences (Fig. 3.3B). The percentages of B cells (CD19+B220+) in the spleen and 
lymph nodes in WT and KO mice were also similar (Fig. 3C). In KO thymi, the percentages of 
CD4 single-positive and CD8 single-positive, CD4CD8 double-positive cells and 
CD4+/FoxP3+ Treg cells were comparable to those in WT thymi (Fig. 3.3D). The comparable 
percentages of Treg cells in the thymi of WT and KO mice were confirmed by the measurement 
of FoxP3+ cells among CD4+CD25+ thymocytes (Fig. 3.3E).  
In the periphery, the percentages of FoxP3+ Treg cells among CD4 cells in the spleen (Fig. 
3.3F) and lymph nodes (Fig. 3.3G) from WT and KO mice were also similar. 
These results show that Stra6 KO mice have normal lymphoid organ and T-cell development. 
Normal activation, proliferation and differentiation of Stra6 KO T cells  
KO and WT T cells were stimulated by solid-phase anti-CD3 mAb for 16 h. The activation 
markers CD25 and CD69 in CD4 and CD8 T cells were quantified by flow cytometry. KO and 
WT T cells showed similar up-regulation of these markers (Fig. 3.4A). To assess T-cell 
proliferation, KO and WT T cells in total spleen cells were loaded with CFSE and stimulated 
by soluble anti-CD3 mAb. After 3 days, their proliferation was assessed by flow cytometry. 
CD4 and CD8 KO T cells proliferated like their WT counterparts, as shown in Figure 4B. To 
measure T-cell homeostatic expansion, spleen T cells were loaded with CFSE and then 
injected into sub-lethally-irradiated syngeneic recipients. The proliferation of these transferred 
KO CD4 and CD8 cells in recipient spleens and LN during the 5 days after the injection was 
measured based on their CFSE content according to flow cytometry. As shown in Figure 3.4C, 
the cells from WT and KO mice proliferated similarly in vivo. Therefore, KO T-cell 
proliferation, whether caused by TCR stimulation in vitro or homeostatic expansion in vivo, 
was not defective. 
When KO and WT naïve CD4 cells were cultured under Th1, Th2, Th17 and Treg conditions, 
they achieved comparable Th1, Th2, Th17 and Treg cell percentages (Fig. 3.5), indicating 
normal differentiation of naïve KO CD4 cells into these subpopulations. 
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The effect of Stra6 deletion in anti-LCMV immune responses in vivo 
The function of Stra6 KO T cells in vivo was evaluated in the LCMV infection model. As 
illustrated in Figure 3.6A, the number of total splenocytes, and CD4 and CD8 cells on day 8 
post-infection (8 dpi) presented no significant differences in WT and KO mice (Fig. 3.6A). 
The absolute numbers (Fig. 3.6B) and relative percentages (Fig. 6C) of LCMV-specific 
tetramer-positive (gp33+, np396+ and gp276+) CD8 cells in virus-infected mice were all 
increased in comparison to uninfected control C57BL/6 mice (data not shown), but there were 
no significant differences between KO and WT mice with regard to these parameters. The 
absolute numbers and relative percentages of LCMV-specific TNF-α-producing CD4 (gp61) 
and CD8 cells (gp33) (Figs. 3.6D and 6E), and LCMV-specific IFN-γ-producing CD4 and 
CD8 cells (Figs. 3.6F and 6G) in KO mice were comparable to those in WT controls. These 
results indicate that the STRA6 deletion had no discernable effect on anti-LCMV immune 
responses.  
Normal glucose tolerance in Stra6 KO mice 
One report suggests that Stra6 stimulation by RBP induces the expression of SOCS3, which 
inhibits insulin signaling [12]. We assessed the glucose tolerance of KO mice and found that 
KO and WT mice showed no significant difference in glucose tolerance (Fig. 3.7), suggesting 
that in the absence of Stra6, the insulin signaling of the KO mice on a normal diet is not 
enhanced. 
Organ retinyl ester and retinol levels in Stra6 KO mice 
As vitamin A has been reported to play an important role in immune regulation [12-17], a lack 
of immunological phenotype so-far tested in the KO mice prompted us to examine vitamin A 
contents of lymphoid organs as well as several other organs including the eyes. Vitamin A is 
stored in organs predominantly in the form of retinyl ester, which is a lipid and can reach high 
concentrations. A minor stored form is retinol bound to CRBP, and the retinol content in the 
cells is limited by the availability of CRBP. Retinyl esters and retinol and can be quickly 
converted to each other inside the cells. We thus measured the contents of both retinyl esters 
and retinol in these organs.  
As shown in Figure 3.8A, the WT and KO spleen and thymus had no significant difference in 
their retinyl ester contents, nor did the brains and kidneys. The retinyl ester contents in WT 
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eyes were much higher than that of other organs, and the contents in the KO eyes were 
significantly lower compared to those of the WT counterparts. WT or KO blood had no 
detectable retinyl ester (data not shown).  Retinyl ester is known to be high in the blood only 
right after a meal enriched in vitamin A.   
The retinol levels in these WT and KO organs were of the same pattern as retinyl ester, 
although at much lower levels (Fig. 3.8B; note the scale difference). The KO spleen, thymus, 
kidney and brain had no significant difference in retinol contents compared to their WT 
counterparts. Unlike retinyl ester, the retinol was detectable in the sera, but was of similar 
levels in WT and KO sera. The eyes contained the highest levels of retinol. KO eyes presented 
significantly lower levels of retinol than the WT counterparts.    
These data indicate that under a vitamin A sufficient condition, lymphoid organs still take up 
vitamin A without Stra6 in mice. This explains the lack of immunological phenotype in the 
KO mice. However, even under such a vitamin A sufficient condition, the eyes still heavily 
depend on Stra6 for vitamin A uptake, as they are the organs with the highest vitamin A 
demand.  
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Discussion 
STRA6 is a receptor of holo-RBP (i.e., vitamin A-bound RBP) for cellular vitamin A uptake. 
Stra6 is up-regulated after T-cell activation. In this study, we generated Stra6 KO mice to 
assess whether such up-regulation was essential for T cell-mediated immune responses and 
Stra6’s role in vitamin A uptake. Under a vitamin A sufficient condition, Stra6 KO mice 
developed normally and were fertile. Their T cells presented no signs of abnormality in terms 
of development, activation marker up-regulation, proliferation, and Th and Treg cell 
differentiation. KO mice also had normal anti-LCMV immune responses. There was no 
significant difference in intracellular vitamin A content, in the forms of both retinyl ester and 
retinol, in lymphoid organs from WT and KO mice. However, even under the vitamin A 
sufficient condition, the KO eyes contained significantly lower amounts of retinyl ester and 
retinol, indicating a critical role of vitamin A uptake in this organ. 
A caveat of whole organ retinoid analysis is that contribution of retinoid in the blood can 
affect the total retinoid levels. This is especially true if the organ is rich in blood, which 
contains RBP-bound vitamin A. Despite this caveat, whole organ retinoid analysis can be used 
as an approximation of cellular retinoid uptake. This is especially true as several of the organs  
we tested (i.e., the thymus, brain and eyes) are not blood rich. Moreover, sera had no 
detectable retinyl ester (data not shown); so the retinyl ester levels of the organs tested will not 
be upward influenced by the blood retinyl ester levels. The reduced vitamin A contents in the 
eyes of Stra6 KO mice is not unexpected, as the eyes have the highest concentrations of 
vitamin A among all the organs (Fig. 3.8) due to its heavy reliance on vitamin A for vision, 
and probably need all the capacities of vitamin A transport including the pathway of 
RBP/STRA6 to achieve this high vitamin A content, even in vitamin A sufficiency. Consistent 
to our findings, RBP KO mice have normal vitamin A levels in most of their organs, but a 
reduced one in the eyes [35]. 
Vitamin A and its metabolites – retinoic acids – are clearly required in immune responses [13-
18, 36]. It is reported that in hepatocytes, holo-RBP triggers STRA6, leading to the activation 
of JAK2/STAT5 signaling pathway, which is also essential in the activation and function of 
immune cells. Stra6 is up-regulated within 24 h of T-cell activation (Fig. 3.1B). Is such up-
regulation, or more fundamentally, the existence of Stra6, essential for T cell-mediated 
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immune responses? We demonstrated that in Stra6 KO mice, a lack of Stra6 did not affect T-
cell activation/proliferation/differentiation in vitro and anti-viral immune responses in vivo 
under a vitamin A sufficient condition. These observations suggest following possible and not 
necessarily mutually exclusive explanations: 1) STRA6 up-regulation/existence only becomes 
important for T-cell functions during vitamin A deficiency, when all capacities of vitamin A 
import to immune cells are required; 2) STRA6 homologue RBPR2 can compensate for 
STRA6 function in the immune cells, as this homologue is expressed in the spleen; also, 
retinyl esters bound to lipoproteins secreted by the small intestine can deliver vitamin A to 
peripheral organs under vitamin A sufficient conditions; 3) STRA6 plays a minimal role in 
modulating the JAK2/STAT5 signalling pathway in immune cells, and its upregulation after T 
cell activation has nothing to do with JAK2/STAT5 signaling; 4) We cannot exclude the 
possibility that Stra6 deletion might still affect certain T cell-mediated immune responses to 
some extent, but they have not been assessed in our experiments, or their magnitude was too 
small to be discerned by current assays; 5) Such up-regulation might be a parallel and 
irrelevant event during T-cell activation.  
There is little systemic documentation on vitamin A sufficiency status in wild mammals in 
today’s world. However, it is well-documented that vitamin A deficiency is prevalent in 
African and Southeast Asian populations, particularly affecting children and pregnant women, 
according to the World Health Organization [37], and such deficiency predisposes them to 
infectious diseases [38]. It is conceivable that, during evolution, mammals might have 
experienced vitamin A deficiencies in certain periods or regions in the world. Better cellular 
vitamin A transport will confer an evolutionary advantage to these animals with regard to but 
not restricted by their ability to cope with infectious diseases. If STAR6 is universally critical 
in all cell types for vitamin A uptake, its function should be revealed in immune responses in 
vitamin A deficiency. Experiments addressing this possibility are in progress.  
STRA6 point mutations are found in some patients, with microphthalmia, anophthalmia, 
coloboma [7] and Matthew-Wood syndrome [referring to combinations of 
microphthalmia/anophthalmia, cardiac malformations, pulmonary dysgenesis, and 
diaphragmatic hernia; ref. 9]. In a study of 2 unrelated consanguineous families with 
malformation syndromes sharing anophthalmia and distinct eyebrows as common signs, 
homozygous mutations were identified in STRA6 [6]. Our Stra6 KO mice and those generated 
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by Ruiz et al. [10] did not have dramatic phenotypes, such as a total absence of eyes, as seen 
in humans with STRA6 mutations.  
Why cannot Stra6 KO in mice reproduce human disease phenotypes caused by STRA6 
mutations? A simple explanation is that this is due to species differences.  It is not 
unprecedented that gene mutations in mice and humans have very different phenotypes. For 
example, partial or complete loss of ABCA4 functions cause many blinding diseases in 
humans including retinitis pigmentosa, cone-rod dystrophy and Stargdardt macular dystrophy, 
but ABCA4 KO in mice does not cause blindness unless combined with a deletion of other 
genes such as RDH8 [39-41]. On the other hand, disease loci of microphthalmia and 
anophthalmia have been mapped to multiple chromosomes [42-45]. Patients with Matthew-
Wood syndrome or malformation syndromes have quite large phenotype variations in terms of 
organ affliction and disease severity. Such observations suggest that these syndromes are not 
monogenic, and STRA6 mutation alone is not sufficient to evoke all such phenotypes. It could 
explain why no serious ophthalmic [13] or other organ malformations are apparent in Stra6 
null mutation mice. If STRA6’s major function is cellular vitamin A uptake, and human organ 
malformation syndromes are mainly caused by a lack of available intracellular vitamin A, it 
would support the notion that STRA6 only plays a minor role in cellular vitamin A uptake in 
vitamin A sufficiency, especially in organs other than the eyes. Unless other routes of cellular 
vitamin A uptake such as  those mediated by RBPR2 or by retinyl esters bound to lipoproteins 
are simultaneously compromised, vitamin A in the cells of most, if not all, organs vitamin A 
contents will remain in the normal range, and the organs will develop and function normally in 
vitamin A sufficiency. However, significant phenotype might be revealed in vitamin A 
deficiency. This hypothesis is supported by results from RBP KO mice. These KO mice are 
fertile and have no organ abnormality other than the vision phenotype [46-48], as is the case of 
Stra6 KO mice when fed with a vitamin A sufficient diet. However, they manifest severe 
systemic phenotype of embryonic lethality under a vitamin A deficient condition [49,50]. 
Consistently, in mouse embryo culture where is no retinyl ester pathway, RBP knockdown 
also causes severe developmental defects [51].   
In summary, we conclude that, under normal dietary conditions, mouse lymphoid organ 
development, T-cell activation and differentiation, including Treg cell development, and anti-
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LCMV responses, could proceed normally in the absence of Stra6 under vitamin A sufficient 
conditions.   
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Tables 
Table 3.1 Antibodies for flow cytometry 
 
Antibody Supplier 
PE-donkey anti-goat IgG R & D Systems 
APC-rat anti-mouse CD25 (clone PC61) BD Biosciences 
FITC-rat anti-mouse CD25 (clone 7D4) BD Biosciences 
PE-rat anti-mouse CD4 (clones GK1.5 and H129.19) BD Biosciences 
PerCP-rat anti-mouse CD4 (clone RM4-5) BD Biosciences 
biotin-rat anti mouse CD8b (clone 53-5.8) BD Biosciences 
APC-Cy7- anti-mouse B220 (clone RA3-6B2) BD Biosciences 
PE- or APC-hamster anti-mouse CD3ε (clone 145-
2C11) 
BD Biosciences 
biotin- or FITC-rat anti-mouse CD44 (clone 1M7) BD Biosciences 
FITC- or PE-rat anti-mouse CD8α (clone 53-6.7) BD Biosciences 
APC-rat anti-mouse CD8α (clone H57-597) BD Biosciences 
PE-rat anti-mouse IL-17A BD Biosciences 
PE- and APC-rat anti-mouse IFN-γ BD Biosciences 
PE- and APC-rat anti-mouse IL4 mAbs BD Biosciences 
PerCP-streptavidin and 7-Amino-actinomycin D (7-
AAD) 
BD Biosciences 
APC-Cy7-Streptavidin™ BioLegend 
APC-rat anti-mouse TNF-α (clone MP6-XT22) eBioscience (San Diego, CA) 
FITC-rat anti-mouse IFN-γ (clone XMG1.2) eBioscience 
APC-rat anti-mouse IL17A (clone eBio17B7) eBioscience 
APC-rat anti mouse/rat Foxp3 (clone FJK-16s) mAbs eBioscience 
PE-Cy7-streptavidin eBioscience 
intracellular antigen fixation buffer eBioscience 
10X permeabilization buffer eBioscience 
 APC-Cy™ PE-rat anti-mouse CD25 (clone PC61) Cedarlane Laboratories Ltd (Burlington, Ontario, 
Canada) 
Goat anti-mouse STRA6 Ab Everest Biotech (Upper Heyford, Oxfordshire, UK) 
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Figure legends 
Figure 3.1. Stra6 mRNA expression in organs and activated T cells 
Stra6 mRNA in organs (A) and activated total spleen T cells (B) was measured by RT-qPCR. 
WT spleen total T cells were cultured in wells coated with solid-phase anti-CD3 mAb and 
anti-CD28 mAb (0.5 µg/ml and 4 µg/ml, respectively, for coating) for the durations indicated. 
The cells were then harvested and their STRA6 mRNA levels measured by RT-qPCR. 
Samples were in triplicate for RT-qPCR and means + SD of ratios versus β-actin signals are 
reported. Experiments were conducted twice, and representative data are illustrated. 
Figure 3.2. Generation of Stra6 KO mice 
A. Targeting strategy for generating Stra6 KO mice  
The red squares on the 5’ and 3’ sides of the mouse Stra6 WT genomic sequence represent the 
sequences serving as probes for genotyping by Southern blotting.  
B. Genotyping of Stra6 mutant mice 
Tail DNA was digested with XbaI, and analyzed by Southern blotting (top panel), with the 5’ 
probe whose location is indicated in A. A 7.8-kb band representing the WT allele and a 5.2-kb 
band representing the recombinant allele are indicated by arrows. Similarly, tail DNA was 
digested with ScaI and analyzed with the 3’ probe (bottom panel). A 6.9-kb band representing 
the WT allele and a 4.3-kb band representing the recombinant allele are indicated by arrows. 
C. Absence of Stra6 mRNA expression in Stra6 KO splenocytes 
Stra6 mRNA levels from WT and KO splenocytes were analyzed by RT-qPCR. The RT-qPCR 
samples were in triplicate and the results are expressed as ratios of Stra6 versus β-actin 
mRNA signals with means + SD indicated. The experiments were conducted twice and 
representative data of one experiment are shown. 
D. Absence of Stra6 protein expression in KO thymocytes 
WT and KO thymocytes were stained with goat anti-mouse Stra6 Ab and analyzed by flow 
cytometry. The shaded area is the isotypic Ab staining control using WT thymocytes. The 
thick line represents WT thymocytes stained with anti-Stra6 Ab, and the dotted line, KO 
thymocytes stained with anti-Stra6 Ab. The experiments were carried out three times and a 
representative histogram is shown. 
Figure 3.3. Stra6 KO mice presented normal lymphoid organs and lymphocyte subpopulations 
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A. Weight and cellularity of WT and KO thymi and spleens 
Mouse number (n) in each group is shown. No significant difference is detected in weight and 
cellularity between KO and WT organs (p>0.01, paired Student’s t test). 
B. CD4 and CD8 T-cell subpopulations in WT and KO spleens and LN 
Splenocytes and LN cells were analyzed by 2-color flow cytometry for percentages of CD4 
and CD8 T cells.  
C. B cell populations in the spleen and LN of WT and KO mice 
Splenocytes and LN cells were analyzed by 2-color flow cytometry for percentages of 
CD19+/B220+ B cells.  
D and E. Normal thymocyte subpopulations and endogenous Treg cells in KO thymi 
CD4/CD8 double-negative, CD4/CD8 double-positive, CD4 single-positive and CD8 single-
positive cells and CD4+CD8-FoxP3+ Treg cells in KO and WT thymi were analyzed by 3-color 
flow cytometry (D). CD4+CD25+FoxP3+ Treg cells in the WT and KO thymi were also 
analyzed by 3-color flow cytometry (E).  
F and G. CD4+CD8-FoxP3+ Treg cells in KO and WT spleens and LN  
CD4+CD8-FoxP3+ Treg cells in KO and WT spleens (F) and LN (G) were analyzed by 3-color 
flow cytometry. 
The experiments in B through G were conducted more than 3 times, and representative 
histograms are presented. Percentages of relevant populations are indicated.  
Figure 3.4. Normal activation and proliferation of KO T cells 
A. Normal activation marker CD69 and CD25 expression on KO T cells 
Total spleen cells were stimulated overnight by soluble anti-CD3 mAb (0.5 µg/ml). CD69 and 
CD25 expression on CD4 (left panel) and CD8 (right panel) T cells was measured by 3-color 
flow cytometry.  
B. Normal proliferation of KO CD4 and CD8 cells upon TCR activation in vitro 
Total spleen cells were loaded with CFSE and then stimulated with soluble anti-CD3 mAb 
(0.5 µg/ml). The cells were harvested after 72 h, and stained for CD4 and CD8; CFSE levels 
in these cells were analyzed by 3-color flow cytometry.  
C. KO CD4 and CD8 cells present normal homeostatic expansion in vivo 
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Five million CFSE-loaded spleen cells were injected i.v. into sub-lethally irradiated (650 Rad) 
C57BL/6 recipients 5 h after the irradiation.  On days 6, the CFSE fluorescence of CD4 and 
CD8 cells from the spleen and LN was analyzed by flow cytometry.   
All experiments in this figure were conducted twice or more, and representative histograms 
are shown. 
Figure 3.5. Normal differentiation of Stra6 KO CD4 cells in vitro 
Naïve CD4 cells were cultured under conditions favouring Th1 (A), Th2 (B), Th17 (C) and 
Treg (D) cell differentiation. Their intracellular cytokine or FoxP3 expression was quantified 
by flow cytometry on day 3 for Th1, Th17 and Treg cells, and on day 5 for Th2 cells. 
Experiments were repeated more than 3 times, and representative histograms are shown.  
Figure 3.6. Normal in vivo anti-LCMV immune responses of Stra6 KO mice 
A. Spleen cell numbers on day 8 after LCMV infection 
Means + SD of absolute numbers of total splenocytes, CD4+ cells, and CD8+ cells in spleens 
of WT littermate control (n=4) and KO (n=4) mice on day 8 post-LCMV infection are 
presented.  
B and C. LCMV-specific CD8 cells on day 8 post-LCMV infection 
On day 8 post-infection, the absolute numbers of gp33, np396 and gp276 tetramer-positive 
CD8 T cells per spleen (B) and the percentage of gp33, np396 and gp276 tetramer-positive 
cells among CD8 cells (C) were measured by flow cytometry. Means + SD of data from 4 
pairs of WT littermate control and Stra6 KO mice are presented.  
D and E. LCMV-specific TNF-α-producing CD4 and CD8 cells on day 8 post-LCMV infection 
The absolute number of TNF-α-producing LCMV-specific CD4 cells (gp61-specific) and 
CD8 cells (gp33-specific) per spleen (D) and percentage (E) of these cells among total spleen 
cells of KO and WT mice on day 8 post-LCMV infection. Means + SD of data from 4 pairs of 
Stra6 KO mice and WT littermate controls are shown.  
F and G. Virus-specific IFN-γ-producing CD4 and CD8 cells on day 8 post-LCMV infection 
The absolute number of TNF-α-producing LCMV-specific CD4 cells (gp61-specific) and 
CD8 cells (gp33-specific) per spleen (D) and percentage (E) of these cells among total spleen 
cells of KO and WT mice on day 8 post-LCMV infection. Means + SD of data from 4 pairs of 
Stra6 KO mice and WT littermate controls are shown.  
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The results in this figure are analyzed by Student’s t test. No significant difference was found 
between WT and groups. 
Figure 3.7. Glucose tolerance of KO and WT mice 
WT (n=5) and KO (n=7) mice were fasted for 16 h, and then injected i.p. with D-glucose (2 
mg/g body weight). Blood glucose was measured at different time points from the time of 
injection until 120 min. Means + SD of glucose levels (mg/dL) are reported. No statistical 
significant difference is observed between the KO and WT groups (ANOVA). 
Figure 3.8. Intracellular retinoid contents in lymphoid and other organs of Stra6 KO mice 
were comparable to those of WT mice 
Retinoid (retinyl ester, A; retinol, B) contents (nmol/gram tissue or nmol/ml serum) of the 
eyes, brain, kidney, spleen, thymus, spleen, thymus and sera from KO and WT mice were 
measured by HPLC. The mouse numbers (n) per group are indicated. The results are expressed 
as means + SD. The p-values are indicated when significant (Student’s t test). 
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Figures 
 
Figure 3.1 Stra6 mRNA expression in organs and activated T cells 
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Figure 3.2 Generation of Stra6 KO mice 
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Figure 3.3 Stra6 KO mice presented normal lymphoid organs and lymphocyte subpopulations 
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Figure 3.4 Normal activation and proliferation of KO T cells 
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Figure 3.5 Normal differentiation of Stra6 KO CD4 cells in vitro 
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Figure 3.6 Normal in vivo anti-LCMV immune responses of Stra6 KO mice 
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Figure 3.7 Glucose tolerance of KO and WT mice 
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Figure 3.8 Intracellular retinoid contents in lymphoid and other organs of Stra6 KO mice were 
comparable to those of WT mice 
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Chapter 4 Article-3 
Armc5 deletion causes developmental defects and 
compromises T cell immune responses 
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Abstract 
Armadillo repeat containing 5 (ARMC5) is a cytosolic protein with no enzymatic activities. 
Little is known about its function and mechanisms of action, except that gene mutations are 
associated with risks of primary macronodular adrenal gland hyperplasia. We have mapped 
Armc5 expression by in situ hybridization, and generated Armc5 knockout (KO) mice, which 
are small in body size. Here we show that these KO mice present with compromised T cell 
proliferation and differentiation into Th1 and Th17 cells, increased T cell apoptosis, reduced 
severity of experimental autoimmune encephalitis, and defective immune responses to 
lymphocytic choriomeningitis virus infection. KO mice develop adrenal gland hyperplasia in 
old age. Yeast 2-hybrid assays identify 16 ARMC5-binding partners. These data indicate that 
ARMC5 is crucial in fetal development, T cell function and adrenal gland growth 
homeostasis, and that the functions of ARMC5 likely depend on its interaction with molecules 
involved in multiple signaling pathways. 
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Introduction 
The gene Armadillo was first identified in the fruit fly Drosophila melanogaster as a gene 
controlling larval segmentation with morphological similarity to armadillos1, 2. β-Catenin is 
the human and mouse orthologue of fruit fly Armadillo3. Armadillo/β-catenin protein contains 
13 and 12 conserved armadillo (ARM) repeats, respectively: each repeat is about 40 amino 
acid (aa) long and consists of 3 α-helices4. Multiple repeats form an ARM domain which has a 
groove for binding various other proteins in its tertiary structure5. More than 240 proteins, 
from yeasts to humans, are known to contain an ARM domain6, 7. Although β-catenin is 
believed to interact with and regulate cytoskeleton function, its roles and those of ARM 
domain-containing proteins, in general, are very versatile in cell biology, including 
cytoskeleton organization8, cell-cell interactions9, protein nuclear import10, degradation11 and 
folding12, cell signaling/sensing13, 14, 15, molecular chaperoning16, cell 
invasion/mobility/migration17, transcription control18, cell division/proliferation19, and spindle 
formation20, to name some of them. 	
 
At the tissue and organ levels, ARM domain-containing proteins are involved in T cell 
development21, lung morphogenesis22, limb dorsal-ventral axis formation23, neural tube 
development24, osteoblast/chondrocyte switch25, synovial joint formation26, adrenal gland 
cortex development27, and tumor suppression28. 	
 
Due to the very diverse functions of ARM domain-containing proteins, it is challenging to 
predict their mechanisms of action. Indeed, these aspects of many ARM domain-containing 
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proteins remain undeciphered, and quite a number of them are given the name ARMC (ARM 
repeat-containing), followed by Arabic numbers (e.g., ARMC1, 2, 3 and so on). ARMC5 is 
one such protein.	
 
Human and mouse ARMC5 proteins share 90% aa sequence homology and have similar 
structures29, 30. Mouse ARMC5 is 926 aa in length and contains 7 ARM repeats. A BTB/POZ 
domain towards its C-terminus is responsible for dimerization or trimerization31, 32, 33. Several 
groups reported in 2013 and 2014 that ARMC5 gene mutations are associated with primary 
macronodular adrenal hyperplasia (PMAH) and Cushing’s syndrome34, 35, 36. Assié et al.34 
demonstrated that no viable HeLa cells could be obtained when they were stably transfected 
with ARMC5-expressing vectors. They suggested that the default function of wild type (WT) 
ARMC5 is the suppression of cell proliferation or promotion of apoptosis, which might 
explain the adrenal cortex hyperplasia seen in patients with ARMC mutations. No other 
reports on ARMC5 function and mechanisms of action are available in the literature. 
 
In the present work, we have studied the tissue-specific expression of Armc5. We have 
generated Armc5 gene knockout (KO) mice, and revealed that ARMC5 is vital in development 
and immune responses. We also show that aged KO mice develop adrenal gland hyperplasia. 
We have identified a group of ARMC5-interacting proteins by yeast 2-hybrid (Y2H) assay, 
paving the way for further mechanistic and functional investigations of ARMC5.  
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Materials and Methods 
ISH 
To localize Armc5 mRNA, 1526-bp (starting from GATATC to the end) mouse Armc5 cDNA 
(GenBank: BC032200, cDNA clone MGC: 36606) in pSPORT1 was employed as template for 
S and AS riboprobe synthesis, with SP6 and T7 RNA polymerase for both 35S-UTP and 35S-
CTP incorporation37. 
 
Tissues from WT mice were frozen in -35˚C isopentane and kept at -80˚C until they were 
sectioned. ISH, X-ray and emulsion autoradiography focused on 10-µm thick cryostat-cut 
sections. Briefly, overnight hybridization at 55 ˚C was followed by extensive washing and 
digestion with RNase to eliminate non-specifically bound probes.  Anatomical level images of 
ISH were generated using X-Ray film autoradiography after 4 days’ exposure. Microscopical 
level ISH was produced by dipping sections in NTB-2 photographic emulsion (Kodak).  The 
exposure time was 28 days.  The autoradiography labelling was revealed by D19 Developer 
(Kodak) and fixation with 35% sodium thiosulphate. Slides were left unstained or slightly 
stained with haematoxylin/eosin37. 
 
RT-qPCR  
Armc5 mRNA in thymocytes, T cells, B cells and tissues from KO and WT mice was 
measured by RT-qPCR. Total RNA was extracted with TRIzol® (Invitrogen, Carlsbad, CA, 
USA) and then reverse-transcribed with Superscript IITM reverse-transcriptase (Invitrogen). 
Thymocytes were stained with anti-CD4 (1:400, Clone RM4-5, BD Bioscience), anti-CD8 
(1:400, Clone 53-6.7, BioLegend), anti-CD25 (1:200, Clone PC61.5, eBioscience) and anti-
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CD44 (1:200, Clone IM7, BioLegend) Abs. CD4+ cells, CD8+ cells, DP cells, DN cells and 
DN cells in different stages were sorted by flow cytometry. T cells and B cells were isolated 
by magnetic beads (EasySepTM, Stem Cell Technology, Vancouver, BC, Canada). For RT-
qPCR measurement of Armc5 expression during T cell activation, mouse T-activator 
CD3/CD28 Dynabeads (ThermoFisher Scientific, Burlington, ON, Canada) were used for T 
cell activation in vitro, to avoid introducing Ag-presenting cells into purified CD4 or CD8 
cells.   
 
Forward and reverse primers were 5’-CAG TTA TGT GGT GAA GCT GGC GAA-3’ and 5’-
ACC CTC AGA AAT CAG CCA CAA CCT-3’, respectively. A 139-bp product was detected 
with the following amplification program: 95˚C×15 min, 1 cycle; 95˚C×10 s, 59˚C×15 s, 
72˚C×25 s, 35 cycles. β-actin mRNA levels were measured as internal controls. Forward and 
reverse primers were 5’-TCG TAC CAC AGG CAT TGT GAT GGA-3’ and 5’-TGA TGT 
CAC GCA CGA TTT CCC TCT-3’, respectively, with the same amplification program as for 
Armc5 mRNA. The data were expressed as ratios of Armc5 versus β-actin signals. 
 
Armc5 overexpression in L cells 
L cells (ATCC CRL-2648, ATCC) were transiently transfected with pReceiver-Lv120 plasmid 
expressing mouse Armc5 with HA tag (EX-Mm23477-LV120, GeneCopoeia, Rockville, MD, 
USA) for 2 days, and fixed with 4% paraformaldehyde. Subcellular Armc5 localization in L 
cells was detected by immunofluorescence with biotinylated rat anti-HA Ab (1:500, 
12158167001, Roche, Laval, QC, Canada), followed by FITC-conjugated streptavidin 
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(1:2000, S11223, ThermoFisher, Burlington, ON, Canada). The L cells were not authenticated 
and possible mycoplasma contamination was not tested.  
 
Generation of Armc5 KO mice 
A PCR fragment amplified from the Armc5 cDNA sequence served as probe to isolate 
genomic BAC DNA clone 7O8 from the RPCI-22 129/sv mouse BAC genomic library. The 
targeting vector was constructed by recombination and routine cloning methods, with a 15-kb 
Armc5 genomic fragment from clone 7O8 as starting material. A 2.7-kb HindIII/EcoRV 
genomic fragment containing exon 1-3 was replaced by a 1.1-kb Neo cassette from 
pMC1Neo-Poly A flanked by 2 diagnostic restriction sites, EcoRV, and HindIII, as illustrated 
in Figure 2a. The final targeting fragment was excised from its cloning vector backbone by 
NotI/EcoRI digestion and electroporated into R1 embryonic stem (ES) cells for G418 
selection. Targeted ES cell clones were injected into C57BL/6J blastocysts. Chimeric male 
mice were mated with C57BL/6 females to establish mutated Armc5 allele germline 
transmission. 
 
Southern blotting with probes corresponding to 5’ and 3’ sequences outside the targeting 
region, as illustrated in Figure 2a (red squares), screened for gene-targeted ES cells and 
eventually confirmed gene deletion in mouse tail DNA. With the 5’ probe, the targeted allele 
presented a 6.6-kb EcoRV band, and the WT allele, a 9.3-kb EcoRV band. With the 3’ probe, 
the targeted allele presented an 8.7-kb HindIII band, and the WT allele, a 12.5-kb HindIII 
band (Supplementary Fig. 3). 
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Heterozygous mice were backcrossed to the C57BL/6J background for 8 generations and then 
crossed with 129/sv mice. WT and KO mice in the C57BL/6J×129/sv F1 background were 
studied. All animals were housed under specific pathogen-free conditions and handled in 
accordance with a protocol approved by the Institutional Animal Protection Committees of the 
CRCHUM and INRS-IAF. 
 
Serum total IgG measurement 
Flat bottom 96-well plates (Costar EIA/RIA, No. 3369, Fisher Scientific) were coated with 
goat anti-mouse IgG (100 µl/well, 1 µg/ml in PBS) and incubated overnight at 4°C. After five 
times of washings with PBS containing 0.05% Tween 20, the plates were blocked with PBS 
containing 3% BSA and 5% FBS for 1.5 h at room temperature. After 5 washings, diluted 
serum samples (1:105) and serially-diluted standard mouse IgG (sc-2025, Santa Cruz) were 
added to the wells (100 µl/well) and incubated at 37°C for 1 h. The plates were then washed 
10 times, and diluted (1:4000) horse radish peroxidase-conjugated horse anti-mouse IgG 
(#7076S, Cell Signaling Technology) was added (100 µl/well) to the wells. The plates were 
incubated for 1 h at 37°C. After another 10 washings, 1-Step™ Ultra TMB-ELISA Substrate 
Solution (#34028, Thermo Scientific) was added to the wells (100 µl/well). The plates were 
incubated in the dark at room temperature for 20-30 min, and the reaction was stopped by 2M 
sulfuric acid (100 µl/well). Optical density at 450 nm of reactants was measured. Samples 
were assayed in duplicate. Mouse total IgG concentrations were calculated according to a 
standard curve established by serial dilutions of standard mouse IgG. Assay sensitivity was in 
the 0.39 and 6.25 ng/ml range. 
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Enzyme-linked immunosorbent assay (ELISA) 
Glucocorticoid levels in WT and KO mouse sera were quantified by ELISA, detecting mouse 
glucocorticoids according to the manufacturer’s instructions (MBS028416, MyBioSource, San 
Diego, CA, USA).  
 
Flow cytometry  
Single cell suspensions from the thymus, spleen and LN were prepared and stained 
immediately or after culture with Abs against CD3 (1:200, Clone 145-2C11, BD Bioscience), 
CD4 (1:400, Clone RM4-5, BD Bioscience), CD8 (1:400, Clone 53-6.7, BioLegend), CD25 
(1:200, Clone PC61.5, eBioscience), CD44 (1:200, Clone IM7, BioLegend), CD45.1 (1:200, 
Clone A20, BD Bioscience), CD45.2 (1:200, Clone 104, BD Bioscience), CD62L (1:200, 
Clone MEL-14, BD Bioscience), CD107a (1:200, Clone 1D4B, BD Bioscience), CD127 
(1:200, A019D5, BioLegend), KLRG1 (1:200, Clone 2F1/KLRG1, BioLegend), Thy1.2 
(1:1000, Clone 30-H12, BioLegend), B220 (1:200, Clone RA3-6B2, BD Bioscience), 7AAD 
(1:25, 51-68981E, BD Bioscience), Annexin-V (1:50, 550474, BD Bioscience). In some 
experiments, intracellular proteins, such as IFN-γ (1:200, Clone XMG1.2, BD Bioscience), IL-
17 (1:200, Clone TC11-18H10, BD Bioscience), FoxP3 (1;200, Clone 150D, BioLegend), T-
bet (1:200, Clone 4B10, BioLegend), RORγt (1:200, Clone B2D, eBioscience) and TNF-
α (1;200, Clone MP6-XT22, BD Bioscience) and Granzyme B (1;200, Clone GB11, 
BioLegend), were detected after the cells were pre-stained with Abs against cell surface Ag, 
permeabilized with BD Cytofix/CytopermTM solution (BD Biosciences), and then stained with 
Abs against intracellular Ag 38, 39. 
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Flow cytometry was also employed to assess LCMV-specific T cells. The synthetic peptides 
gp33-41: KAVYNFATC (LCMV-GP, H-2Db), np396-405: FQPQNGQFI (LCMV-NP, H-2Db) and 
gp276-286: SGVENPGGYCL (LCMV-GP, H-2Db) were purchased from Sigma-Genosys 
(Oakville, ON, Canada). PE-gp33-41, PE-np396-405, and PE-gp276-286 H-2Db tetrameric complexes 
were synthesized in-house and applied at 1/100 dilution 39. These MHC-tetramers served to 
detect LCMV-specific CD8+ T cells on day 8 post-LCMV infection. Briefly, splenocytes were 
first stained with PE-gp33-41, PE-np396-405 or PE-gp276-286 tetramers for 30 min at 37°C, directly 
followed by surface staining (CD3, CD8, CD44, and CD62L) and dead cell exclusion (7AAD) 
for another 20 min at 4°C. The cells were then fixed with 1% paraformaldehyde, and samples 
were analyzed by flow cytometry.  
 
For intracellular cytokine staining, 106 splenocytes from LCMV-infected mice were 
maintained for 5 h at 37°C in RPMI-1640 with 10% FCS and 55 µg/mL β-ME, supplemented 
with a final concentration of 50 U/ml IL-2, 5 µg/ml Brefeldin A, 2 µM Monensin, 2.5 µg/mL 
FITC-labeled anti-mouse CD107a and 5 µM gp33-41 or gp61-80 GLNGPDIYKGVYQFKSVEFD 
(LCMV-GP, I-Ab) synthetic peptide from Sigma-Genosys. After ex vivo incubation, surface 
staining and cell viability were verified with anti-mouse CD8a, CD4 and CD62L mAbs and 
7AAD. The cells were then fixed, permeabilized and stained with anti-mouse TNF-α, IFN-γ 
and Granzyme B mAbs. Cytokine-producing T cells were analyzed by flow cytometry 40. 
 
Lymphocyte proliferation and apoptosis in vitro 
Spleen cells were loaded with carboxyfluorescein succinimidyl ester (CFSE: 5 µM for 5 min). 
After washing, they were stimulated with soluble hamster anti-mouse CD3ε mAb (clone 145-
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2C11, 2 µg/ml; BD Biosciences) for T cell proliferation assays. This protocol allows best 
long-term T cell proliferation over a 4-day period, for clear demonstration of multiple cell 
proliferation rounds according to CFSE staining. In B-cell proliferation assays, CFSE-loaded 
Spleen cells were stimulated with goat anti-mouse IgM (5 µg/ml; Jackson ImmunoResearch), 
IL-4 (10 ng/ml) and goat-anti-mouse CD40 (2 µg/ml, Jackson ImmunoResearch). After 3-4 
days, the cells were gated on CD4-, CD8- or B220-positive cells, and their CFSE intensity was 
ascertained by flow cytometry. 
 
To assess Th1 and Th17 cell proliferation, naïve CD4 cells were loaded with CFSE, and 
cultured under Th1 and Th17 conditions for 4 days (detailed below). CD4+ or intracellular 
IFN-γ+ or IL-17+ cells were then gated, and their CFSE intensity was assessed by flow 
cytometry. 
 
For cell cycle analysis, total spleen cells were stimulated with anti-CD3ε mAb, as described 
above, and stained with anti-Thy1.2 mAb and propidium iodide (PI: 20 µg/ml) on days 0, 1 
and 2. Thy1.2+ T cells were gated and their PI signal strength was measured by flow 
cytometry. 
 
For T cell apoptosis analysis, spleen cells were stimulated with anti-CD3ε mAb (2 µg/ml) plus 
crosslinked human FasL-FLAG (0.133 µg/ml; FasL–FLAG was pre-incubated for 24 hours at 
4°C at a 1:1 ratio with 0.133 µg/ml mouse monoclonal Ab against FLAG (F1804, Sigma); the 
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final concentration of crosslinked FasL-FLAG for culture was 0.6 µg/ml 41) and cultured for 4 
h. Cells positive for CD4 or CD8 were gated and analyzed for annexin V expression.  
 
Th1 and Th17 cell differentiation in vitro 
T cell differentiation in vitro was undertaken as follows 38, 39. Naïve CD4+ T cells (CD4+ 
CD62L+CD44low) were isolated from KO or WT mouse Spleen with EasySepTM mouse naïve 
CD4+ T cell isolation kits (19765, Stem Cell Technology). Naïve CD4+ T cells from WT and 
KO mice (0.1×106 cells/well) were mixed with feeder cells (0.5×106 cells/well) and cultured in 
96-well plates in the presence of soluble anti-CD3ε Ab (2 µg/ml). Feeder cells plus anti CD3ε 
Ab were used, as in our hands, they achieved the most consistent Th1 and Th17 differentiation 
conditions. Cultures were supplemented with recombinant mouse IL-12 (10 ng/ml; 419-ML, R 
& D Systems, Minneapolis, MN, USA) and anti-IL-4 mAb (5 µg/ml; MAB404, R & D 
Systems) for the Th1 condition, with recombinant mouse IL-6 (20 ng/ml; 406-ML, R & D 
Systems), recombinant human TGF-β1 (5 ng/ml; 240-B, R & D Systems) and anti-IL-4 (5 
µg/ml) and anti-IFN-γ mAbs (5 µg/ml; MAB485, R & D Systems) for the Th17 condition. The 
cells were stimulated with PMA (10µM) and ionomycin (100 µg/ml) in the presence of 5 
µg/ml Brefeldin A for the last 4 h of culture, and their intracellular IFN-γ, T-bet, IL-17, and 
RORγt were analyzed by flow cytometry.  
 
Chimera generation 
Eight- to 10-week-old C57BL/6J (CD45.2+) × C57B6.SJL (CD45.1+) F1 mice were irradiated 
at 1,100 rads. Twenty-four h later, they received i.v. 2×106 fetal liver cells from WT or KO 
mice) in the C57BL/6J×129/sv (CD45.2+) F1 background. Peripheral white blood cells of 
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recipients were analyzed by flow cytometry 8 weeks after fetal liver cell transplantation. 
Twelve weeks after transplantation, chimeras with successful implantation of donor-derived 
white blood cells were studied in in vitro T cell function experiments and for EAE induction. 
 
EAE induction and assessment  
EAE was induced in 8- to 12-week-old female WT and KO mice42. Briefly, mice were 
immunized with 300 µg MOG35-55 peptide (Biomatik, Wilmington, DE, USA) emulsified in 
complete Freund’s adjuvant, followed by i.p. injection of 400 ng pertussis toxin (List 
Biological Laboratories, Campbell, CA, USA) on days 0 and 2. EAE development was scored 
daily between days 0 and 35 according to a scale ranging from 0 to 5, as follows: 0, no sign of 
paralysis, 1, weak tail; 2, paralyzed tail; 3, paralyzed tail and weakness of hind limbs; 4, 
completely paralyzed hind limbs; 5, moribund. Scores were assigned in 0.5 unit increments 
when symptoms fell between 2 full scores. 
 
Female chimeras with successful donor cell implantation (verified according to CD45.2 
single- positive cells in peripheral blood) 12 weeks after fetal liver transplantation were also 
used for EAE induction. The same protocol described above was followed, except that 200 µg 
MOG35-55 peptide for immunization and 200 ng pertussis toxin/injection were administered to 
each chimeric mouse. 
 
EAE histology 
To assess the degree of inflammation and CNS demyelination, EAE mice were euthanized on 
day 30 and perfused by intra-cardiac injection of PBS. Spinal cord sections were stained with 
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H/E or NovaUltraTM Luxol Fast Blue Staining Kit (IHC World, Woodstock, MD, USA), 
according to the manufacturer’s instructions. Each SC section was subdivided into 4 regions: 1 
anterior, 1 posterior, and 2 lateral. Each region was scored on a scale of 0 to 3 for lymphocyte 
infiltration and demyelination in a 1-way blinded fashion. Thus, each animal had a potentially 
maximal score of 12 points for lymphocyte infiltration and demyelination, respectively 43, 44. 
Total pathological scores were the sum of these 2 parameters. 
 
Isolation of mononuclear cells from the spinal cord and brain 
Peripheral blood was removed from the spinal cord and brain by intra-cardiac perfusion 
through the left ventricle with heparinized ice-cold PBS. The spinal cord and brain were 
harvested, ground and then passed through a 70-µm mesh screen. The cells were centrifuged 
through a 40%-60%-90% discontinuous Percoll gradient. Mononuclear cells at the 40% to 
60% Percoll interface were collected and stained for phenotype analysis. 
 
Differentiation/characterization of mouse Th1 and Th17 cells  
Cells from draining LN and mononuclear cells from the spinal cord and brain were further 
stimulated with PMA (5 nM) and ionomycin (500 ng/ml) for 4 h in the presence of Golgi Stop 
(554724, BD Biosciences), before being harvested. They were stained with Abs against cell 
surface Ag, fixed with Cytofix/CytopermTM solution (555028, BD Biosciences), and then 
stained with mAbs against intracellular IFN-γ (1:200, Clone XMG1.2, BD Bioscience) and IL-
17 (1:200, Clone TC11-18H10, BD Bioscience). Stained cells were analyzed by flow 
cytometry. 
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LCMV infection 
LCMV-WE was obtained from Dr. R.M. Zinkernagel (University of Zurich, Zurich, 
Switzerland). Viral stock was propagated in vitro, and viral titers were quantified by focus-
forming assay 40. Mice were infected by the i.v. route with 200 focus-forming units (ffu) of 
LCMV-WE. They were sacrificed 8 days post-infection, and their spleens were harvested for 
primary immune response analysis. CD8+ T cells were isolated from the spleen of naïve or 
infected WT mice, with EasySepTM mouse CD8+ T cell isolation kits (19853, Stem Cell 
Technology). RNA from isolated cells was extracted with TRIzol® (Invitrogen), followed by 
RT-qPCR.  
 
Y2H assay 
Y2H screening was performed by Hybrigenics Services (Paris, France). The coding sequence 
for human ARMC5 cDNA (aa 30-935) (GenBank accession number GI: 157426855) was 
PCR-amplified and cloned into pB29 as a N-terminal fusion protein to LexA (N-ARMC5-
LexA-C). The construct was verified by sequencing the entire insert and served as bait to 
screen a random-primed human thymocyte cDNA library constructed in the pP6 plasmid. 
pB29 and pP6 vectors were derived from the original pBTM116 45, 46 and pGADGH 47 
plasmids,  respectively. 
 
Eighty million yeast clones (8-fold the complexity of the library) were screened via a mating 
approach with YHGX13 (Y187 ade2-10: loxP-kanMX-loxP, matα) and L40Gal4 (mata) yeast 
strains 48. One hundred and sixty-five His+ colonies were selected on medium lacking 
tryptophan, leucine, and histidine, and supplemented with 5.0 mM of 3-aminotriazole to 
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quench bait auto-activation. Prey fragments of positive clones were amplified by PCR and 
sequenced at their 5’ and 3’ junctions. The resulting sequences were considered to identify 
corresponding interacting proteins in the GenBank database via a fully-automated procedure. 
A Predicted Biological Confidence score was attributed to each interaction 36. 
 
Statistics and general methods 
For in vivo animal studies, the sample size was determined by estimation, based on our past 
experience and literature. No formal randomization was used, but littermates or age and sex 
matched WT and KO mice were used. In general, two-tailed Student’s t tests were used. Chi-
square test was used to compare the difference between two proportions. One-way ANOVA 
followed with Bonferroni’s multiple comparisons test was used in data from more than three 
groups. For the histology experiments, one-way blind examination was performed. 
 
Data availability 
The data that support the findings of this study are available in the text and the supplementary 
data files, or from the corresponding author upon request. 
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Results 
Armc5 expression in mice and T cells 
Armc5 mRNA expression was analyzed by in situ hybridization (ISH) in adult WT mice. 
Hematoxylin/eosin (HE) staining of a consecutive sagittal whole body section preceded ISH 
(Fig. 1a, upper panel). Armc5 expression, based on anti-sense riboprobe hybridization (Fig. 1a, 
middle panel), was high in the thymus, stomach, bone marrow, and lymphatic tissues 
(including lymph nodes and intestinal wall). The hybridization was also apparent in the 
adrenal gland, and skin. Some hybridization occurred in brain structures, with noticeable 
levels found in the cerebellum. Control hybridization with sense (S) riboprobes revealed a 
faint nonspecific background (Fig. 1a, bottom panel). 
 
At the anatomical level, Armc5 expression was high in the thymus cortex (Fig. 1b, upper left 
panel). This was confirmed at the microscopic level (Fig. 1b, bottom left panel). The higher 
Armc5 signals in the cortex than in the medulla were due to higher cell density in the former. 
Sense riboprobes detected little background noise (Figs. 1b, right column). Based on reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) results, thymic stroma cells 
(including epithelial cells) had Armc5 expression similar to that of thymocytes 
(Supplementary Fig. 1a). Further, there was no significant difference in Armc5 expression 
among thymocyte subpopulations (CD4/CD8 double-negative (DN) 1-4, CD4/CD8 double-
positive (DP), and CD4- or CD8- single-positive (SP); Supplementary Figs. 1b and 1c; gating 
strategy: Supplementary Fig. 2a), and between naïve and memory spleen T cells 
(Supplementary Fig. 1d; gating strategy: Supplementary Fig. 2b). 
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Moderately intense Armc5 labeling was apparent in spleen white pulp but not in red pulp (Fig. 
1c, upper panel). At the microscopic level, small groups of cells in WP displayed Armc5 
signals (Fig. 1c bottom panel). Sense riboprobes detected no signals (Fig. 1c middle panel). 
 
Armc5 mRNA expression was induced rapidly in CD4 cells in 2 h after CD3ε plus CD28 
stimulation, then subsided and remained low between 24 to 72 h post-activation (Fig. 1d, 
upper row). CD8 T cells had less Armc5 induction and the levels remained low between 24 to 
72 h (Fig. 1d, lower row).  
 
ARMC5 was mainly a cytosolic protein, as it was detected in the cytoplasm of L cells 
transiently transfected with a mouse ARMC5 expression construct (Figs. 1e and 1f).  
 
Generation of Armc5 KO mice 
We generated Armc5 KO mice to understand the biological roles of ARMC5 in general and T 
cell-mediated immune responses in particular. Our targeting strategy is illustrated (Fig. 2a). 
Germline transmission was confirmed by Southern blotting of tail DNA (Supplementary Fig. 
3). With the 5’ end probe, the WT allele after EcoRV digestion gave a 9.3-kb band, and the 
KO allele, a 6.6-kb band (Supplementary Fig. 3, upper panel). With the 3’ end probe, the WT 
allele after HindIII digestion presented a 12.5-kb band, and the KO allele, an 8.7-kb band 
(Supplementary Fig. 3, lower panel). WT (mice 3 and 7) and heterozygous mice (mice 1, 2, 4, 
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5 and 6) were thus identified. Mouse 1 in the original 129/sv×C57BL/6J background was 
backcrossed to different genetic backgrounds for experimentation, as detailed below.   
 
Armc5 deletion of KO mice at the mRNA level in spleen T cells, thymocytes, lymph nodes, 
brain and adrenal glands was confirmed by RT-qPCR (Fig. 2b).  
 
General phenotype of Armc5 KO mice 
When Armc5 KO mice were in the C57BL/6J×129/sv F1 background, only about 10% live 
KO pups were delivered in a heterozygous × heterozygous mating strategy, below the 
expected 25% Mendelian rate. After F1 mice were backcrossed to C57BL/6 for 5 or more 
generations, no KO pups could be produced, nor were live KO pups born after the mice were 
backcrossed 8 generations to the 129/sv background. This suggested that Armc5 deletion 
caused embryonic lethality, with its severity depending on genetic background of the mice: 
embryonic lethality became more severe with higher degrees of genetic background purity. 
KO mice in the C57BL/6J×129/sv F1 background were studied in subsequent experiments. 
 
KO embryos were smaller than WT controls at embryonic day 14 (Fig. 3a). These KO pups 
were smaller at age 8-12 weeks (Fig. 3b). Body weight was significantly lower in KO and WT 
mice at age 4 and 8 weeks than in their WT littermates (Fig. 3c). Both male and female KO 
mice weighed only about 60% as much as WT controls.  
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We examined serum growth hormone levels because of growth retardation in KO mice, but no 
significant difference was found between them and their WT counterparts (Supplementary Fig. 
4). 
 
ARMC5 gene mutations have been reported to be linked with PMAH and Cushing’s 
syndrome34. However, KO mice presented normal adrenal gland size and histology 
(Supplementary Fig. 5) and serum glucocorticoid levels (Supplementary Fig. 6) in young age 
(less than age 5 months). In old age (>15 months), grossly, KO mice showed enlarged adrenal 
glands without apparent nodular structure, and histologically, there is no identifiable nodular 
hyperplasia (Fig. 3d). Serum glucocorticoid levels were significantly increased in aged KO 
mice (Fig. 3e), supporting the notion that the adrenal gland hyperplasia is of cortex in nature. 
It is to be noted that the mice were sacrificed between 12:30-1:30pm, and their blood was 
harvested for the measurement of glucocorticoids, whose secretion is at the nadir at this time 
point. The moderate but significant increase of glucocorticoid levels in the KO mice is 
reminiscent of human PMAH, in which the increase of glucocorticoid levels is not drastic and 
is caused by the large mass of the adrenal gland, while on a per cell basis, the secretion is 
reduced34.  
 
Armc5 KO phenotype in lymphoid organs and T cells 
Thymus (Supplementary Fig. 7a) and spleen (Supplementary Fig. 7b) weight and cellularity 
were not significantly different in KO and WT mice. Moreover, thymocyte sub-populations 
(CD4+CD8+ double-positive, CD4+ single-positive and CD8+ single-positive cells) in the KO 
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and WT thymus were comparable (Supplementary Fig. 7c), as were spleen lymphocyte 
subpopulations (Thy1.2+ T cells versus B220+ B cells; CD4+ versus CD8+ T cells; 
Supplementary Fig. 7d).   
 
Despite seemingly normal T cell development in KO mice, T cell proliferation triggered by 
anti-CD3ε was compromised in both CD4 and CD8 cells (Fig. 4A, left and middle panels; 
gating strategy: Supplementary Fig. 2c). It is to be noted that activation markers CD25 and 
CD69 shortly after CD3 stimulation were drastically upregulated and were always comparable 
between WT and KO T cells (Supplementary Fig. 8). The proliferation rate of KO B cells was 
also lower (Fig. 4a, right panel; gating strategy: Supplementary Fig. 2d). Cell cycle analysis 
revealed that G1/S progression was compromised in KO T cells (Fig. 4b; gating strategy: 
Supplementary Fig. 2e). We also demonstrated that KO T cells (gated on CD4+ plus CD8+ 
cells) presented increased FasL-triggered apoptosis (Fig. 4c; gating strategy: Supplementary 
Fig. 2f). 
 
Naïve KO CD4 cells cultured under Th1 and Th17 conditions manifested reduced 
proliferation, as expected (Fig. 5a; gating strategy: Supplementary Fig. 2g). The differentiation 
of naïve CD4 cells into Th1 and Th17 cells was defective (Fig. 5b; gating strategy: 
Supplementary Fig. 2g), since the percentages of Th1 or Th17 cells were decreased among 
CD4 cells, which had already proliferated. The expression of transcription factors T-bet and 
RORγt - essential for Th1 and Th17 differentiation, respectively - were normal in KO CD4 
cells cultured under Th1 and Th17 differentiation conditions (Figs. 5c and 5d), when gated on 
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either total CD4 cells or on those already differentiated cells (IFN-γ+ or IL-17+ cells), 
suggesting that the defective differentiation is not caused by a lack of these transcription 
factors. 
 
As for humoral immune responses, KO serum IgG levels were comparable to those of WT 
controls (Supplementary Fig. 9). 
 
We generated chimeric mice by transplanting KO and WT fetal liver cells in the 
C57BL/6J×129/sv F1 background (CD45.2+ single-positive) into lethally irradiated 
C57BL/6J×C57B6.SJL F1 mice (CD45.1+CD45.2+ double-positive). Peripheral white blood 
cells of the recipients were analyzed by flow cytometry 8 weeks after transplantation, and 
recipients of similar degrees of KO and WT chimerism were paired for experimentation. 
Typically, about 80-85% of peripheral white blood cells were of donor origin (CD45.2+ single-
positive), and 12-15%, of recipient origin (CD45.1+CD45.2+ double-positive). In spleen 
Thy1.2+ total T cells, CD4+ T cells and CD8+ T cells, 60-70% were of donor origin, and 30-
35%, of recipient origin (Supplementary Fig. 10). Unlike in Armc5 KO mice, KO T cells in 
chimeras were developed in a WT environment, devoid of influence by putatively unknown 
factors which might exist in the total KO environment and have aberrant effects on T cell 
development. 
 
We showed that donor-derived KO naïve CD4 cells were defective in differentiating into Th1 
cells (Fig. 5e; gating strategy: Supplementary Fig. 2h), similar to CD4 cells from 
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unmanipulated, naïve KO mice (Fig. 5b). The KO Th17 cell differentiation in this model was 
also compromised, although did not reach statistical significance, probably due to an 
inadequate sample size (Fig. 5e).  
 
 Experimental autoimmune encephalomyelitis (EAE) in KO mice 
To understand the role of ARMC5 in in vivo T cell immune responses, particularly CD4-
mediated immune responses, we induced experimental autoimmune encephalomyelitis (EAE) 
in Armc5 WT and KO mice. As shown in Figure 6a, WT mice started to manifest clinical 
signs of EAE on day 13.2 ± 1. 30 (means ± SEM) after immunization, and their symptoms 
peaked on day 23. The onset of clinical symptoms in KO mice was delayed by about 7 days, 
and their maximum disease score was significantly lower than that of WT controls (p<0.01, 
two-tailed Student’s t test) after day 18. Disease incidence was lower in KO mice between 
days 15 to 18, although it reached 100% in both KO and WT groups after day 28 (Fig. 6b). A 
trend toward less body weight loss in KO mice was noted after EAE induction compared to 
WT controls, but statistically significant difference was reached only on day 22 (Fig. 6c).  
 
KO mice had significantly fewer cells in their draining LN and fewer infiltrating mononuclear 
cells in the brain and spinal cords on day 14 after MOG immunization compared to WT 
controls (Fig. 6d). After ex vivo PMA/ionomycin stimulation, the percentage of interferon-
gamma (IFN-γ+) CD4 cells among total CD4 cells from the LN of KO mice was significantly 
lower than that of WT mice (6.2% versus 15.4%), although the percentage of IL-17+ cells 
among CD4 cells was similar in KO and WT draining LN (Fig. 6e). The percentages of IFN-γ+ 
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and IL-17+ populations in CD4+ T cells from the central nervous system (CNS) of KO mice 
were significantly lower after ex vivo PMA/ionomycin stimulation than in WT mice (Fig. 6f).   
 
Histologically, spinal cords from KO animals on day 30 after MOG immunization showed less 
severe mononuclear cell infiltration and demyelination, according to hematoxylin/eosin and 
Luxol Fast Blue staining, respectively, compared to their WT counterparts (Fig. 6g). 
Histological data from 4 KO and 5 WT spinal cords are summarized (Fig. 6h). Mononuclear 
cell infiltration in KO spinal cords was significantly lower than in WT controls. Although 
demyelination in the former was also lower, it did not reach statistical significance. However, 
combined pathological scores, which included degrees of both mononuclear cell infiltration 
and demyelination, were significantly lower in KO mice. We did not observe changes in the 
percentages of Treg cells in the spleen of naïve KO mice or in the draining LN of KO mice on 
day 17 during EAE induction, compared to WT controls (Fig. 6i; gating strategy: 
Supplementary Fig. 2i). Therefore, it is unlikely that Treg cells are implicated in reduced EAE 
severity in KO mice. 
 
To exclude the possible influence of the Armc5 KO background on the immune system of KO 
mice, EAE was also induced in chimeras transplanted with fetal liver cells from Armc5 WT 
and KO embryos on day 13-15. Overall, KO chimeras still displayed a lower degree of EAE 
than WT chimeras, but the difference was not as dramatic as in real KO versus WT mice. The 
onset of clinical symptoms in KO chimeras occurred 2.5 days (mean) later than in WT 
chimeras. KO chimera clinical scores tended to be lower than those of WT mice, but were 
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only significantly different between day 12 and 14 (Fig. 6j). EAE incidence was significantly 
lower on days 11, 12 and 14 after immunization (Fig. 6k). A trend of less body weight loss 
was noted in KO chimeric mice, although no statistical difference was apparent between the 
KO and WT groups (Fig. 6l). When stimulated ex vivo by PMA/ionomycin, the percentage of 
KO donor-derived IFN-γ+ CD4 cells among total KO donor-derived CD4 cells from the CNS 
was significantly lower than in WT controls (Fig. 6m; gating strategy: Supplementary Fig. 2h), 
as was the case in real KO mice. However, there was no significant difference between the 
percentage of KO donor-derived IL-17+ CD4 cells among total KO donor-derived CD4 cells 
and that of WT mice. The reduced degree of difference in EAE manifestation in KO versus 
WT chimeras, compared to that in real KO versus WT mice, was not unexpected, as KO 
chimeras contained about 30% recipient-derived T cells, which were fully immuno-competent 
WT T cells.  
 
Antiviral immune responses in KO mice 
CD8 T cell-mediated immune responses play a critical role against lymphocytic 
choriomeningitis virus (LCMV) infection. Therefore, we assessed KO CD8+ T cell functions 
in LCMV infection. Eight days after mice were infected with LCMV (strain WE), absolute 
numbers of WT CD8+ T cells but not CD4+ T cells increased significantly (Fig. 7a; gating 
strategy: Supplementary Fig. 2j). LCMV tetramer staining showed that both the number of 
gp33-41-, np 396-405- and gp276-286-specific CD8 T cells per spleen and their percentage among 
total spleen CD8+ T cells were significantly lower in KO than in WT mice (Fig. 7b, 7c and 7d; 
gating strategy: Supplementary Fig. 2k), suggesting compromised CD8 cell clonal expansion 
after viral Ag stimulation in KO mice. 
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After infection, CD8 cells develop into KLRG1hiCD127lo short-lived effector cells (SLEC) 
and KLRG1loCD127med memory precursor effector cells (MPEC)35. In KO mice, 8 days after 
LCMV infection, the percentage of SLEC among CD8 T cells was significantly lower (Fig. 7e 
and 7f; gating strategy: Supplementary Fig. 2k), indicating defective anti-virus effector cell 
development. At the same time, MPEC percentage among CD8 T cells was increased in KO 
mice. The significance of this finding is not clear at present, although the percentage of 
CD62LloCD44hi effector memory cells among total CD8 cells (Supplementary Fig. 11a) and 
LCMV subdominant epitope (np396-405 and gp276-286)-specific CD8 T cells (Fig. 7g; gating 
strategy, Supplementary Fig. 2k) in KO mice was reduced.  
 
We next examined the presence of LCMV-specific, cytokine-producing splenic T cells in 
virus-infected mice. As seen in Figure 7h (gating strategy: Supplementary Fig. 2k), the 
absolute number of gp33-41-specific TNF-α-positive CD8+ T cells, IFN-γ-positive CD8+ T 
cells, and IFN-γ/TNF-α double-positive CD8 T cells per spleen was significantly lower in KO 
than in WT mice 8 days post-infection. Significantly lower percentages of gp33-41-specific, 
IFN-γ-positive CD8 T cells and IFN-γ/TNF-α double-positive CD8+ T cells, but not TNF-α-
positive CD8 T cells, among total spleen CD8 T cells, were found in KO spleens (Fig. 7i, 
representative dot plots shown in Supplementary Fig. 11c). Similarly decreased numbers and 
percentages of LCMV-specific cytokine-producing cells were observed in the CD4 cell 
population, although the reduction was of lower magnitude compared to those in the CD8 cells 
(Fig. 7j; representative dot plots shown in Supplementary Fig. 12d).    
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In addition, lower percentages of gp33-41-specific CD107a+GranB+ T cells among total CD8+ T 
cells were observed in KO spleen (Fig. 7k; representative dot plots shown in Supplementary 
Fig. 11f), implying the presence of fewer functional virus-specific cytotoxic CD8+ T cells in 
KO mice. Virus titers in the kidneys, liver and spleen were significantly higher in KO mice 8 
days post-LCMV infection, suggesting compromised virus clearance (Fig. 7l).  
 
Identification of ARMC5-binding proteins by Y2H assay 
ARMC5 has no enzymatic activity: its functions depend on interaction with molecules 
involved in different signaling pathways. To identify ARMC5-binding proteins, we conducted 
Y2H assays with human ARMC5 protein (Glu30-Ala935) as bait, and a human primary 
thymocyte cDNA expression library as prey. The binding proteins were given Predicted 
Biological Confidence (PBC) scores36, and 16 proteins with scores between A and D (“A” 
having the highest confidence of binding) are found (Table 1), if their coding sequences are in-
frame and have no in-frame stop codons. A complete list of binding proteins identified by 
Y2H assay and a map showing the interaction regions between ARMC5 and its binding 
partners are provided in the Supplementary materials section (Supplementary Data 1 and 
Supplementary Fig. 12). 
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Discussion 
Our study demonstrated that Armc5 mRNA was highly expressed in the thymus and adrenal 
glands. Its deletion led to small body size in mice and compromised T cell proliferation and 
differentiation. KO mice presented defective induction of EAE and anti-LCMV immune 
responses. KO mice developed adrenal gland hyperplasia in old age. ARMC5 is a protein 
without enzymatic activity. Our Y2H assays identified 16 candidate ARMC5-binding proteins 
potentially capable of linking ARMC5 to different signaling pathways involved in cell cycling 
and apoptosis. 
 
Armc5 expression at the mRNA level was upregulated immediately (within 2 h) after CD4 T 
cell activation by TCR ligation and less so and at a slower pace in CD8 cells. Its expression 
level then declined in the following days (Fig. 1d). Armc5 expression in CD4 cells cultured 
under Th1 or Th17 conditions after 1 day remained low (Supplementary Fig. 13), and was not 
influenced by the presence of different lymphokines, such as IL-2, IL-6, or TGF-β1 
(Supplementary Fig. 14). Armc5 mRNA expression in CD8 cells 8 days after LCMV infection 
was significantly lower than in naïve CD8 cells (Supplementary Fig. 15). These data suggest 
that this molecule is probably important in the early stage of TCR-triggered T cell activation 
to prepare cells for entry into the cell cycle. This notion is supported by cell cycle analysis, 
which revealed that KO T cells were compromised in G1/S progression (Fig. 4b).  
 
We found reduced numbers of infiltrating T cells as well as Th1 (IFN-γ+) and Th17 (IL-17+) 
cells in the CNS of KO EAE mice compared to WT EAE controls. Such decreases were likely 
responsible for the diminished EAE manifestations in KO mice. Reduced CNS lymphocyte 
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infiltration could be caused by compromised clonal expansion/differentiation of T cells in the 
periphery, defective migration of such cells into the CNS, reduced expansion/differentiation of 
these cells in the CNS, decreased apoptosis of cells in the periphery and CNS, or all of the 
above. Defective KO T cell clonal expansion/differentiation in the periphery was apparent 
according to our in vitro and in vivo results (Figs. 4 and 7b), but whether this is also the case in 
the CNS remains to be studied.  
 
We demonstrated that ARMC5 deletion resulted in comprised TCR-stimulated proliferation of 
both CD4+ and CD8+ T cells in vitro and LCMV-specific CD8+ T cell clonal expansion in 
vivo. Moreover, we observed a significant reduction in SLECs in KO mice following LCMV 
infection while MPECs were increased. Taken together, these results suggest a function for 
ARMC5 in promoting T cell growth following TCR engagement possibly by regulating 
activation threshold levels; this provides a potential explanation for the observed increase in T 
cell death following FasL engagement (Fig. 4c) in KO mice. It is possible that augmented 
apoptosis also plays a role in compromised Th1 and Th17 development from naïve KO CD4 
cells. However, ARMC5 mutations lead to PMAH in humans and diffuse adrenal gland 
hyperplasia in mice (Fig. 3d), indicating that it has a default function of repressing adrenal cell 
proliferation, or a default pro-apoptotic function, or both. Indeed, an in vitro study of the 
human adrenal gland cell line H295R revealed that ARMC5 overexpression culminates in 
apoptosis34, supporting its putative default anti-apoptotic function in adrenal glands. 
Dichotomous functions of ARMC5 in T cells versus adrenal glands indicate its tissue- or 
context-specificity, likely due to ARMC5’s association with different binding partners. In 
different types of cells, ARMC5 might preferentially bind to a certain partner, depending on 
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its relative abundance in a given cell type or cell status. Consequently, the default function of 
ARMC5 in certain types of cells or cells with a given status could be either pro- or anti-
proliferation, pro- or anti-apoptosis, or neutral. It could explain the different phenotypes seen 
in T cells versus adrenal glands, in terms of proliferation and apoptosis. It could also explain 
the obvious dilemma that KO T cell development in the thymus, which involves fast 
thymocyte proliferation, is normal, but TCR-stimulated T cell proliferation/differentiation and 
virus-induced T cell clonal expansion are defective in KO mice. 
 
Although B cells were not the focus of this study, we did demonstrate that KO B cells were 
compromised in proliferation triggered by BCR ligation. Although KO mice had normal 
serum IgG levels, it is possible that, under strenuous conditions, KO mice might manifest 
defective humoral immune responses.  
 
Based on the functional results of our ARMC5 study, those from PMAH investigations, and 
protein association information from Y2H assays, we propose the following speculative model 
of ARMC5 mechanisms of action. ARMC5 transcription and protein expression are increased 
when the cells are activated. Induced ARMC5 forms dimers (or multimers) in cytosol. Such 
dimers are able to interact with different molecules in pathways regulating cell cycling and 
apoptosis, e.g., CUL3 for cell cycling, and DAPK1 for apoptosis. Therefore, depending on the 
relative abundance of binding proteins in different cell types and cells in different states, 
ARMC5 may interact preferentially with one or the other, leading to opposite functions in 
regulating cell proliferation and apoptosis. It should be noted that list of associating proteins 
might expand, pending further verification. 
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In summary, we demonstrated that ARMC5 has vital functions in fetal development, T cell 
biology, immune responses and adrenal gland biology. We have created Armc5 KO mice as 
the first animal model of a rare human disease: PMAH. Our mechanistic study to identify 
ARMC5-binding partners has laid the groundwork for further elucidation of ARMC5’s 
mechanisms of action. With a better understanding of these mechanisms, this molecule may be 
deployed as a therapeutic target in immune and endocrine disorders. 
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Tables 
Table 4.1 ARMC5-binding proteins identified by Y2H assay 
Gene 
name 
PBC score Binding 
clones 
Different 
clones 
Major known function 
DAPK1 A 13 4 Tumor suppressor, apoptosis, 
autophagy  
ARMC5 B 2 2 Self-	dimerization 
STK24 B 3 3 Apoptosis, upstream of MAPK, acts 
on Tao  
TTF1 B 3 2 Transcription terminator, apoptosis, 
tumor risk  
POLR2A B 3 2 DNA-directed RNA polymerase II 
subunit RPB1  
CUL3 C 2 2 E3 component, WNK degradation, 
BTB domain, cell cycle, cyclin E 
degradation  
CDCA7L D 1 1 Cell cycle, transcription co-activator, 
c-Myc interactor, FoxP3-binding  
C10orf46 
(CACUL1) 
D 1 1 CDK2-associated, cell cycle, 
promotes prolifereation  
E2F2 D 1 1 Cell cycle, transcription factor, T cell 
quiescence  
FAM65B D 1 1 Skeletal muscle development, 
hearing  
FLJ20105 
(PICH) 
D 1 1 cell division  
HUWE1 D 6 1 Ubiquitination and proteasomal 
degradation, Base-excision repair, 
neural differentiation and 
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proliferation  
KIF11 D 1 1 ATP-dependent microtubule motor 
activity  
PCBP1 D 2 1 Cadherin binding, involved in cell-
cell adhesion, Burkitt lymphoma  
RPN2 D 1 1 Endopeptidase activity, ubiquitin-
dependent protein catabolic process  
TCF12 D 1 1 Immune response, regulation of 
transcription  
ZBTB40 D 2 1 Bone mineralization, cellular 
response to DNA damage stimulus  
 
 
 
Y2H assays were performed by Hybrigenics Services (Paris, France). The coding sequence for 
human ARMC5 cDNA (aa 30-935) served as bait to screen a random-primed human 
thymocyte cDNA library. Eighty million yeast clones (8-fold the complexity of the library) 
were screened. One hundred and sixty-five His+ colonies were selected. The prey fragments of 
positive clones were amplified by PCR and sequenced at their 5’ and 3’ junctions. The 
resulting sequences were used to identify corresponding interacting proteins in the GenBank 
database via a fully-automated procedure. A Predicted Biological Confidence (PBC) score 
(from A-F; A being of very high confidence in the interaction and F being experimentally-
proven artifacts) was attributed to each interaction. Sixteen proteins with PBC scores between 
A and D are listed, if their coding sequences are in-frame and have no in-frame stop codons. 
Binding clones: number of total clones interacting with the bait. Different clones: number of 
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different clones of the same cDNA interacting with the bait. Known functions of the prey 
proteins are described. 
 
 
 
(Notes on supplementary information) 
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Figure legends 
Figure 4.1 Armc5 tissue-specific expression  
 Armc5 mRNA expression in mice is assessed by ISH. (a) Armc5 expression in adult mouse 
using whole-body sections. Upper panel: H/E staining; middle and bottom panels: dark field 
X-ray film autography with anti-sense (AS) cRNA or sense (S) cRNA as probes, respectively. 
Bar = 1 cm. AG: adrenal gland; B: bone; BM: bone marrow; Cb: cerebellum; K: kidney; Lint: 
large intestine; LT: lymphatic tissue; Sk: skin; ST: stomach; Th: thymus; VB: vertebrae. (b) 
Armc5 expression in the adult thymus. Upper row: dark field X-ray film autography; lower 
row: bright field emulsion autoradiography; left column: anti-sense probe; right column: sense 
probe. Bars = 2 mm and 20 µm. Cx: cortex; Me: medulla. (c) Armc5 expression in the adult 
spleen. Upper and middle panels: dark field X-ray film autography, with anti-sense and sense 
probes, respectively; bottom panel: bright field emulsion autoradiography. Bars=2 mm and 20 
µm. WP: white pulp; RP: red pulp; CAr: central artery; Cp: capillary. (d) Armc5 mRNA in 
mouse spleen CD4 and CD8 cells measured by RT-qPCR. Experiments were performed 3 
times. The results of representative experiments are shown. To facilitate comparison, 
normalized ratios of Armc5 versus β-actin signals (means ± SEM) are presented; the 0-h signal 
ratio of each experiment is considered as 1. (e) ARMC5 subcellular localization in L cells was 
detected immufluorescence. L cells were transfected with HA-tagged mouse ARMC5-
expressing construct or an empty vector, as indicated. (f) Phase contract micrographs of views 
in (e). The experiments were conducted 3 times, and micrographs of a representative 
experiment are shown. Scale bar: 5 µm. 
 
Figure 4.2 Generation of Armc5 KO mice  
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(a) Armc5 KO mice were generated by targeted gene deletion. The targeting strategy is 
depicted. Red squares on 5’ and 3’ sides of the mouse Armc5 WT genomic sequence represent 
sequences serving as probes for genotyping by Southern blotting. (b) Armc5 mRNA deletion 
in KO mice was confirmed by RT-qPCR. The results are expressed as normalized ratios 
(means ± SEM) of Armc5 versus β-actin mRNA signals. The values from WT mice are 
considered as 1.  Experiments were conducted more than 3 times, and representative results 
are reported.  
 
Figure 4.3 General phenotype of KO mice 
 (a) Representative photos of WT, HT, KO fetuses on embryonic day 14. (b) Representative 
photos of adult KO and WT littermates. Left panel: males (8 weeks old); right panel: females 
(12 weeks old). (c) Body weight (means ± SEM) of Armc5 KO and WT littermates at age 4 
and 8 weeks. Mouse numbers (n) per group are indicated. *p<0.001 (two-tailed Student’s t 
test). (d) Morphology (upper panel) and histology (lower panel, HE staining) of adrenal glands 
from old KO mice (19 months old). Magnification: 5X. Scale bar: 500 µm. (e) Serum 
glucocorticoid levels in old KO mice. Means ± SEM of serum glucocorticoids in old KO and 
WT mice are shown. Age of each group (means ± SEM) and mouse number per group are 
indicated. Two-tailed Student’s t test was used for statistical analysis. 
 
Figure 4.4 KO T cell proliferation and apoptosis  
(a) Proliferation of spleen CD4+ and CD8+ T cells and B220+ B cells from WT and KO mice 
according to CFSE staining. CFSE intensity was ascertained by flow cytometry. Experiments 
were conducted independently 4-6 times. Representative histograms are shown. (b) Cell cycle 
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progression of spleen T cells from WT and KO mice. The percentages of cells in G1, S and G2 
phases are indicated. Experiments were conducted independently 3 times. Representative 
histograms are shown. (c) Apoptosis of WT and KO spleen T cells (gated on CD4+ plus CD8+ 
cells) upon FasL stimulation was determined by their annexin V expression according to flow 
cytometry. Experiments were conducted independently 3 times. Representative histograms are 
shown. 
 
Figure 4.5 Proliferation and differentiation of naïve KO CD4 cells into Th1 and Th17 cells 
(a) Proliferation of WT and KO naïve spleen CD4 cells under Th1 and Th17 conditions was 
assessed based on CFSE content according to flow cytometry. Experiments were conducted 3 
times, and representative histograms are shown. Grey peaks represent the CFSE content of 
CD4 cells at day 0. (b) These cells’ differentiation into Th1 and Th17 cells was also 
determined by flow cytometry according to intracellular IFN-γ and IL-17 positivity (gated on 
total CD4+). Representative dot plots are shown in the left panel. Means ± SEM of data from 3 
experiments are presented as bar graphs in the right panel. Mouse numbers (n) per group are 
indicated. p-values are reported in the bar graphs (two-tailed Student’s t test). (c and d) T-bet 
and RORγt expression in CD4 cells cultured under Th1 and Th17 conditions or in IFNγ+ or IL-
17+ cells was determined by flow cytometry. Experiments were conducted 3 times. 
Representative histograms are shown. (e) Th1 and Th17 differentiation of naïve spleen CD4 
cells (CD45.2 single-positive) derived from WT and KO donors in chimeric mice was 
analyzed by flow cytometry based on their intracellular IFN-γ and IL-17 expression. 
Representative dot plots are shown in the left panel. Means ± SEM of data from 3 experiments 
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are presented as bar graphs in the right panel. Mouse numbers (n) per group are indicated. p-
values are reported in the bar graphs (two-tailed Student’s t test).  
 
Figure 4.6 EAE induction in KO mice 
(a) Means ± SEM of EAE clinical scores of KO and WT mice. *p<0.05 (two-tailed Student’s t 
test). (b) EAE incidence in KO and WT mice. *p<0.05 (chi-square test). (c) Means ± SEM of 
body weight of KO and WT mice during EAE induction. Body weight of mice on day 10 post-
immunization was considered as 100%.  *p<0.05 (two-tailed Student’s t test). (d) Means ± 
SEM of cellularity in draining LN and of cells infiltrating the CNS of mice 14 days after MOG 
immunization. Mouse numbers (n) and p-values (paired two-tailed Student’s t test) are 
indicated. (e and f) Cytokine-producing cells among CD4 cells from draining LN (e) and CNS 
(f) on days 13-18 after MOG immunization. Left panels: representative dot plots; right panel: 
bar graphs (means +SEM) summarizing all the results, with mouse numbers and p-values 
(two-tailed Student’s t test) indicated. (g) HE (left column) or Luxol Fast Blue (right column) 
staining of spinal cords 30 days after MOG immunization. Asterisks indicate cell infiltration. 
Arrows point to demyelination. (h) Means ± SEM of mononuclear cell infiltration scores, 
demyelination scores, and total pathological scores, which is the sum of the first 2 scores. 
Mouse numbers (n) and p-values (two-tailed Student’s t test) are indicated. (i) Treg cells in 
naïve KO mice on day 17 during EAE induction. Left panel; representative dot plots; right 
panel: means + SEM of data from 3 experiments. NS: not significant (two-tailed Student’s t 
test). (j) Means ± SEM of EAE clinical scores of chimeric mice. *p<0.05 (two-tailed Student’s 
t test). (k) EAE incidence in chimeric mice. *p<0.05 (chi-square test). (l) Means ± SEM of 
body weight of chimeric mice with body weight on day 10 after MOG immunization 
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considered as 100%. No significant difference is found (two-tailed Student’s t test). (m) 
Cytokine-producing donor-derived CD4 cells in the CNS of chimeric mice on day 14 after 
MOG immunization. Left panel: representative dot plots; right panel: summary (means ± 
SEM) of all the results, with mouse numbers (n) and p-values (paired two-tailed Student’s t 
test) indicated. 
 
Figure 4.7 Anti-LCMV immune responses in KO mice  
(a) Spleen CD8 cell numbers in KO mice on day 8 after LCMV infection as determined by 
flow cytometry. Mice number (n), means ± SEM and p-values (two-tailed Student’s t test) are 
indicated. (b) Virus-specific spleen CD8 cells in KO mice on day 8 post-LCMV infection 
according to flow cytometry. Representative dot plots are shown. (c) Means ± SEM of 
percentages of gp33-41, np396-405 and gp276-286 tetramer-positive cells among spleen CD8 cells 
from all the results are presented. Numbers (n) of mice per group and p-values (two-tailed 
Student’s t test) are indicated.  (d) Means ± SEM of absolute numbers of gp33-41, np396-405 and 
gp276-286 tetramer-positive CD8 cells in the KO and WT mouse spleens on day 8 post-
infection. Numbers (n) of mice per group and p-values (two-tailed Student’s t test) are 
indicated.  (e and f) Memory and effector CD8 cell maturation in LCMV-infected WT and 
KO mice on day 8 post-LCMV infection. KLRG1loCD127hi cells are considered as memory 
precursor effector cells (MPEC), and KLRG1hiCD127lo cells as short-lived effector cells 
(SLEC). Means ± SEM are presented. Numbers (n) of mice per group and p-values (two-tailed 
Student’s t test) are indicated (e). Representative dot plots are shown (f). (g) On day 8 post-
infection, total gp33-41 np396-405 and gp276-286 tetramer-positive CD8 cells in KO and WT mouse 
spleen were assessed for activation markers. Means ± SEM are presented. Numbers (n) of 
mice per group and p-values (two-tailed Student’s t test) are indicated. (h) Absolute number of 
virus-specific, cytokine-producing CD8 cells. (i and j) Percentages of virus-specific, cytokine-
producing cells among CD8 cells (i) and CD4 cells (j) on day 8 post-LCMV infection. Means 
± SEM of data are shown. Mouse numbers (n) per group and p-values (two-tailed Student’s t 
test) are indicated. (k) Means ± SEM of percentages of gp33-41-specific CD107a+GranB+ CD8 
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T cells on day 8 post-LCMV infection. Mouse numbers (n) per group and p-values (two-tailed 
Student’s t test) are indicated. (l) Means + SEM of viral titers in the kidney, liver and spleen 
on day 8 post-LCMV infection. Mouse numbers (n) per group and p-values (two-tailed 
Student’s t test) are indicated.  
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Figures 
Figure 4.1 Armc5 tissue-specific expression  
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Figure 4.2 Generation of Armc5 KO mice  
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Figure 4.3 General phenotype of KO mice 
 
  
 168 
Figure 4.4 Armc5 KO mice presented normal thymus and spleen weight, cellularity and cell 
subpopulations 
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Figure 4.5 KO T cells are compromised in proliferation and differentiation 
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Figure 4.6  KO T cells developed from the chimeric mice were compromised in proliferation 
and differentiation  
 
 171 
Figure 4.6 continued 
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Figure 4.7 KO mice are resistant to EAE induction 
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Figure 4.7 continued 
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Figure 4.8 KO mice present compromised anti-LCMV immune response 
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Figure 4.9 Hypothetical model of ARMC5 action mechanisms 
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Chapter 5 Discussion 
Receptor tyrosine kinases are a group of key signaling molecules, which have dual functions: 
sensing the environmental stimuli outside the cells and transmitting them into the cells. They 
are particularly important in the immune cells according to the existing literature. Based on 
this conviction, in the past 20 years, our laboratory has elected to study the function of T cell 
abundant receptor tyrosine kinase, Ephb6. A large number of publications result from this 
endeavor. As both Efnb1 and Efnb2 are the ligands for Ephb6, we then proceeded to study 
their roles in T cell biology in multiple ways. We created single gene KO of Efnb1, Efnb2 in T 
cells in mice, as well as Efnb1/Efnb2 double KO. We found that only the double KO mice 
showed the phenotype in T cell biology.    
Naïve T cells have the ability to expansion and differentiation into effector cells once they 
encounter foreign antigens. Stimuli can trigger T lymphocytes proliferation and differentiation 
signaling pathways only when both the TCR activation and co-stimulation signals are 
triggered. During T cell activation, a huge number of molecules are modulated. Some of these 
molecules play essential regulatory roles, while others exert house-keeping functions and/or 
act as supporters to cope with increased or changed metabolic demands. As Ephb6 deletion in 
T cells causes compromised T cell activation/proliferation, we speculated that molecules with 
altered expression during T cell activation in WT versus Ephb6 gene KO are critical in T cell 
activation. We thus did DNA microarray analysis to identify potential targets that were 
differentially expressed in WT versus Ephb6 KO T cells in the early T-cell activation stage. 
About 30 molecules were up- or down-regulated more than three folds in WT T cells 
compared with KO T cells shortly after TCR stimulation. Stra6 and Armc5 were among those 
that had been validated for their altered expression. We generated mice with these two genes 
deleted to study their roles in T cell biology. Stra6 KO mice were normal in their immune 
responses, while Armc5 KO resulted in resistance to autoimmune disease and compromised 
anti-virus immune responses. 
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Several issues arising from our studies are worth discussing. 
The role of Efnb1/b2, Stra6 and Armc5 in CD4+ T cell activation 
CD4+ T cell activation triggers T cell function in terms of proliferation, differentiation, 
migration, as well as cytokine production. As mentioned earlier in this thesis, lots of 
molecules participate in CD4+ T cell activation at multiple levels. Efnb1/b2, Stra6 and Armc5 
are proteins of different families with distinct functions. Even though their expression levels 
can be changed upon anti-CD3 stimulation, their potential roles in regulating T cell activation 
are totally different. 
A decade ago, our group found that solid-phase EFNB1 and EFNB2 act as costimulatory 
factors in T cell activation. Receptors of ephrin B1 and ephrin B2 can co-localize with TCR 
ten minutes after anti-CD3 crosslink, which augments the MAPK/ERK pathway (Yu et al., 
2003a, 2004). This indicates that forward signaling is essential for CD4+ T cell activation. 
Efnb1/Efnb2 double KO mice were then generated. We found that the Efnb1 and Efnb2 
reverse signaling are also critical for T cell homeostatic expansion, for T cell differentiation 
into Th1 and Th17, as well as for IL-6 signaling (Luo, Charpentier, et al., 2011). Based on 
these, in this thesis, using lentivirus containing truncated Efnb1 and Efnb2 intracellular tail 
regions, we confirmed that reverse signaling regulates T cell chemotaxis. Moreover, several 
tyrosine residues in the intracellular region of Efnb1 and Efnb2, which are just beneath the cell 
surface, are the major players in regulating T cell migration. Whether the same mechanism 
applies to T cell activation remains unknown. However, based on these results, we postulate 
that Efnb1 and Efnb2, as cell surface receptors, may enhance CD4+ T cell activation signal on 
the cell surface or intracellularly just beneath the cell membrane, even though detailed 
mechanisms are poorly understood. 
Comparing with EFNB1 and EFNB2, ARMC5 is mainly a cytosolic protein, as it was detected 
in the cytoplasm of L cells transiently transfected with a human ARMC5 expression construct. 
Our study found Armc5 mRNA expression was rapidly induced in T cells within 1-2 h after 
anti-CD3 plus anti-CD28 stimulation, and then subsided. Most importantly, the T cell 
proliferation and differentiation in Armc5 KO mice are impaired. This means that the change 
at the mRNA level for T cell activation might be the first trigger for T cell proliferation and 
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differentiation. We thus postulate that Armc5 participate in T cell activation by regulating its 
downstream signaling pathways in the cytosol or even in the nucleus. Further studies are 
required to address questions like the Armc5 expression pattern at the protein level after 
activation, the part of the TCR stimulation/co-stimulatory pathway that actually links to 
Armc5, and the underlying mechanisms of ARMC5 in T cell activation, etc.             
Vitamin A and its metabolites are needed for CD4+ T cell activation (Benson, Pino-Lagos, 
Rosemblatt, & Noelle, 2007; Hall, Grainger, et al., 2011). However, in this study, we found 
that Stra6 KO mice does not contribute to T cell activation as far as we can detect. This 
indicates that Stra6 might not be necessary for the vitamin A transport in T cells. Other 
compensate pathways may exist. However, this is the issue yet to be solved (Terra et al., 
2013).    
 
Redundancy 
Our previous in vitro study showed that solid phase EFNB1 or EFNB2 was capable of 
increasing T cell response to TCR stimulation (Yu et al., 2004). However, neither Efnb1 nor 
Efnb2 single deletion in mice showed apparent impact on T cell immune responses. For 
STRA6, in spite of published articles claiming that this molecule is absolutely necessary for 
cellular vitamin A import, its deletion did not lead to any discernable changes in mouse 
development, physiology, and cellular vitamin A content, or to any abnormalities in the 
immune system. For Armc5 deletion, although the KO mice showed a strong phenotype in 
terms of body size, the lymphoid organ size, cellularity and lymphocyte subpopulations were 
still normal. However, we found that in KO mice, the T cell proliferation/differentiation and 
anti-virus immune responses, were compromised. 
Throughout the evolutionary history of life, our biological systems have developed high 
redundancy to overcome possible aberrant mutations that might lead to disastrous 
consequences. Genes of the same family or genes with similar functions are usually involved 
in such compensative mechanism. Efnb1 and Efnb2 are cases in the former point. Deletion of 
either of them shows no immunological phenotype, but if both of them are deleted, their 
importance is revealed. This type of redundancy guarantees that the functional roles of this 
family in T cell biology. Secondly, the biological system might use a totally different 
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mechanism of redundancy for certain functions. This is evidenced in the case of STRA6. 
Although this molecule has been shown to facilitate cellular vitamin A import, for most cell 
types, passive vitamin A diffusion is probably sufficient for the need. Our results also 
demonstrate that claims in the published articles, even those in high-impact journals such as 
Nature, could be flawed, as STRA6 was dubbed as an indispensable molecule from vitamin A 
cellular import, but obviously, this is not the case based on our gene KO study. Thirdly, other 
genes might partially compensate for the function of a certain molecule, as in the case of 
ARMC5. Such compensation seems to be sufficient for T cell development, which also needs 
proliferation, but it is not sufficient when there are strong provocations such as EAE induction 
or virus infection.   
Spinal Bifida phenotype 
We were not able to get live Armc5 KO mice in either the pure C57BL/6 or 129/sv 
background. In an attempt to get live KO mice, we crossed heterozygous Armc5 mice in the 
129/sv background with CD-1 IGS outbred mice. We observed a higher percentage (42%) of 
KO mice with kinky tails in this mixed background comparing with their WT littermates 
(16%) (Fig. 5.1). Further study revealed that a higher percentage of Armc5 KO fetuses on 
embryonic day 11.5 presented anencephaly (Data not shown). Both kinky tail and anencephaly 
are the clinical signs of neural tube defects, which are congenital malformations of the brain 
and spinal cord. The neural tube development can be regulated by multiple factors related to 
the proliferation and migration of neuroectodermal cells during embryonic development 
(Padmanabhan, 2006) (Pulikkunnel & Thomas, 2005). Our in situ hybridization also revealed 
that on embryonic day 11, Armc5 was highly expressed in the neural tube (data not shown), 
supporting its potential role in neural tube development. Since this phenotype is prominent 
only in the 129/sv × CD-1 IGS F1 mice, we postulate that some contributions from the CD1 
IGS genetic background act in concert with Armc5 for the observed neural tube defects; these 
concerted effects might cause defective neural cell proliferation or migration, leading to neural 
tube defects. 
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Figure 5.1 Percentage of mice with kinky tails in 129/sv × CD-1 IGS F1 background  
ARMC5 in primary macronodular adrenal gland hyperplasia (PMAH) 
During our investigation on the functions of ARMC5, several authors have reported that 
ARMC5 mutations in human patients are associated with PMAH. Assié G et al. found that 
ARMC5 expression was lower in the tumor mass from macronodular adrenal gland 
hyperplasia individual carrying ARMC5 mutations (Assie et al., 2013). In the same study, 
siRNA knockdown of ARMC5 in adrenocortical H295R cells reduced gene expression of 
several steroidogenic enzymes and adrenal transcription factors at the mRNA levels (Assie et 
al., 2013). However, in our study, Armc5 KO mice did not show any abnormality in adrenal 
histology or serum glucocorticoid titers. These may be due to several reasons. Firstly, it is 
possible that the discrepancy is caused by species difference between humans and mice (Terra 
et al., 2013). The second possibility is that Armc5 has different functions in different types of 
tissues. Thirdly, PMAH is typically diagnosed in patients between 40-60 years of age, due to 
the slow progress of the adrenal gland hyperplasia (Assie et al., 2013; Bourdeau et al., 2016). 
However, in our study, both the adrenal histology and serum glucocorticoid titers are 
measured from mice less than 16 weeks old, which is equivalent to 20-30 years of age in 
human beings. It is worth examining the adrenal glands of KO mice when they are at old ages. 
However, we think that it is unlikely that aged KO mice will develop adrenal gland 
abnormality for the following reasons. Not all individuals with ARMC5 mutations develop 
PMAH, and only 25% PMAH patients have ARMC5 mutations (Hsiao et al., 2009), suggesting 
that PMAH is not a monogenic disease, and it takes time to accumulate the second or third hit 
of mutation in the tissue to alter the function or expression of ARMC5 to allow the hyperplasia 
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to occur. That is probably the reason why PMAH is developed at a later part of the life in 
humans. However, our KO mice already have the gene completely deleted, but they do not 
manifest adrenal gland phenotype. In this case, waiting for a longer time will not contribute to 
the alteration or dysfunction of ARMC5, as it is already deleted. We are more inclined to 
believe that in humans, ARMC5 mutations leads to altered or gain-of-function of ARMC5, 
which causes the proliferative phenotype of the adrenal gland. Mutations of ARMC5 gene in 
humans are not equivalent to loss-of-function, as in the case of Armc5 gene KO in mice. In 
fact, there is no solid evidence showing that PMAH patients have ARMC5 loss-of-function 
occurring in their adrenal glands. Although Assie et al. showed that the PMAH adrenal 
nodules had reduced ARMC5 expression according to immunoblotting, these data are not 
convincing, as none of the commercial anti-ARMC5 Abs is specific according to our 
assessment. 
The role of ARMC5 in cell proliferation versus apoptosis 
We demonstrated that the knockout of Armc5 resulted in comprised TCR-stimulated 
proliferation of both CD4+ and CD8+ T cells in vitro. Such a handicap contributed to 
diminished in vivo anti-virus responses in KO mice, particularly in the form of CD8 clonal 
expansion. Taken together, these indicate Armc5 may function as a positive regulator of T cell 
growth. However, mutations of ARMC5 results in adrenal hyperplasia in PMAH, suggesting 
that it may function as a negative regulator of tumor cell growth. Further, in vitro study in 
H295R cell line showed that overexpression of ARMC5 results in cell apoptosis (Assie et al., 
2013). Cell proliferation and cell death are such diametrically opposed cellular events, making 
us wondering how Armc5 accomplishes these two opposing tasks. There are several possible 
explanations for this. 
First of all, the most well known molecules that have mechanistic overlap between cell 
proliferation and apoptosis are probably the proto-oncogenes. Proto-oncogenes have their 
roles both during normal cell physiological processes such as cell growth, proliferation, 
survival, as well as during tumor cell malignant transformation. c-Myc is a two-edged sword 
in oncogenesis, which is capable of concomitantly inducing cell proliferation and apoptosis 
(Shortt & Johnstone, 2012). On one hand, c-Myc is a central molecule in regulating cell 
proliferation. This involves multiple signaling pathways triggered by nutrients, growth factors 
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and mitogenic stimuli, resulting in the stabilization of Myc protein for optimal growth 
condition under a physiological condition. Also, the c-myc gene promoter is capable of 
receiving signals from distinct transcription factors to regulate multiple events in cell cycling. 
For example, the general transcription factor IIH (TFIIH) regulates c-Myc transcription at 
multiple points between initiation and promoter escape (Weber, Liu, Collins, & Levens, 
2005). Under certain conditions, transcription factor NFAT1 (nuclear factor of activated T 
cells 1) can directly bind to the c-Myc promoter and also interact with a variety of 
transcriptional cofactors (Mognol, de Araujo-Souza, Robbs, Teixeira, & Viola, 2012). On the 
other hand, c-Myc can prevent inappropriate cell growth, making it a safeguard against 
malignant transformation (Lowe, Cepero, & Evan, 2004). Clinical evidence supports this as 
more Myc is expressed in some cancer, especially in late-stage cancer (Terunuma et al., 2014; 
Wolfer et al., 2010). The apoptotic machinery of c-Myc is not limited to its ability to amplify 
both known pathways of apoptosis, but can interact with the tumor suppressor gene product 
p53 at different molecular levels (Hoffman & Liebermann, 2008). Therefore, based on our 
results and the current understanding of proto-oncogenes, we postulate that ARMC5 may play 
important roles in both cell expansion and apoptosis, depending on the cellular context. 
Mechanistically, both the ARM domain and the BTB domain of ARMC5 molecule provide 
interaction surface, which permits dimerization and the ability to bind to other molecules. 
Binding with versatile molecules leads to the activation of different signaling pathways 
involving distinct biological functions. The ARM repeat-containing proteins are known to be 
crucial for different cell functions such as cell adhesion, cell fate specification, cell migration 
and cell proliferation, depending on what proteins they associate with. The BTB domain 
controls a wealth of cell functions, including modulate transcription in the nuclei, regulate 
cytoskeleton dynamics in the cytoplasm, control ion channel assembly and gating in the cell 
membrane, again depending on the proteins it interacts with.    
As mentioned in the Introduction, the positively charged ARM repeat region of β-catenin is 
particularly critical for interaction with its binding partners. Even though these binding 
partners have no apparent evolutionary relationship (Fig. 5.2), they share several peculiar 
characteristics. First, they usually contain ~30 amino acids and contact the ARM domain on an 
excessively large surface area. Second, these binding motifs frequently have phosphorylated 
Ser/Thr residues, which greatly enhanced their binding to the ARM domain (Ha, Tonozuka, 
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Stamos, Choi, & Weis, 2004). Third, some of them have same motifs contain Asp and Glu 
residues to form salt bridges with Lys435 and Lys 312 located in the binding groove of β-
catenin (Graham, Weaver, Mao, Kimelman, & Xu, 2000).  
Among the 12 armadillo repeats in the β-catenin binding groove, repeats 5-9 is the essential 
sites that intact with Tcf, cadherin, APC and ICAT (W. Xu & Kimelman, 2007). Also, the 
groove in ARMC repeats 3-4 is also critical for binding with Tcf, axin, and part of APC and 
cadherin (Graham, Ferkey, Mao, Kimelman, & Xu, 2001; Xing, Clements, Kimelman, & Xu, 
2003) (Xing et al., 2004). The NTD and CTD at both end of β-catenin also have binding 
partners of their own, but they could function as a regulator for the association of ARM repeat 
and their binding partners.   
The BTB domain usually contains ~120 aa. It is a structurally conserved domain for protein-
protein interactions. The variation of highly variable residues buried within the core domain 
scaffold and specific domains at the both end of the each BTB-containing proteins contribute 
to different behaviors of the BTB domain.  
 
 
Some proteins are simply made up of BTB domain. However, more frequently as it is in 
ARMC5, the BTB-containing proteins typically host a second protein-protein interaction 
domain. This allows the BTB domain-containing proteins to carry out multiple functions, 
depending on which proteins they associate with. For example, the BTB domain in BTB-ZF 
transcription factors provides a dimerization interface, which could promote DNA binding 
ability. Several BTB-Kelch proteins are known for the regulation of actin function because of 
the Kelch domain they bear.  
Thus, as both ARM repeats and the BTB domain provide a versatile protein-protein interacting 
surface, the functions of the ARM repeat-containing and BTB domain-containing proteins are 
very diverse because a variety of proteins could bind to them.  This provides a molecular base 
for the possible divergent functions of ARMC5. 
Y2H data  
Y2H assays are efficient for mapping the whole protein-protein interactomes. Using ARMC5 
protein from Glu30-Ala935 as bait, a human primary thymocyte cDNA library was screened 
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for potential ARMC5-binding partners. Eight proteins including ARMC5 itself lie within the 
confidence category “D” or above. Several potential binding regions of bait and preys are 
consistent with existing literature. For example, in our Y2H, ARMC5 bait was found to 
interact with two CUL3 prey fragments at 3-1130 nt and 54-1556 nt. Both encode a peptide 
sequence at the N-terminal domain of CUL3, and this peptide sequence includes a 388-amino 
acid segment which is known to be associated with the BTB domain of BTB-Kelch family of 
E3 ubiquitin ligases (Canning et al., 2013). Needless to say, further validation of the 
association between ARMC5 and binding proteins found in Y2H is warranted.  
Based on the functional results of ARMC5 from our study and those from PMAH studies, and 
the protein association information from Y2H, we propose the following model for the 
mechanisms for the action of ARMC5, as illustrated in Figure 3. When cells are activated, 
there is increased ARMC5 transcription and protein expression. The upregulated ARMC5 
forms dimers in the cytosol. Such dimers will bind to a variety of molecules to regulate cell 
cycling and apoptosis. Therefore, ARMC5 may function as cell proliferation or apoptosis 
promoters or suppressors. 
Summary and Future Directions 
In this thesis study, the potential functions of EFNB1, EFNB2, STRA6 and ARMC5 in T cell 
biology were investigated. Using in vitro and in vivo approaches, such as primary cell culture 
and animal disease models like CIA, EAE, the underlying molecular mechanisms were 
investigated. We have following essential findings.  
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Figure 5.3 Putative function of ARMC5 
 
1. By studying T cells specific Efnb1 and Efnb2 double KO mice, their new roles in T cells 
function were studied in the CIA model.  
2. We proved that T cell-specific EFNB1 expression level can be a potential marker for 
monitoring RA disease activity. 
3. The deletion of STRA6 does not affect the T-cell immune responses, nor does the cellular 
vitamin A import. 
4. We investigated the expression patterns and function of Armc5 by in situ hybridization and 
gene knockout mice.  
5. Armc5 is critical for T cell proliferation and differentiation in vitro.  
6. Armc5 is essential for the pathogenesis of EAE and anti-virus immune response in mice. 
Some interesting questions remain to be further investigated in the future. 
1.  To validate the interaction between ARMC5 and the Y2H hits  
a) To confirm the Y2H results by co-immunoprecipitation. 
b) To dissect which part of ARMC5 interacts with the true binding partner using deletion 
mutations. 
    c) To knockdown the expression of the potential binding partner of ARMC5 using siRNA, 
thus, to confirm the functional significance of the binding.  
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2. To study the potential function of ARMC5 in cell apoptosis and cell growth 
As ARMC5 might be involved in multiple processes of cell biology such as apoptosis, cell 
cycle regulation, and protein degradation, we want to find out the mechanism which ARMC5 
exerts its roles in these processes. 
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Abstract 
TNF-like ligand 1A (TL1A), also known as TNFSF15, is a member of the TNF superfamily.  
Its known receptor is death receptor 3 (DR3). In humans, TL1A also binds to a secreted TNF 
family member called decoy receptor 3, which interferes with the interaction between TL1A 
and DR3. TL1A/DR3 signal has been implicated in several autoimmune diseases in animal 
models as well as in clinical conditions. We generated TL1A gene knockout (KO) mice to 
assess its role in collagen-induced arthritis (CIA), a mouse model of human rheumatoid 
arthritis. The KO mice were fertile and had no visible anomalies. Their lymphoid organ size 
and cellularity, T and B cell subpopulations, helper T cell and regulatory T cell development 
in vivo and in vitro and anti-viral immune responses were comparable to those of wild type 
mice. However, the KO mice presented ameliorated CIA in terms of clinical scores, disease 
incidence and pathological scores. The KO mice had reduced titres of pathogenic anti-collagen 
Abs in the sera. No apparent defect was found in the function of follicular helper T cells. We 
revealed that plasma cells but not B cells expressed high levels of DR3, and were direct targets 
of TL1A. In the presence of TL1A, they survived better and produced more pathogenic Ab. 
This study presented novel knowledge about the role of TL1A in humoral immune responses 
and its mechanism of action in CIA pathogenesis.    
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Introduction 
TNF-like ligand 1A (TL1A), also called TNFSF15, is a member of the TNF superfamily.  It 
was identified during homology searches in an endothelial cell cDNA library.  It is produced 
by the endothelial cells(1), monocytes, dendritic cells, T cells, natural killer T cells (NKT), 
synovial fibroblasts and chondrocytes, either upon stimulation or in situ in inflammatory 
sites(2-6).  Like other TNF superfamily members, TL1A can either be membrane-bound or 
soluble after being cleaved from the cell surface, but the cleavage happens on dendritic cells 
(DC) and not on T cells(1, 7). It was also discovered that the soluble form of TL1A was more 
potent in inducing IFN-γ production by T cells(8). 
The receptor of TL1A death receptor 3 (DR3) is also called TNFRSF25, Apo3, WSL-1, 
TRAMP or LARD(9).  In addition to the full length isoform, murine DR3 was reported to 
have two truncated variants: one secreted form displaying no transmembrane region and 
another lacking the fourth CRD in its extracellular sequence (10).  A repertoire of all DR3-
expressing cells has not yet been completed.  DR3 is detectable on T cells, NK cells, NKT 
cells, osteocytes, renal tubule epithelial cells and in vitro plasma cells, but primary B cells 
express very low levels of DR3(3, 11-13). Previous studies of the immunological functions of 
TL1A and DR3 primarily focused on T cells, NK cells and NKT cells(3, 12, 14-16). In 
addition to DR3, decoy receptor 3 could also bind to TL1A in humans, and blocks the 
interaction between TL1A and DR3(1). Mice do not have a human decoy receptor 3 ortholog. 
Earlier in vitro studies have shown that TL1A promotes T cell proliferation, Th17 
differentiation and the production of pro-inflammatory cytokines by T cells (9), indicating its 
potential role in inflammatory autoimmune diseases.  The presence of TL1A in diseased 
tissues, fluids and sera from patients of chronic colitis and rheumatoid arthritis (RA) 
corroborates the findings in animal models (2, 5, 17-19). In vivo studies of different animal 
models have provided direct evidence supporting the role of TL1A in autoimmune diseases. 
We have demonstrated that the administration of recombinant TL1A to mice with collagen-
induced arthritis (CIA) aggravates the disease (5). Furthermore, overexpression of TL1A in 
transgenic mice results in spontaneous inflammatory bowel disease (IBD) as well as increased 
number of T helper cells (9, 20, 21).  On the other hand, DR3 gene knockout (KO) mice have 
reduced disease severity of allergic lung inflammation and antigen-induced arthritis  and 
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present less effective anti-viral and anti-bacterial immune responses(15, 22-25). Blocking 
DR3-TL1A interaction by TL1A-neutralizing Ab would partially protect the KO mice from 
CIA, lung inflammation, and 2,4,6-trinitrobenzene sulfonic acid (TNBS)- and dextran sodium 
sulphate (DSS)-induced colitis(3, 4, 9, 23).  TL1A KO mice are less susceptible to 
experimental autoimmune encephalomyelitis (EAE) induction(22).   
Rheumatoid arthritis (RA) is a chronic polygenic autoimmune disease characterized by 
chronic systemic inflammation that may affect various tissues and organs. Joints and their 
surrounding tissues are most frequently affected. Often, there is persistent synovitis and 
presence of auto-Abs leading to progressive destruction of cartilage and bone in the joints 
(26). The pathogenesis of RA is not fully understood with three primary, outstanding 
questions to be fully answered: (1) How is the immune response initiated by genetic and/or 
environmental factors? (2) How does the immune response lead to local joint inflammation? 
(3) How does the inflammation cause bone destruction? There are some findings from patients 
and animal models that have provided some partial answers to these questions(27-36). 
In the current study, we generated TL1A knockout (KO) mice to study the role of TL1A in 
CIA pathogenesis. We found TL1A KO mice had significantly lower CIA clinical scores and 
incidence, and lower serum anti-collagen Ab titres than their wild type (WT) counterparts.  
Deletion of TL1A minimally affected T cell functions; however, TL1A could directly deliver 
survival signals to plasma cells as a way to promote pathogenic collagen-specific Ab 
production. Our findings revealed previously undocumented functions of TL1A in RA 
pathogenesis. 
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Materials and methods 
Generation of TL1A KO mice  
A polymerase chain reaction (PCR) fragment amplified from the TL1A cDNA was used as a 
probe to isolate genomic BAC DNA clone 112H6 from the 129/sv mouse BAC genomic 
library RPCI-22.  The targeting vector was constructed by recombination and routine cloning 
methods using an 11-kb TL1A genomic fragment from clone 112H6 as the starting material 
(Fig. 1A) (37).  The 2.05-kb ScaI-XhoI genomic fragment containing exon 1 was replaced by 
a 1.1-kb Neo cassette from pMC1Neo Poly A (Fig. 1A).  The final targeting fragment was 
excised from its cloning vector backbone by Not I digestion and electroporated into R1 
embryonic stem (ES) cells for G418 (38).   The targeted ES cell clones were injected into 
C57BL/6 blastocysts.  Chimeric male mice were mated with C57BL/6 females to establish 
mutated TL1A allele germline transmission.   
Southern blotting with a probe corresponding to the 5’ sequence outside the targeting region, 
as illustrated in Figure 1A (hatched rectangle) was used to screen gene-targeted ES cells and 
eventually for the confirmation of the gene deletion in mouse tail DNA.  The targeted allele 
showed an 11.7-kb StulI/StulI band, and the WT allele, a 5.4-kb StulI/StulI band.   
The TL1A-KO mice were subsequently backcrossed to the DBA/1LacJ for 8 generations for 
experimentation in this study.  The littermate WT mice served as controls.  In the beginning of 
the experiments, mice were on average 8 to 12 weeks of age.   
PCR was adopted for routine genotyping of the targeted allele(s).  The following PCR 
conditions were applied: 4 min at 94  oC, followed by 35 cycles of 30 s at 94 oC, 30 s at 68 oC, 
and 30 s at 72 oC with a final incubation at 72 oC for 10 min.  One forward primer and two 
reverse primers (forward primer 5'- TCC ACA GCC AAC ATA GGC AAG GA-3'; reverse 
primers 1: 5'- GTG TGG CTT GCA ACA GGA AAT GGA -3'; reverse primer 2 5'- ACC 
TGC GTG CAA TCC ATC TTG TTC-3') were included in the PCR which amplified a 581-bp 
fragment from the targeted allele and a 335-bp fragment from the WT allele. All mice were 
housed under specific pathogen-free conditions and studied according to protocols approved 
by the Institutional Animal Protection Committees of the CRCHUM and INRS-IAF. 
Reverse transcription-quantitative PCR (RT-qPCR) 
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Murine TL1A and DR3 mRNA was measured by RT-qPCR.  Total RNA was isolated from 
cells or tissues with Trizol reagent (Invitrogen, Carlsbad CA).  For TL1A mRNA 
measurement, the forward primer 5’-TCA TTT CCC ATC CTC GCA GGA CTT-3’ and 
reverse primer 5’-TAA TTG TCA GGT GTG CTC TCG GCT-3’ were used to generate a 166-
bp fragment.  For measurement of mRNA of all 3 DR3 isoforms (the full length one, the one 
with transmembrane domain deletion and the one with deletion of the extracellular CRD 
domain), the forward primer 5’-AGA GGT ATG GCC CGT TTT G-3’ and reverse primer 5’-
AAG TGG TTG TCT CTG GTC AAG-3’ were used to generate a 133-bp fragment.  For 
mRNA of the full-length DR3 isoform, the forward primer 5’-TGC CTG GCT GGC TTC 
TAT ATA CGT G -3’ and reverse primer 5’-ACA GAC AGC AGT GCA AGC CTT A-3’ 
were used to generate a 92-bp fragment.  The PCR conditions for both reactions were as 
follows: 2 min at 95oC followed by 45 cycles of 10 s at 95oC, 15 s at 56oC and 20 s at 72oC.  
Samples were in triplicates.  β-actin mRNA levels were measured as described in our previous 
publication and taken as internal controls(5).  The data were expressed as signal ratios of 
either TL1A mRNA/β-acting mRNA or DR3 mRNA/β-actin mRNA. 
Flow cytometry 
Single cell suspensions from the thymus, spleen and lymph nodes (LN) were prepared and 
stained immediately or after culture for 2-, 3-, 4- or 5-color flow cytometry.  Mouse anti-
mouse TL1A mAb (Tandys1a) was from eBioscience (San Diego, CA). Anti-PD-1 mAb; anti-
GL7 mAb, anti-ICOS mAb, anti-CD40L mAb, anti-CXCR5 mAb, and anti-DR3 mAb were 
from BD Biosciences (Missisauga, ON, Canada) and eBioscience. The rest mAbs used in flow 
cytometry are described in our previous publications(39).   
Cell culture and in vitro T help cells (Th) differentiation 
In general, total spleen or LN cells, T cell subpopulations, B cell subpopulations or bone 
marrow cells were prepared, isolated with Miltanyii beads or sorted by flow cytometry as 
indicated and then cultured in RPMI1640 medium containing 10% FCS, 100 µg/ml 
streptomycin, 100 units/ml penicillin G, 1× nonessential amino acids, 1 µM sodium pyruvate, 
2.5 µM β-mercaptoethanol and other supplements as indicated.  In some cases, recombinant 
mouse TL1A (aa76-252; R & D systems, Minneapolis, MN) was added to the culture.   
In vitro Th differentiation was conducted as follows.  Naïve CD4 T cells (CD4+CD62L+ 
CD44low) were isolated from TL1A KO or WT mouse spleens with MagCellect Mouse Naïve 
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CD4+ T cell Isolation kits (R & D Systems). T cell-depleted TL1A KO or WT spleen cells 
were irradiated at 3000 Rad and used as feeder cells. The naïve CD4 cells (0.1×106/ well) were 
mixed with the feeder cells (0.5×106/well) and cultured in 96-well plates in the presence of 
soluble anti-CD3ε mAb (clone 145-2C11, 2 µg/ml; BD Biosciences). Cultures were 
supplemented with recombinant mouse IL-12 (10 ng/ml; R & D Systems) and anti-IL-4 mAb 
(10 µg/ml; R & D Systems) for the Th1 condition; recombinant mouse IL-4 (20 ng/ml; R & D 
Systems), anti-IL-12 mAb (10 µg/ml; BD Biosciences) and anti-IFN-γ mAb (10 µg/ml; R & D 
Systems) for the Th2 condition; recombinant mouse IL-6 (20 ng/ml; R & D Systems), 
recombinant human TGF-β1 (5 ng/ml; R & D Systems) and anti-IL-4 and anti-IFN-γ mAb (10 
µg/ml; R & D Systems) for the Th17 condition; recombinant human TGF-β1 (5 ng/ml; R & D 
Systems), anti-IL-4 and anti-IFN-γ mAb (10 µg/ml; R & D Systems) for the Treg condition; 
and recombinant mouse IL-6 (20 ng/ml; R & D Systems), anti-IL-4 and anti-IFN-γ mAb (10 
µg/ml) for the Tfh-like cell condition, without any supplement for the Th0 condition. 
Mouse CIA model 
Eight- to 12-week old TL1A KO mice and their WT littermates in the DBA/1LacJ background 
were used in the experiments. Details of the induction of CIA in these mice were previously 
described (5). Briefly, mice were immunized with single intradermal injection at the base of 
the tail with 100 µg of bovine type II collagen (BTIIC; Chondrex, Redmond, WA), which was 
emulsified in equal volumes of complete Freund’s adjuvant (CFA; 4 mg/ml Mycobacterium 
tuberculosis, strain H37Ra; Difco, Detroit, MI) on day 0. The mice were examined for their 
development and severity of arthritis from day 20 to 50. Disease severity was scored on a 
scale from 0 to 4 by visual inspection of each paw according to methodology of Brand et al. 
with some modifications as follows: 0 = normal paw; 1 = erythema and mild swelling 
confined to two or more digits, or the tarsal, or the ankle joint; 2 = erythema and mild swelling 
of any two regions of the metatarsal, tarsal or ankle joint; 3 = erythema and moderate swelling 
extending from the ankle to metatarsal joints; 4 = erythema and severe swelling encompassing 
the ankle, foot and digits, or ankylosis of the limb (40). The scores for each of four paws were 
added to give a final score, such that the maximal severity score was 16 for each mouse. The 
mice were considered as having arthritis, if their clinical score was equal to or above 1. 
Histology 
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Mice immunized with BTIIC/CFA were sacrificed on day 50, and then their paws including 
ankles were surgically removed and fixed in 10% buffered formalin. Following decalcification 
in 5% formic acid, the specimens were processed for paraffin embedding. Tissue sections (7 
µm) that were stained with hematoxylin/eosin and Safranin O (for cartilage staining) were 
scored according to three parameters, i.e., lining hyperplasia, bone erosion destruction and cell 
infiltration, in one-way blind fashion with the examiner not knowing the identity of the 
sections. Each parameter was scored on a 0–3 scale, as previously described, and all four paws 
(one section per paw) of each animal were scored. The overall score of an animal was the sum 
of the three parameters of the four paws(41).   
Isolation of infiltrating cells of hematopoietic origin in paws 
The mouse vascular system was perfused with 20 ml PBS under anaesthesia. The paws were 
then harvested, skinned and minced into small pieces, which was then digested with 
collagenase II (2 mg/ml, Chondrex, Redmont, WA) and dispase II (250 µg/ml, Roche 
Diagnostics, Indianapolis, IN) in 5 ml Hank’s balanced salt solution at 37 oC for 40 min. The 
digested product was washed and passed through cell strainers (BD bioscience, San Jose, CA) 
of 70 µm in pore size, consecutively. Cells in the passing-through liquid were enumerated and 
stained with anti-CD45.2, CD11c, CD11b, Thy1.2 and B220 mAbs, and analysed and counted 
with flow cytometry. 
Enzyme-linked immunoabsorbent assay (ELISA) for the titres of anti-BTIIC Abs 
ELISA was used to measure the titres of mouse serum anti-BTIIC Abs. Flat-bottom 96-well 
plates (Costar EIA/RIA plate #3590, Fisher Scientific, Pittsburgh, PA) were coated with 
BTIIC in PBS (100 µl/well) overnight at 4 oC. After blocking for 1 h at room temperature with 
3% BSA in PBS, the plates were washed with PBS containing 0.05% Tween 20. Samples in 
duplicate were added to the wells (50 µl/well) and incubated overnight at 4 oC.  After 
extensive washes, 50 µl horse radish peroixdase-conjugated goat anti-mouse IgG1, IgG2a and 
IgG2b antisera (1:5000 dilution; Southern Biotechnology, Birmingham, AL) or rabbit anti-
mouse IgG (1:5000 dilutions; GE healthcare life sciences, Little Chalfont, Bucks, United 
Kindom) were added to each well.  Two hours later, the plates were washed, and 
tetramethylbenzidine (50 µl/well; BD Biosciences, San Jose, CA) was added followed by 10 
min incubation at room temperature in the dark. Finally, 2N H2SO4 (50 µl/well) was added to 
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the wells to stop the reaction, and optical densities were determined at 450 nm. The serum 
anti-BTIIC Ab titre of a WT with the highest level of anti-BTIIC Ab on day 28 after the 
BTIIC/CFA immunization was arbitrarily designated as a titre of one and used as a standard to 
determine the titres of all the serum samples.   
ELISPOT for enumeration of anti-BTIIC Ab-producing cells   
Multiscreen® filter plate (Millipore, Billerica, MA) was coated with BTIIC as described for 
ELISA. The wells were blocked with culture medium (RPMI1640 medium containing 10% 
FCS) for 2 h at 37 oC and then washed. Cells from draining LN (1×105 cells/100 µl/well) or 
bone marrow (BM; 5×105 cells/100 µl/well) in culture medium were added to the wells and 
incubated for 4 h at 37 oC. The plates were then washed, and biotin-Streptavidin conjugated 
AffiniPure F(ab’)2 fragment of goat anti-mouse IgG Ab (Jackson ImmunoResearch, West 
Grove, PA) was applied. After overnight incubation at 4 oC, the plates were extensively 
washed. Alkaline-phosphatase conjugated-streptavidin (1:60 R&D systems) was added to the 
wells and incubated for 2 h at room temperature.  The spots were visualized by adding 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrate (R&D systems). Pictures 
of each well were taken with an ELISPOT reader (C.T.L., Shaker Heights, OH) and spots 
were counted visually.   
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Results 
Generation of TL1A KO mice and general features of their immune system  
To understand the role of TL1A in immune responses, we generated TL1A KO mice.  The 
targeting strategy was illustrated in Figure 1A.  Germ-line transmission of targeted TL1A was 
confirmed by Southern blotting using tail DNA (Fig. 1B), and PCR was used for routine 
genotyping of KO, WT and heterozygous pups (Fig. 1C). TL1A deletion of KO mice at the 
mRNA level was verified by RT/qPCR as shown in Figure 1D.  The deletion of TL1A protein 
in T cells from KO mice was demonstrated in Figure 1E according to flow cyotmetry.  The 
KO mice were fertile and had no visible anomaly.  Lymphoid organs such as the thymus, 
spleens and lymph nodes were of normal sizes and cellularity (data not shown). The CD4CD8 
double-negative (DN), CD4CD8 double-positive, CD4 single-positive and CD8 single-
positive subpopulations in the TL1A KO thymi were comparable to those in the WT thymi 
(Fig. 2A).  The CD4 and CD8 T cell percentages (Fig. 2A) and B (Fig. 2B) cell percentages in 
the spleen and lymph nodes of TL1A KO mice were in the normal ranges. These results 
indicate that TL1A KO does not significantly affect T and B cell development.  
We examined Th1, Th17 and Treg cell populations in the spleen and lymph nodes of TL1A 
KO and WT mice ex vivo, but no apparent differences were found (Fig. 2C). Th2 cells in the 
KO and WT spleens were below the reliable detection level (data not shown). We next 
assessed whether a lack of TL1A affected Th1, Th2, Th17 and Treg cell development in vitro. 
We compared WT and KO T cell-depleted splenocytes in their capacity to support the 
development of the said T cell populations, using naïve KO CD4 T cells as starting cells, 
which were used because they did not produce TL1A to confound result interpretation.  The 
KO non-T splenocytes were capable of supporting the naïve KO CD4 T cells differentiating 
into Th1, Th2, Th17 and Treg cells in a similar fashion as were their WT counterparts in 
supporting of naïve KO CD4 T cells (Fig. 2D). This suggests that a lack of TL1A minimally 
affects Th1, Th2, Th17 and Treg development in vitro. 
The anti-viral immune responses of TL1A KO mice were evaluated in a lymphocytic 
choriomeningitis virus (LCMV) infection model.  As illustrated in Supplementary Figure 1A, 
the number of CD4 cells and CD8 cells in the spleens on day 8 post-infection (8 dpi) presented 
no significant differences in WT and TL1A KO mice. The absolute numbers and relative 
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percentages of LCMV-specific, tetramer-positive (gp33-41+ and np396-404+) CD8 cells in virus-
infected mice were all increased in comparison to uninfected control C57BL/6 mice (data not 
shown), but there were no significant differences between TL1A KO and WT mice with 
regard to these parameters (Supplementary Figs. 1B and 1C).  The absolute number and 
relative percentages of LCMV-specific TNF-α-producing CD4 (gp61-80+) and CD8 cells (gp33-
41
+) (Supplementary Figs.  1D and 1E), and LCMV-specific IFN-γ-producing CD4 (gp61-80+) 
and CD8 cells (gp33-41+) (Supplementary Figs. 1F and 1G) in TL1A-KO mice were comparable 
to those in WT controls.  This result indicates that TL1A is not essential in anti-LCMV 
immune responses.  
TL1A KO mice presented ameliorated CIA 
Our previous study demonstrated that administering recombinant TL1A aggravates CIA (5). 
Bull et al. demonstrated that neutralizing Ab against TL1A partially blocks antigen-induced 
arthritis (23). We wondered whether a total lack of TL1A would affect RA pathogenesis in the 
CIA model. TL1A KO and WT mice in the DBA/1LacJ background were immunized with 
BTIIC/CFA to induce CIA. The draining lymph nodes (dLN) of the immunized mice were 
assessed on day 14 after BTIIC/CFA immunization, a mid-term point between the starting of 
the immunization and a full-fledged CIA. The KO dLN were smaller in size (Fig. 3A, 1st 
panel) and lower in cellularity (2nd panel) compared to their WT counterparts. The absolute 
numbers of T cells and B cells in these KO dLN were significantly lower than those in the WT 
dLN (3rd and 4th panels). We assessed the size of the germinal centres (GC) and the percentage 
and an absolute number of GC B cells in the dLN. As shown in Supplementary Figure 2A, 
TL1A KO dLN showed no abnormality in term of the size of the GC. This is consistent with 
the fact that the percentages of GC B cells among the total dLNs cells were comparable 
between WT and KO (Supplementary Figure 2B). However, the absolute number of GC B 
cells in the dLNs was significantly lower in KO than in WT mice (Supplementary Figure 2C), 
because of a reduction of the cellularity of the KO dLNs. 
The TL1A KO mice displayed slower onset of CIA and significantly lower clinical scores 
(Fig. 3B). The incidence of CIA in the TL1A KO mice was also lower compared to that 
amongst the WT controls before day 31 after the immunization, although all TL1A KO mice 
eventually developed CIA (Fig. 3C). At the end of the experiment, on day 50, the arthritic 
paws of the TL1A KO and WT groups were collected and then assessed histologically. As 
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illustrated in Fig. 3D, the TL1A KO paws had less synovial membrane hyperplasia (asterisks), 
less immune cell infiltration and milder cartilage erosion (arrow heads). The pathological 
scores of the TL1A KO groups were significantly lower compared to the WT controls’ (Fig. 
3E).  We isolated cells from paws on day 19 after BTIIC/CFA immunization, which was 
chosen because it was shortly before the onset of the disease and paws were still normal in 
appearance, so that the selection of the paws was in no way biased. The number of cells of the 
hematopoietic origin isolated from the paws was significantly smaller in TL1A KO mice than 
in WT mice, but the percentages of DC, neutrophils/macrophages/monocytes, T cells, and B 
cells among the total isolated cells from TL1A KO and WT paws showed no statistically 
significant differences (Fig. 3F).   
These results clearly show that a lack of TL1A diminishes the severity of CIA. 
TL1A KO mice had lower collagen-specific Ab titres after BTIIC/CFA immunization 
The non-immunized TL1A KO and WT mice had comparable levels of total serum IgG, IgM, 
IgA, and IgG subtypes IgG1, IgG2a and IgG2b, IgG3 (Supplementary Fig. 3). Auto-Abs are 
pathogenic in RA (42, 43), and anti-collagen Ab is especially so in CIA. We measured the 
BTIIC-specific Ab during the course of CIA from day 14 to day 50 after BTIIC/CFA 
immunization. The BTIIC-specific total IgG titres in the KO mice were significantly lower 
than their WT counterparts at all time points starting from day 21 (Fig. 4A).  Among the IgG 
isotypes, BTIIC-specific IgG2a and IgG2b but not IgG1 titres in the TL1A KO mice were 
significantly lower than in the WT mice (Figs.  4B-D). The reduced titres of collagen-specific 
Abs titres, especially the IgG2a and IgG2b isotypes, which are major pathogenic Ab isotypes in 
CIA (44), is likely a relevant factor for the observed reduced CIA severity in the TL1A KO 
mice.   
CIA-related T cell functions in TL1A KO mice   
T cells are a major type of target cells of TL1A, and play a vital role in RA pathogenesis 
including producing inflammatory lymphokines such as IFN-γ and IL-17 and providing help 
to B cells for pathogenic Ab production. We assessed the antigen-specific dLN T cells for 
their IFN-γ- and IL-17-production and proliferation upon in vitro collagen restimulation 
shortly before the onset of CIA on day 14 after the immunization, a time point these cells 
reportedly become detectable in this location (45, 46). However, no significant difference 
between TL1A KO and WT dLN was found (Supplementary Figures 4A, 4B). This finding is 
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in agreement with a previous study concerning the role of TL1A in antigen-specific responses. 
In the OT-II system, deficiency of TL1A/DR3 signal does not affect naïve T cells 
differentiation under antigen-specific stimulation, and DR3 KO dLN cells from EAE mice 
proliferate normally to the stimulation of MOG peptides in vitro(15). It is also compatible with 
the data of polyclonal T cell activation as shown in Figure 2. 
CRCXR5+/PD-1+ follicle T help cells (Tfh) express CD40L and ICOS on the cell surface and 
produce IL-21, all of which are essential in B cell survival, differentiation and eventually Ab 
production. We examined Tfh in the dLN on day 18 after the immunization, shortly before the 
lower titres of BTIIC-specific Abs in the KO CIA mice became apparent. The TL1A KO and 
WT dLN harboured similar percentages of CRCXR5+/PD-1+ Tfh (Fig. 5A, left column); 
TL1A KO and WT Tfh cells expressed comparable levels of CD40L and ICOS (Fig. 5A, right 
column). Probably as a consequence, the Fas+GL7+ germinal centre B cells percentages in the 
dLN of TL1A KO and WT were not different (Fig. 5B). With that said, since the absolute 
number of T cells in the KO dLN was reduced (Fig. 3A), the absolute number of Tfh in the 
KO dLN was still smaller than that of WT dLN. We confirmed that undifferentiated CD4 T 
cells (Th0) did not expression DR3, but Th1, Th17 and Tfh cells all expressed DR3, providing 
a basis for them to respond to TL1A  (Fig. 5C).  In vitro differentiated Tfh cells from naïve 
TL1A KO and WT CD4 cells were all capable of produce high levels of IL-21, compared to 
KO Th0, Th1 and Th17 cells (Fig. 5D). Exogenous TL1A did not enhance IL-21 production 
by KO Tfh cells (Fig. 5D).  The results of this section suggest that the deletion or exogenous 
TL1A does not have significant effect on Tfh cells with regard to their B cell helper functions, 
such as their CD40L/ICOS expression and IL-21 production, although the diminished absolute 
number of Tfh in the KO dLN might be a factor contributing to the reduced level of collagen-
specific Abs in KO CIA mice.    
Plasma cells are direct target cells of TL1A 
It is puzzling that in TL1A KO CIA mice, there was an obvious decrease in antigen-specific 
Ab production, yet T cell’s B-cell-facilitating function showed no signs of compromise, with 
the exception of a decrease of the absolute number of Tfh. To date, B cells and their derivative 
plasma cells are not known target cells of TL1A, as an earlier study demonstrate that B cells 
do not express or express very little DR3 (3, 13), although Pelletier et al. did reveal that in 
vitro generated human plasma cells express DR3 at the protein level(47). We confirmed that 
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indeed, B220+CD138- B cells did not express DR3, nor did B220+CD138+ plasmablasts (Fig. 
6A, left and middle panel). However, we discovered that plasma cells from dLN of 
BTIIC/CFA-immunized WT mice expressed very high levels of DR3 (Fig. 6A, right panel). 
DR3 has a full-length isoform and also truncated isoforms (10). According to RT/qPCR, T 
cells and plasma cells expressed similar levels of the full-length DR3 isoform Fig. 6B, left 
panel), while the former expressed more isoforms with deletions (Fig. 6B, middle and right 
panels). The expression of the full length DR3 isoform on plasma cells provided a basis for 
them to respond to TL1A. We then interrogated the effect of TL1A on plasma cells. B cells 
and plasma cells from draining LN of KO mice 21 days after BTIIC/CFA immunization were 
negatively selected using B cell negative selection kit (STEMCELL Technologies) by 
eliminating T, NK, monocyte/macrophages and dendritic cells. The remaining B cells and 
plasma cells were cultured for six days in the presence of exogenous TL1A, as there was no 
endogenous TL1A in this system. In the presence of TL1A, significantly more plasma cells 
survived after the six-day culture (Fig. 6C, left panel) and there were higher levels of collagen-
specific IgG secreted into the supernatants (Fig. 6C, right panel), compared to the culture 
without TL1A. In support of such in vitro results, on day 28 after the BTIIC/CFA 
immunization, when the anti-BTIIC Ab production was actively produced and WT mice had 
significantly higher titres of serum anti-BTIIC Abs, draining LN cells and bone marrow cells 
from WT mice presented significantly higher numbers of anti-BTIIC Ab-secreting plasma 
cells compared to those from TL1A KO draining LN, according to ELISPOT (Figs.  6D-6F). 
Collectively, the data from this section suggest that TL1A can directly promote plasma cell 
survival and function in terms of Ab production, and this effect in turn contributes to the 
elevated pathogenic Ab production in CIA.  Conversely, in the absence of TL1A, the well-
being of the plasma cells is compromised, and this is one of the factors leading to decreased 
levels of pathogenic anti-collagen Ab in TL1A KO mice.   
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Discussion 
In this study, we revealed that TL1A KO mice had ameliorated CIA compared to WT mice.  
No significant T cell dysfunction including Th17 and Treg differentiation was apparent in the 
absence of TL1A, and the TL1A KO mice had normal anti-LCMV immune responses. The 
KO mice presented reduced production of pathogenic anti-collagen Ab.  A novel finding in 
this study is that plasma cells were a direct target of TL1A, that these cells expressed high 
levels of the full-length isoform of TL1A receptor DR3. TL1A promoted plasma cell’s 
survival and Ab-production.  
The results of our current study and several previous studies support the general concept that 
TL1A can intensify inflammatory response.  For example, DR3 KO mice present reduced 
EAE and antigen-induced arthritis (15). The administration of exogenous TL1A aggravates 
CIA, while TL1A neutralizing Ab reduces the severity of CIA(5, 23). Transgenic 
overexpression of TL1A worsens DSS-induced colitis and causes intestinal mucosal 
inflammation(9, 20, 21, 48). Several mechanistic aspects of these disease models corroborate 
each other. For example, our data using TL1A KO mice showed that TL1A was not required 
for constitutive or induced Th1, Th2, Th17 and Treg cell development; studies using deletion 
of DR3 reached the same conclusion(15). However, there are also discrepancies between the 
conclusions obtained from DR3 KO mice versus TL1A KO mice, and from TL1A 
administration/overexpression vs. TL1A/DR3 deletion studies. The discrepancies and possible 
explanations are discussed as follows.   
It seems that excessive TL1A, either from exogenous recombinant protein or endogenous 
transgenic over-expression often results in enhanced IFN-γ and IL-17 expression, but TL1A 
KO or DR3 KO has minimal effect on constitutive or inducible Th1 and Th17 cell 
development (5, 9, 15, 48). A possible explanation for this discrepancy is that such Th cell 
development is vital to the biological system, and there is sufficient redundancy to compensate 
for the missing DR3 or TL1A in the KO mice. As a consequence, in the absence of DR3 or 
TL1A, Th cells could still be developed to near-normal levels. Alternatively, DR3 and TL1A 
are not utterly essential in Th cell development; the enhanced Th cell development in the 
presence of non-physiological high doses of exogenous or transgenic TL1A is due to its cross-
reaction with other TNFR superfamily members (12). The results from CIA mice treated with 
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TL1A neutralizing Ab favour the first explanation (23). In this model, there is no excessive 
exogenous TL1A, and the reduction of the bio-active TL1A occurs at the adult stage and is not 
complete, less likely triggering a drastic compensation. Such a neutralizing Ab treatment can 
hamper the development of Th1 and Th17 cells, which are reported essential in CIA 
pathogenesis, and results in reduced CIA severity (49).  
We demonstrated that TL1A KO mice showed no abnormality in anti-viral immune responses 
against LCMV. However, DR3-KO mice manifest compromised anti-MCMV immunity (24).  
Although TL1A is a ligand of DR3, there are around 20 other TNF superfamily members that 
share some degrees of homology with TL1A. In the absence of TL1A, other members of the 
TNF superfamily might individually or collectively bind to DR3, albeit at a lower affinity, and 
such binding might trigger some low level DR3 signalling, which could be sufficient to 
compensate for the missing TL1A. On the other hand, a missing DR3 will totally eliminate the 
DR3 signalling, resulting more drastic phenotype including compromised anti-virus immune 
responses. Although we favour this hypothesis, we cannot exclude the possibility that the 
observed difference in DR3 KO and TL1A KO regarding the anti-virus immune responses is 
caused by different viruses, i.e., MCMV vs. LCMV.   
Another interesting point is the role of TL1A in Treg development. In our TL1A KO and WT 
mice, no difference was found in constitutive or induced Treg populations. Not surprisingly, 
there was no aggravation but amelioration of CIA in the TL1A KO mice. In mice with 
transgenic TL1A expression or mice administered with exogenous recombinant TL1A, the 
immune/inflammation responses were aggravated but not ameliorated (5, 9, 21, 48).  In all the 
studies using either TL1A or DR3 KO mice models or TL1A neutralizing Abs(3, 15, 23-25), 
the immune responses were abated. Although the Treg status of the above mentioned studies 
are not always assessed, at least we could conclude that excessive TL1A does not lead to 
reduced immune response, a possible functional consequence of Treg upregulation. 
Conversely, TL1A or DR3 deletion does not lead to exuberant immune responses, which are a 
possible functional consequence of Treg downregulation.  
Our ex vivo data indicated that the percentages of Th1 and Th17 cells in draining LN were 
comparable between CIA WT and CIA KO mice. However, since there was a drastic reduction 
of cellularity and absolute T cell number in the draining lymph nodes of KO mice, the 
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absolute numbers of these effector cells were also reduced. Such reduction could likely cause 
a compromised CIA development in the TL1A KO mice.  
Several members of TNF family are involved in regulating the humoral immune responses. 
They could either affect the B cells directly or indirectly through T cells. A well-studied 
member is CD40L, which is essential to the generation of plasma cells (50). CD40/CD40L 
signalling initiates GC responses, GC B cell proliferation, isotype switching and 
differentiation of B cells into plasma cells (51). Since DR3 was reportedly expressed mainly 
on T cells in the immune system, we assessed the effect of TL1A on Tfh cells. Our ex vivo 
data indicated that the percentages of Tfh cells in draining LN were comparable between WT 
and KO mice with CIA. The functions of KO Tfh cells, in terms of CD40L expression and IL-
21 production, were not compromised, neither. However, because there was a significant 
reduction of absolute T cell number in the draining LN of KO mice, comparing to that of WT 
mice, it is conceivable that the absolute number of Tfh and GC B cells in the draining LN of 
KO mice was reduced. Such reduction might contribute to compromised collagen-specific Ab 
production in CIA TL1A KO mice. 
We found that the plasma cells also expressed functional DR3. This finding pin-pointed such 
plasma cells as a target cell population for TL1A’s effect. We demonstrated that TL1A could 
promote draining LN plasma cell survival in vitro.  The direct effect of TL1A on plasma cell 
survival might be one of the contributing mechanisms for the following observation: 1) TL1A 
KO results in reduced number of collagen-specific Ab producing plasma cells ex vivo, and 
reduced collagen-specific Ab titers in vivo; 2) recombinant TL1A enhanced collagen-specific 
Ab production in vitro. However, we noticed that in unimmunized KO mice, their total serum 
IgG levels, and plasma cell population were comparable to those of WT mice. It is possible 
that the benefit of TL1A to plasma cells is only for a limited time during a humoral response, 
and perhaps even specific to a restricted stage of the plasma cells.  
We demonstrated that reduced pathogenic Ab production is a mechanism contributing to 
milder CIA in the TL1A-KO mice. However, it is probably not the only mechanism 
responsible for this phenotype.  We have assessed several T cells function in the absence of 
TL1A, and did not find any anomaly, but such assessment is by no means exhaustive. We did 
find that there was a significant reduction of inflammatory immune cell infiltration in the CIA 
paws, and this phenomenon is consistent with the findings with several disease models in that 
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there is always a reduction of inflammatory cells in the diseased organ or tissues when DR3 or 
TL1A is missing (15, 22). This is certainly an additional mechanism by which TL1A 
contributes to the pathogenesis of CIA. We tested TL1A KO T cell chemotaxis toward several 
CIA-related chemokines in vitro using Transwell, but no significant defect was detected. More 
comprehensive investigations in this aspect including assessing local chemokine secretion by 
T cells, monocyte/macrophages, and DC, and the endothelium permeability in the excessive or 
absence of TL1A are warranted.   
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Figure legends 
Figure 1.  Generation of TL1A KO mice 
A.  Targeting strategy to generate TL1A KO mice. The shaded rectangle on the 5’ side of the 
mouse TL1A WT genomic sequence represents the sequence serving as a probe for 
genotyping by Southern blotting.   
B and C.  Genotyping of TL1A mutant mice. Tail DNA was digested with StuI, and analyzed 
by Southern blotting, with the 5’ probe whose location is indicated in A. Arrows indicate 11.7-
kb bands representing the WT allele and a 5.4-kb band representing the recombinant allele 
(B).  PCR was used for routine genotyping with ear-lobe tissue DNA. The 335-bp bands 
representing the WT allele and the 581-bp bands representing the recombinant allele are 
indicated by arrows (C). HET: heterozygous. 
D.  Absence of TL1A mRNA expression in TL1A KO T cells.  Spleen T cells from WT and 
TL1A KO mice were stimulated with solid anti-CD3 (2µg/ml) and anti-CD28 (2µg/ml) for 24 
h.  Cell RNA was extracted and analyzed by RT-qPCR for TL1A expression. The results are 
expressed as ratios of TL1A versus β-actin signals with means + SD indicated.   
E.  Absence of TL1A protein expression in KO T cells. WT and TL1A KO spleen T cells were 
stimulated as in (D) and stained with anti-CD4 mAb and anti-TL1A Ab and analyzed by 2-
color flow cytometry. The shaded lines represent the isotypic Ab control, and the thick lines 
represent TL1A staining of CD4+-gated T cells of WT (left panel) and KO (right panel) mice. 
Experiments in D and E were repeated at least twice and representative data are shown. 
Figure 2.  TL1A KO mice presented normal lymphocyte subpopulations  
Experiments in this figure were repeated more than three times, and representative data are 
presented (A, B and D).  
A.   T-cell populations in WT and TL1A KO LN, spleens and thymus. Thymocytes, mesenteric 
LN cells, splenocytes were analyzed by 2-color flow cytometry for percentages of different T 
cell subpopulations.   
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B.  B-cell populations in the LN and spleen of WT and KO mice. Mesenteric LN cells and 
splenocytes were analyzed by 2-color flow cytometry for percentages of CD19+/B220+ B cells.   
C.   Normal Th1, Th17 and Treg populations in TL1A KO mice ex vivo. WT or TL1A KO 
spleen cells were stimulated with PMA (50ng/ml) and ionomycin (1µg/ml) for 4 h in the 
presence of BD Golgistop, and analyzed by flow cytometry ex vivo for Th1, Th17 and Treg 
cell populations based on intracellular IFN-γ, IL-17 and FoxP3 staining. The bar graphs 
represent the summary of data from 3-4 experiments, with Mean + SD indicated.  
D.  Normal differentiation of TL1A-KO CD4 cells in vitro. Naïve TL1A-KO CD4 cells were 
cultured under conditions favouring Th1, Th2, Th17 and Treg cells, using WT or TL1A KO 
feeder cells, as indicated. Their intracellular cytokine or FoxP3 expression was quantified by 
3-color flow cytometry on day 3 for Th1, Th17 and Treg cells, and on day 5 for Th2 cells after        
4-h PMA (50ng/ml) and ionomycin (1µg/ml) stimulation in the presence of BD Golgistop 
before the assay.   
Figure 3.  TL1A-KO mice manifested less severe CIA 
A.  Reduced numbers of immune cells in KO draining lymph node during CIA induction. Mice 
were immunized with BTIIC/CFA at the tail base on day 0. On day 14 after the immunization, 
draining lymph nodes (dLNs) were collected and photographed (1st panel), cells from dLN of 
WT (n=10) and TL1A KO (n=11) mice were isolated, enumerated and analysed by flow 
cytometry for subpopulations.  The numbers of total dLN cells per mouse (2nd panel), CD4 T 
cells (CD4+) of the dLNs per mouse (3rd panel) and B cells (B220+) of the dLNs per mouse (4th 
panel) are shown. The horizontal bars indicate the means. Student’s t test was used to assess 
the statistical significance of the difference between WT and TL1A KO mice and the p-value 
is indicated.    
B.  CIA clinical scores of WT and KO mice after BTIIC/CFA immunization. WT (n=8) and 
TL1A KO (n=9) mice were immunized with BTIIC/CFA on day 0, and scored for their RA 
symptoms daily starting from day 21 until day 50.  Mean ± SEM scores are plotted. Scores for 
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the WT and TL1A KO mice were evaluated statistically by 2-Way ANOVA.  P-values are 
indicated.   
C.  CIA incidence in WT and TL1A KO mice.  The CIA incidence of the WT and TL1A KO 
groups in (A) is plotted. 
D and E.  Histology of mouse joints.  WT and TL1A KO Mice from (B) were sacrificed on 
day 50, and all the paws were sectioned and stained with haematoxilin/eosin (H&E) or 
safranin O (for cartilage staining) as indicated. Representative histology images from each 
group are shown (D). Asterisks indicate synovial hyperplasia and arrow heads indicate 
cartilage damage. Naïve: joints from normal unimmunized DBA/1 mice; WT-CIA: joints from 
WT mice immunized with BTIIC/CFA; KO-CIA: joints from KO mice immunized with 
BTIIC/CFA. The histology of each paw (one section per paw) was evaluated by blinded raters 
and scored semi-quantitatively based on lining hyperplasia, bone erosion and cell infiltration. 
Each parameter was scored on a 0-3 scale, and all four paws of each animal were scored. The 
overall score for each animal, which is the sum of the three parameters of the four paws, is 
shown in the plot and the horizontal bars represent the mean scores (E). Student’s t test was 
performed to assess the statistical significant of the difference between WT and TL1A KO 
mice and the p-value is indicated.   
F.  Reduced numbers of infiltrating immune cells in KO paws during CIA induction. On day 
19 after BTIIC/CFA immunization, before the onset of CIA symptoms, cells infiltrating the 
paws of WT and TL1A KO mice were isolated, enumerated and analysed by flow cytometry 
for subpopulations. The total numbers of infiltrating cells of hematopoietic origin (CD45.2+) 
per paw is shown in the left panel; percentage of dendritic cells (CD11c+), in the second panel; 
percentage of neutrophils/monocytes/macrophages (CD11b+), the third panel; percentage of T 
cells (Thy1.2+), in the fourth panel; and percentage of B cells (B220+), in the last panel. Mouse 
numbers per group are indicated. Student’s t test was used to assess the statistical significance 
of the difference between WT and TL1A KO mice and the p-value is indicated.   
Figure 4.  Reduced collagen-specific Ab production in KO mice with CIA   
Sera were obtained from WT (n=7) and TL1A KO (n=7) mice on 14, 21, 28, 35, 42 and 50 
days after BCTII/CFA immunization. Arbitrary titres of collagen-specific total IgG (A), IgG1 
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(B), IgG2a (C) and IgG2b (D) were determined by ELISA. Serum from a WT mouse exhibiting 
typical arthritis was arbitrarily given a titre of 1 and used as a reference in each assay. For A, 
B, C, D, mean ± SEM are presented and evaluated statistically by 2-Way ANOVA. P-values 
are indicated.   
Figure 5.  TL1A T cells presented normal help to B cells  
The experiments in this figure were repeated three times and representative data are shown.  
A.  Flow cytometry analysis of Tfh in draining LN of mice after BTIIC/CFA immunization.  
WT or TL1A KO mice were immunized with BCTII/CFA and then sacrificed on day 18. 
CD4+ T cells from dLN were purified and stimulated with solid anti-CD3ε (2µg/ml) and anti-
CD28 (2µg/ml) Ab for 30 min. The percentage of CD4+PD-1+CXCR5+ Tfh cells among CD4+ 
cells were determined by flow cytometry and shown (right column).  The gated Tfh were 
further analyzed for their CD40L and ICOS expressions (left column), and the percentages of 
CD40L+ and ICOS+ cells among Tfh (PD-1+/CXCR5+) cells are indicated. 
B. Flow cytometry analysis of germinal centre (GC) B cell populations.  B220+ B cells from 
the draining LN of WT and TL1A KO mice on day 18 after BTIIC/CFA immunization were 
analysed for GL7 and Fas expression. The percentages of B220+GL7+ Fas+ GC B cells among 
B220+ B cells are indicated. 
C.  DR3 expression on Th and Tfh cells. Naïve CD4+ T cells were cultured on anti-CD3ε 
(2µg/ml for coating) and anti-CD28 (2µg/ml for coating) Ab-coated wells under Th1, Th17 
and Tfh-like cell differentiation conditions. After 3 days, DR3 expression on CD4+ cells was 
assessed by flow cyotmetry.  Shaded area: isotypic controls.  Thick lines: DR3 signals.  
D.  IL-21 production by in vitro differentiated WT and KO Tfh cells. WT or TL1A KO naïve 
CD4+ T cells were cultured in anti-CD3 and anti-CD28 Ab-coated wells under the Tfh-like 
cell differentiation condition. They were also cultured under Th0 (without reagents for Th 
differentiation except anti-CD3ε, anti-IFN-γ and anti-IL-4 Abs), Th1 or Th17 conditions as 
controls.  TL1A at 10 and 50 ng/ml was added to some cultures as indicated.  On day 3, the 
cells were re-stimulated with PMA/ionomycin for 9 hours and IL-21 in the supernatants was 
measured by ELISA. Samples in ELISA were in duplicate and means ± SD are shown.   
Figure 6.  The effect of TL1A on plasma cells 
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The experiments in A, B and C were repeated three times and representative data are shown.  
A.  DR3 expression in plasma cells. dLN cells from WT mice on day 15 after BTIIC/CFA 
immunization were gated on B220+CD138- regular B cells (left panel), B220+CD138+ 
plasmablast and Dump-B220-CD138+ plasma cells and analyzed for their DR3 expression by 
three-color or four-color flow cytometry. Shaded areas: isotypic controls. Thick lines: DR3 
signals. Dump staining used anti-CD8, anti-CD11b, anti-CD11c, anti-F4/80, anti-IgM, anti-
IgD and anti-CD4 mAbs. 
B.  DR3 isoform expression in CD4 cell and plasma cells. RT-qPCR was used to detect the 
mRNA of full-length DR3 and all DR3 isoforms (including the full-length and all truncated 
isoforms) in flow cytometer-sorted CD4+ T cells (as controls) and Dump-B220-CD138+ 
plasma cells. The results are expressed as ratios of DR3 (full-length or all isoforms) versus β-
actin signals with means + SD indicated. Left panel: full-length DR3 isoform expression in 
CD4 T and plasma cells; middle panel: the expression all DR3 isoforms (full-length plus all 
truncated isoforms) in CD4 T and plasma cells; right panel: ratios of full-length DR3 versus 
all isoforms of DR3. 
C.  Higher plasma cell numbers in and collagen-specific Ab production by WT dLN cells 
cultured in the presence of TL1A. dLN cells from WT mice 21 days after BTIIC/CFA 
immunization were cultured in the absence or presence of TL1A (50 ng/ml) for 6 days. The 
number of Dump-B220-CD138+ plasma cells were counted by flow cytometry four times on 
day 6 and the plasma cell numbers per 1×106 total dLN cells (means ± SD) are shown (left 
panel).  The culture supernatants were harvested on day 6 and collagen-specific IgG levels in 
the supernatants were determined by ELISA, which was conducted in triplicate samples. 
Arbitrary titres of anti-collagen IgG Abs (means ± SD) are shown (right panel). Experiments 
were repeated at least twice and representative data are shown. Student’s t test was used to 
assess the statistical significance of the difference and the p-value is indicated.   
D-F.  Reduced collagen-specific IgG-producing cells (CSIGGPC) in the dLN and bone 
marrow (BM). Twenty-eight days after BTIIC/CFA immunization, CSIGGPC in the dLN and 
BM  were enumerated by ELISPOT. Representative images of spots in wells were showed in 
D. The spots in 8 replicate wells of each experiment were counted, and the data of three 
 xxxii 
 
similar experiments were pooled and summarized bar graphs (E for dLN and F for BM). Mean 
± SEM are presented.  *p<0.05; **p<0.01 (Student’s t test). 
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Figures 
Figure 1 Generation of TL1A KO mice 
 
 
 
  
 xxxiv 
 
Figure 2 TL1A KO mice presented normal lymphocyte subpopulations  
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Fugure 3 TL1A-KO mice manifested less severe CIA 
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Figure 4 Reduced collagen-specific Ab production in KO mice with CIA   
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Figure 5 TL1A T cells presented normal help to B cells  
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Figure 6 The effect of TL1A on plasma cells 
 
